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  Preface 
1. Preface 
The erroneous incorporation of ribonucleotides into genomic DNA 
occurs very frequently in cells during physiological processes. Several works 
published in literature have demonstrated that more than 100 million rNMPs 
are transiently present in mammalian DNA during each replication cycle, as a 
consequence of: i)  the inability of DNA polymerases to discriminate rNTPs 
from dNTPs; ii)  the abundance of rNTPs compared to dNTPs in the nucleotide 
cell pool and iii)  the presence of residual ribonucleotides belonging to RNA 
primers derived from the incomplete repair of the Okazaki fragments.  
The presence of RNA, as single or more ribonucleotides, into DNA 
results very dangerous for the cell due to its distorting effects on the double 
helix of DNA. For this reason, a specific pathway acts in order to remove this 
lesion called Ribonucleotide Excision Repair (RER) pathway, in which RNase 
H2 plays an important role as endonuclease, able to cleave at the 5’ side of 
normal rNMPs in DNA. Although in the last decade huge steps forward have 
been done in this field, more studies are needed for better understanding the 
impact of this lesion on DNA and their back-up repair mechanism when the 
RER mechanism does not work, as it happens in several pathologies including 
cancer and Aicardi-Goutieres syndrome.  
Notably, nothing is known about the putative ability of this pathway to 
repair modified (i.e. oxidized or abasic) rNMPs within DNA.  
Moreover, because of the importance of the Base Excision Repair 
(BER) in repairing non-bulky lesions, including oxidized and abasic bases, a 
role of the BER mechanism in the removal of rNMPs embedded in DNA needs 
to be addressed. 
The Apurinic/apyrimidinic endonuclease 1 (APE1) is the main protein 
that works in BER pathway as abasic endonuclease. Deoxy- abasic sites, 
generated spontaneously or following the previous processing by glycosylases 
on a damaged (including oxidized) base, are efficiently cut by APE1. The 
importance of APE1 in the BER pathway also comes by its altered expression 
observed in different human pathologies including neurodegenerative 
disorders and cancer. Moreover, APE1 has nucleotide incision repair (NIR) 
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activity on different modified bases, such as 5,6-dihydro-2’-deoxyuridine, 5,6-
dihydrothymidine, 5-hydroxy-2’-deoxyuridine, 5-hydroxycytosine, which are 
directly repaired by APE1 bypassing the action of specific glycosylases. Last, 
but not least, the role of APE1 as a redox co-activator of several transcription 
factors by modulating their DNA binding ability is well ascertained.  
Findings from our and other laboratories revealed an interesting 
involvement of BER in RNA metabolism. Specifically, APE1 can 
endonucleolytically cleave abasic single-stranded RNA, has a 3′-RNA 
phosphatase activity, and a weak 3′-5′ exoribonuclease activity.  
Upon demonstration of the involvement of the BER mechanism in RNA 
metabolism, we hypothesized that BER enzymes could be involved in the 
processing of rNMPs in DNA, particularly in the case of chemically modified 
rNMPs, such as abasic and oxidized rNMPs.  
Although published data have demonstrated that spontaneous 
depurination occurs ~1,000 times slower in RNA than DNA, due to the high 
abundance of rNMPs in genomes, with more than 100 million rNMPs 
transiently present in mammalian DNA, the possibility that abasic and oxidized 
rNMPs (such as 7, 8-Dihydro-8-oxo-riboguanosine) are present in DNA and 
could be considered targets of BER is quite real. These data, together with 
other recent findings of the ability of S. pombe Pol 4, M. smegmatis DinB2 and 
human Polβ  to insert and elongate oxidized rGMP, underscore the necessity 
to determine how cells can target and remove oxidized or abasic rNMPs from 
DNA. 
Identifying and discovering whether BER may target normal and 
modified rNMPs in DNA, can also help to better understand the mechanism of 
genotoxicity of reactive oxygen species as well as the function and the impact 
of BER defects in human disease and cancer mechanisms.  
For all these above reasons, the main focus of this Thesis is to test the 
hypothesis of whether BER enzymes may process oxidized or abasic rNMP 
incorporated in DNA.  
  Abbreviations 
2. Abbreviations 
• DDR: DNA DAMAGE RESPONSE 
• ROS: REACTIVE OXYGEN SPECIES 
• SSB: SINGLE STRAND BREAK 
• D8OXOG: 8-OXO-7,8-DIHYDROGUANINE DEOXYRIBOSE 
• AP: ABASIC SITE 
• BER: BASE EXCISION REPAIR 
• OGG1: 8-OXOGUANINE DNA GLYCOSYLASE 
• APE1: AP-ENDONUCLEASE 1  
• NIR: NUCLEOTIDE INCISION REPAIR  
• DNMPS: DEOXYRIBONUCLEOTIDES MONOPHOSPHATE 
• RNMPS: RIBONUCLEOTIDES MONOPHOSPHATE 
• RER: RIBONUCLEOTIDE EXCISION REPAIR 
• RNASE H: RIBONUCLEASE H 
• AGS: AICARDI GOUTIÈRES SYNDROME 
• RAP: RIBO- ABASIC SITE 
• R8OXOG: 8-OXO-7,8-DIHYDROGUANINE RIBOSE 
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4. Introduction 
4.1 DNA damage versus  DNA repair: an overview 
During its life-span, eukaryotic cells are continuously exposed to 
innumerable environmental conditions, including smog, infectious agents, 
tobacco and UV light, defined as damaging agents because having the ability 
to injury cellular macromolecules (e.g. DNA, lipids and proteins) (Hoeijmakers 
2001).  
DNA is an intrinsically reactive molecule whose integrity should be 
preserved as long as possible in order to guarantee genomic inheritance. If 
DNA is damaged, the consequences for the cell and, consequently, for the 
whole organism, could be disastrous (Chan and Dedon 2010).  
Among DNA damaging agents, a subdivision in two categories based on 
the origin of the damaging agents is preferred:  
• endogenous agents, in which damages induced by physiological 
cellular processes are included, such as: replication errors, oxygen 
metabolism, DNA base mismatches by polymerases, the formation of 
topoisomerase-DNA complexes, spontaneous DNA deamination, 
methylation and abasic sites, ribonucleotides incorporation; 
• exogenous agents, in which chemical and physical agents are 
considered and which are provoked by the environment such as: 
ionizing radiation, UV radiation, alkylating agents, aromatic amines, 
toxins. 
Replication errors, DNA base mismatches, base deamination / alkylation / 
methylation, generation of oxidized and abasic sites are some of several DNA 
injuries (Figure 1). If unrepaired, DNA damage can be the cause of cell death 
or aberrant cell proliferation contributing to premature aging and cancer 
(Wilson and Bohr 2007). To avoid this, each cell is well-equipped with genome 
maintenance systems including DNA repair, cell cycle checkpoint and cell 
death pathways that ensure keeping the DNA integrity (Bauer, Corbett, and 
Doetsch 2015).  
DNA Damage Response (DDR) pathways include several DNA repair 
systems that work in a sophisticated way to recognize and repair a specific 
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type of DNA damage and re-establish the genome integrity. Among the several 
active DDR mechanisms, there are: the Base Excision Repair, Nucleotide 
Excision Repair, Mismatch Repair, Homologous Recombination and Non-
homologous End Joining pathways (Figure 1) (Chatterjee and Walker 2017).  
Although each DNA repair pathway has been originally characterized 
as single entities acting on a specific subtype of DNA lesion, a crosstalk 
between several DNA repair pathways operates in order to properly repair the 
DNA injury. 
An imbalance between DNA damage and repair, or a disruption of DDR 
systems or damage tolerance, increases the risk of genomic instability and 
mutagenesis, promoting several diseases, including cancer, aging or 
neurodegenerative disturbs (Hoeijmakers 2009).  
 
 
In next paragraphs, our attention will be focused on two important DNA 
lesions induced by oxidative stress and rNMP incorporation and their relative 
damage response responsible for restoring the DNA stability.  
  
Figure 1 Overview of different DNA damaging agents, DNA effects, and relative 
DNA repair pathways  
The figure, divided into three panels, recapitulates for each DNA damaging agent 
(upper panel), the lesion induced on DNA (Damaged DNA - middle panel) and finally 
DNA repair pathways acting on the lesion (lower panel). (Chatterjee and Walker, 
2017) 
	 	 Introduction 
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4.2 Oxidative stress and its impact on DNA 
Eukaryotic organisms activate a process called aerobic respiration 
within mitochondria in which several mitochondrial enzymes work to promote 
the conversion of glucose in oxygen to produce CO2, water and energy.  
During the one-electron reduction of oxygen of the aerobic respiration, 
several oxidizing species are generated including superoxide radical (O2˙-), 
non-radical hydrogen peroxide (H2O2) and hydroxyl radicals (˙OH). Some of 
them are defined as Reactive Oxygen Species (ROS), highly reactive product 
of oxygen metabolism (Gebicki 2016). ROS produced during oxidative stress 
are considered as the most dangerous trigger of damage for several 
macromolecules including proteins, lipids and, overall, nucleic acids (Balazy 
and Nigam 2003). In fact, they are electron deficient, so they readily oxidize 
cellular macromolecules particularly DNA and RNA.  
The first product generated during oxygen metabolism is the superoxide 
anion radical (O2˙-). 1-1.5% of the oxygen intake results in the production of 
O2˙-. O2˙- is converted to hydrogen peroxide (H2O2) through an enzymatic 
dismutation process (Boveris and Cadenas 2000; Valdez et al. 2000). Both 
O2˙- and H2O2 are low reactive against biomolecules, so they are not 
considered highly dangerous for the cell. When H2O2 gets in contact with 
transition metals, such as ferrous ions, it is reduced through a Fenton reaction 
generating hydroxyl radicals (˙OH).  
Contrarily to their precursors, ˙OH radicals are highly reactive products 
that are the direct cause of oxidative damage to cellular macromolecules 
(Cadet et al. 2017; Kalyanaraman 2013).  
Moreover, during pathological situations, including type 2 diabetes, 
atherosclerosis and cancer, generation of OH products is increased, and is 
often coupled to the activation of NO-synthase that triggers the release of nitric 
oxide (˙NO) (Boveris et al. 2000). When ˙NO reacts with ˙OH, the combined 
peroxynitrate ONOO-, a powerful reactive nitrogen species (RNS), is produced 
resulting dangerous for the cell (Bustamante et al. 2000; Cadenas et al. 2000).  
Not only aerobic respiration is the cause of ROS generation. In fact, 
oxidative stress can also be induced by exposure to diverse chemical and 
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physical agents such as ionizing radiations, UV radiation, redox cycling drugs, 
carcinogenic compounds and toxins which are critical fonts of damage induced 
by the formation of singlet oxygen (1O2) or OH radicals (Radman 2016).  
All purine and pyrimidines can be attacked upon oxidative stress (Miral 
Dizdaroglu 2012) in both cellular nucleotide pool or directly into DNA (Figure 
2). A multiplicity of structurally different lesions are formed upon endogenous 
and exogenous oxidation. Among all the five bases, the guanine base is the 
more susceptible base to oxidative stress because it possesses the lowest 
redox potential (Cadet 2014). The most important oxidative conversion of the 
guanine is into 8-oxo-7,8-dihydroguanine (8oxoG). 8-oxoguanine can originate 
as 8-oxo-dGTP, generated in the nucleotide pool or by direct oxidation of the 
DNA guanine base. This modified base is so abundant within the cell that it is 
usually used as a cellular biomarker for oxidative stress (Collins et al. 1996). 
8oxoG accumulates in both nuclear and mitochondrial DNA and, because of 
its frequency, it is believed to be the major cause of cancer (Nakabeppu 2014). 
Moreover, reduction of the guanine can lead to the generation of 2,6-diamino-
4-hydroxy-5-formamidopyrimidine (FapyG). Both FapyG and 8oxoG are 
efficiently removed by eukaryotic OGG1, that will be deeper explained in the 
next paragraph (David, O’Shea, and Kundu 2007).  
As for guanine, also adenine can be attacked by ROS giving rise to 8-oxo-7,8-
dihydroadenine (8-oxoA), 4,6-diamino-5-formamidopyrimidine (FapyA) and 2-
hydroxyadenine. Thymine glycol and cytosine glycol are the most common 
products following oxidative stress of thymine and cytosine respectively 
(Figure 2) (Breen and Murphy 1995; Dizdaroglu et al. 1986). 
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8oxoG can also be further oxidized to two major products, 
spiroiminodihydantoin (Sp) and guanidinohydantoin (Gh) (Figure 2) (Neeley 
and Essigmann 2006). Sp and Gh are removed by NEIL1 and NEIL2 
glycosylases, through β,δ-elimination mechanism in double and single strands 
respectively. NEIL3 also acts on these substrates and in oxidized pyrimidines 
(Krishnamurthy et al. 2008).  
Oxidized dGMP assumes an important role in genomic instability when 
embedded in DNA. If not readily repaired, it can cause a G⇾T transversion 
mutation. Upon succeeding DNA replications, 8oxoG will pair with adenine on 
the Hoogsteen face rather than cytosine on the Watson Creek face fixing a T 
mutation in the new DNA strand (Figure 3). This mutagenic state can activate 
a carcinogen process (Lonkar and Dedon 2011). On the contrary, when 8oxoG 
Figure 2 Structure representation about most frequent modified bases that 
commonly occur upon oxidative stress  
All purine and pyrimidines are subject to modification upon oxidative stress. (Lee and 
Wallace, 2016) 
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or FapyG are paired with adenine, eukaryotic MUTYH, a MMR enzyme, will 
preferentially remove adenine in the opposite strand (Takao et al. 1999) giving 
another opportunity to the polymerase to incorporate a correct cytosine (Figure 
3). 
 
 
When lesions induced by oxidative stress are not efficiently repaired, 
the effects on the organism are different, including: aging, cancer and 
neurodegenerative disorders (Islam 2017). Recently, a new unexpected 
concept has been hypothesized. Data obtained in vitro show that the presence 
of 8oxoG containing in transcription factor binding sequences modulates 
negatively the binding affinity of the transcription factor to the DNA. This effect 
was demonstrated in several cases including in SP1, NFkB and CREB 
sequences, some of the most important transcription factors (Fleming, Ding, 
and Burrows 2017; Fleming and Burrows 2017). Actually, it appears that the 
presence of d8oxoGMPs in DNA may epigenetically impact on gene 
transcription, thus opening new questions on non-canonical roles of DNA 
lesions and their impact in vivo. 
In the next paragraph, the pathway deputed on repairing lesions 
induced by oxidative stress is described.   
Figure 3 Two matches are possible when G base is oxidized  
8oxoG can pair with cytosine following Watson Creek face (upper) or with adenine 
following Hoogsteen face (bottom). In the last case, a mutation will be generated 
under subsequent replications. (Faucher et al., 2012) 
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4.3 Base Excision Repair pathway 
BER is a ubiquitous pathway, considered one of the most important 
DNA repair pathway for maintaining genomic integrity to oxidative-based 
damage on DNA (Markkanen 2017). The importance of the BER pathway is 
easily recognized in those cases in which genes of the core BER factors are 
deleted, resulting in embryonic or early post-natal lethality (Iyama and Wilson 
2013). 
The BER mechanism is able to repair DNA damage that does not 
induce DNA helix distortions called non-bulky lesions. These lesions can be 
generated by several DNA damaging agents, including: alkylating, 
deaminating and oxidative agents, both in nuclear and mitochondrial DNA 
(Dianov et al. 2001; Krokan and Bjoras 2013).  
Briefly, the BER pathway is composed of five essential steps, which are 
well conserved from Bacteria to Eukaria (Figure 4): 
i) The first action is carried on by lesion-specific DNA glycosylases. 
These enzymes recognize the damaged base through a flipping 
out mechanism and cleave it through a sophisticated process 
(Wallace 2013).  
ii) After the hydrolysis of the N-glycosyl bond by DNA glycosylases, 
abasic (AP) sites are generated. AP sites are processed by a 
specific apurinic/apyrimidinic endonuclease, APE1 (Bauer, 
Corbett, and Doetsch 2015). APE1 cleaves the phosphodiester 
bond generating two free termini, 3’ OH and 5’ phosphate.  
iii) The abasic dRP intermediate generated is then removed by Polβ  
which also inserts the correct nucleotide (Howard and Wilson 
2017).  
iv) Finally, the ligation of the residual nick is carried on by Ligase III 
(Howes and Tomkinson 2012). 
It has been estimated that up to 10,000 abasic sites are formed per 
human genome per  day by spontaneous hydrolysis of the N-glycosyl bond 
(Dianov and Hübscher 2013; Lindahl 1993), thus the BER mechanism can 
work independently of DNA glycosylases when an AP site is generated.  
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An important diversification of the BER pathway is based on the step 
carried on by the polymerase. The pathway can be completed via a “short 
patch” (SP) or a “long patch” (LP) mechanism.  
In the SP pathway, Polymerase β is engaged to replace the single 
missing nucleotide, then Ligase I or a XRCC1-Ligase III complex is responsible 
for the ligation of the nick (Sobol et al. 1996). In the LP via, preferentially 
chosen during the S-phase of the cell cycle, FEN 1 (flap endonuclease 1) 
excises the displaced strand while Polymerases δ and ε work with the sliding 
clamp PCNA (proliferating cell nuclear antigen), generating an 2-12 
nucleotides strand. The nick is finally sealed by Ligase I (Sung, DeMott, and 
Demple 2005).  
  
	 	 Introduction 
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Figure 4 Chemical representation about principal BER steps  
After the cleavage of the N-glycosyl bond by specific DNA glycosylases, an AP 
endonuclease cuts the phosphodiester bond. The resulting gap is filled with new 
correct dNTPs by DNA polymerases and ligases. (Drohat and Coey, 2016) 
	 	 Introduction 
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Because of its complexity, different theories have been proposed to 
explain in detail how the BER pathway proceeds, including the “passing the 
baton” and “BERosome” models (Almeida and Sobol 2007; Allinson et al. 
2004; Wilson and Kunkel 2000). A fine regulation exists among all the BER 
enzymes in order to coordinate every step of the DNA repair. This coordination 
is possible by means of several post-translational modifications (PTMs) able 
to regulate protein-protein interactions, pathway cascade signaling, cellular 
localization, conformational changes and protein stability (Almeida and Sobol 
2007; Déry and Masson 2007). Moreover, several proteins, including p53 and 
Nucleophosmin, work as BER modulators (Fan and Wilson 2005; Vascotto et 
al. 2009). 
Recently, other important non-canonical functions of the BER pathway, 
and particularly of BER proteins, have been described in literature. 
In Drohat and Coey (and reference therein), a new surprising role of the 
BER, still completely unexplored, has been described. A well-studied 
epigenetic mark is the methylation of cytosine bases. Methylated bases are 
usually sited in repeatable CG dinucleotide sequences, called CpG islands, 
that are associated with gene repressing and chromatin remodeling. 
Specifically, the BER pathway can work as an epigenetic modulator through 
its “repair” ability in removing this epigenetic mark, by modulating the level of 
methylated cytosine and converting it back to unmodified cytosine (Drohat and 
Coey 2016).  
Moreover, BER enzymes, such as APE1, PARP1 and SMUG1, possess 
non-canonical roles, not merely implicated in the BER. As it will be explained 
in next paragraphs, BER enzymes are also related to RNA metabolism, in 
transcriptional regulation of genes and also in miRNAs regulation (Antoniali, 
Lirussi, Poletto, et al. 2014; Ogawa and Baserga 2017; Poletto, Legrand, et al. 
2016; Tell et al. 2009; Antoniali et al. 2017). 
In next paragraphs, I will deeper focus on two main BER enzymes: DNA 
glycosylases and apurinic/ apyrimidinic endonucleases. 
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4.3.1 DNA glycosylases 
Each one of the eleven N-glycosylase proteins present in mammalian 
cells is able to initiate the BER pathway after recognizing specific damaged 
bases. Once the recognition step is performed, its principal function is cleaving 
the damaged base leaving an apurinic/ apyrimidinic (AP) site. In a eukaryotic 
cell, several DNA glycosylases exist and they differ from each other for the 
mechanism of action, substrate specificity and excision kinetics (Sidorenko, 
Nevinsky, and Zharkov 2007; Sidorenko and Zharkov 2008; Takao et al. 1999). 
Although the existence of a high variety of glycosylases in mammalian cells, a 
significant redundancy in their damage selectivity is observed. For this reason, 
it has been observed that single knockout of one of them are not considered 
lethal per se (Wallace 2013). 
Based on their mechanism of action, DNA glycosylases are classified 
in two groups: mono- and bi- functional glycosylases (Figure 5).  
Monofunctional DNA glycosylases (e.g. uracil DNA glycosylases (UDG) 
including the mitochondrial uracil N glycosylases (UNG1), nuclear UNG2 and 
a single strand selective monofunctional uracil DNA glycosylases (SMUG1)) 
process the damaged DNA cleaving the C1-N-glycosidic bond and generating 
an AP site and the liberated nucleobase.  
Bifunctional glycosylases, including the 8-oxoguanine DNA glycosylase 
(OGG1), NTH1 and NEIL family, display, in addition to their glycosylase 
activity, an additional AP-lyase activity (Svilar et al. 2011) (Figure 5). After the 
recognition of the oxidized base, bifunctional glycosylases use an amine 
nucleophile, such as a Lys side chain, to cleave the N-glycosidic bond, 
generating a Schiff base (imine) intermediate (Prakash, Doublié, and Wallace 
2012). Subsequently, through their AP-lyase activity, bifunctional glycosylases 
cleave the DNA phosphodiester backbone on the 3’ side of the lesion through 
a β-elimination resulting in a single strand break. A second cleavage on the 
DNA phosphodiester backbone is also possible on the 5’ side of the lesion 
through δ-elimination (Bailly and Verly 1988) (Figure 5). 
Usually, monofuctional glycosylases are implicated in the SP BER sub-
pathway whereas the bifunctional in the LP BER sub-pathway (Dianov and 
Hübscher 2013). 
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High expression levels of DNA glycosylases, as in the case of other 
BER enzymes, are distinctive of some types of cancer (An et al. 2007). The 
knowledge of different DNA glycosylases and their specific mechanism of 
action will allow the discovery of small molecule inhibitors of these proteins as 
potential therapeutic targets for treatment of several tumors (Donley et al. 
2015).  
 
 
	 	
Figure 5 Mechanism of action of two types of DNA glycosylases in mammalian 
cells  
Mono- and bi- functional glycosylases differ from each other for the 5’-mojety 
generated. Monofuctional glycosylases cleave the N-glycosyl bond to the 5’ side of 
the damaged base. Bifunctional glycosylases are also able to cleave the 
phosphodiester bond at the 3’ side (β-elimination) in addition to a second cleavage at 
the 5’ side (δ-elimination). (Drohat and Coey, 2016) 
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4.3.1.1 8-oxoguanine glycosylase  
Human 8-oxoguanine glycosylase (OGG1) is a bifunctional glycosylase 
working in the BER pathway. The 8oxoG- and FapyG- lesions, opposite to 
cytosine in the complementary strand, are recognized and removed by OGG1. 
OGG1 is able to cleave the N-glycosidic bond of 8-oxo-2’-deoxyguanosine. 
Moreover, belonging to the bifunctional subgroup, OGG1 is able to process 
oxidized bases through β-elimination mechanism and generates abasic sites 
that are subsequently processed by the final BER enzymes, polymerases and 
ligases (Kuznetsov et al. 2005). OGG1 belongs to the HhH-GPD superfamily 
containing conserved structural helix-hairpin-helix and GPD motifs (Yamagata 
2001).  
In the last decades, X-Ray crystallography studies have defined the 
structural binding between DNA and OGG1 (Kuznetsov et al. 2005, 2014; 
Rowland et al. 2014; Šebera et al. 2012). As Figure 6 shows, OGG1, during 
the recognition of the damaged base, forms non-specific electrostatic and 
hydrophobic contacts with the sugar-phosphate backbone kinking the DNA by 
70°. After that, the oxidized G is fully flipped out from the DNA helix and deeply 
inserted into the active site of the enzyme. The cytosine located on the 
complementary strand and paired with 8oxoG starts hydrogen-bonding 
interactions with the amino acids Arg-154 and Arg-204 inserted into the DNA 
helix. After the flipping out of the oxidized G residue, amino acids Asn-149 and 
Tyr-203 are inserted into the abasic site (Kuznetsov et al. 2014). Although 
OGG1 establishes contacts also with undamaged G through its the active 
pocket site, it is able to discriminate and not process it (Fromme et al. 2003).  
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Figure 6 View of the catalytic pocket site of OGG1  
First, specific amino acids contact the 8oxoG (A) and later with the cytosine opposite 
to the oxidized lesion (B). (Modified from Kuznetsov et al., 2014) 
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4.3.2 AP endonuclease 
Unrepaired abasic sites, generated by spontaneous hydrolysis of the 
DNA backbone or following processing by a glycosylase on a damaged base, 
result mutagenic and cytotoxic for the cell (Loeb and Preston 1986).  
In order to maintain genome integrity, mammalian cells are endowed 
with specific enzymes called apurinic/apyrimidinic (AP) endonucleases. The 
importance of this enzymes is easily recognized in those cases in which 
deletions result in embryonic or early post-natal lethality (Iyama and Wilson 
2013). In mammals, the major AP-endonuclease is the apurinic/apyrimidinic 
(AP) endonuclease 1 (APE1) (Demple, Herman, and Chen 1991; Hadi et al. 
2002). Contrary to APE1, apurinic/apyrimidinic (AP) endonuclease 2 (APE2) 
is not involved in the repair of AP sites but is central for normal B cell 
development. APE2 ensures the activation of cytidine deaminase, enzyme 
needed for the expansion of germinal centers and regulating the antibody 
diversification (Guikema et al. 2011; 2014). 
APE1 is a major enzyme of the BER pathway due to its importance in 
the correct progression of DNA repair (Tell et al. 2009, 1). Remarkably, as 
recently discovered, APE1 has several other activities besides its BER role 
(Antoniali, Malfatti, and Tell 2017) that will be further discussed. 
The  ape1  gene is mapped on chromosome 14q11.2-q12 consisting of 
five exons and four small introns for a total of 2.6 kbp (Robson et al. 1992). Its 
transcription is regulated during the cell cycle with an increased transcription 
during the S-phase (Rivkees and Kelley 1994). 
APE1 is a monomeric protein of about 36 kDa, composed of 318 amino 
acids, member of the homologous family comprising E.coli exonuclease III. 
APE1 is structured in α/β-sandwich globular fold coupled to an unstructured 
part composed of first 48 amino acids in the N-terminal (Gorman et al. 1997).  
Two domains of APE1 can be functionally identified: 
- the N-terminal domain (1-127) deputed to protein-protein 
interactions and RNA interaction, as well as the redox-dependent 
activity toward different transcription factors (Fantini et al. 2010, 1); 
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- the C-terminal globular region (residues 61-318), responsible for the 
endonuclease activity (Tell et al. 2009, 1).  
APE1 undergoes different post-translational modifications in vitro as shown in 
Figure 7, although their effects in vivo are largely unknown.  
Only a PTM on APE1 has been well described in vivo  to be able to 
generate a truncated form of APE1. The first 33-amino acids located at the N-
terminal domain can be cleaved by an unknown Granzyme-like activity 
(Yoshida et al. 2003). This mutant form lacks the nucleolar localization signal 
(NLS) sequences and its ability to interact with other proteins. The N-terminal 
domain can be subjected to phosphorylation affecting APE1 stability. 
Phosphorylation inactivates APE1 endonuclease activity (Huang et al. 2010; 
Busso, Lake, and Izumi 2010), while APE1 redox activity is increased. Another 
interesting modification of the N-terminal domain of APE1 is acetylation of 
different Lysins including Lys27-35 cluster. Positive charges of this 
acetylatable lysine residues of APE1 are essential for chromatin association. 
Their acetylation affects the ability of the protein to interact with NPM1 
inhibiting APE1 accumulation into nucleoli (Lirussi et al. 2012; Busso, Lake, 
and Izumi 2010). Moreover, acetylation-mediated neutralization of the positive 
charges of the lysine residues induces a conformational change that enhances 
the AP endonuclease activity of APE1(Roychoudhury et al. 2017; Fantini et al. 
2010). Acetylation of APE1 was detected in a subtype of breast cancer 
demonstrating how an aberrant modulation of APE1 has detrimental 
consequences on cell stability (Poletto et al. 2012).		
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Figure 7 Structural and functional organization of APE1 protein 
a)  Each domain of APE1 has a specific function. Specifically, the N-terminal domain 
is deputed on nucleolar localization, protein-protein interaction, structure-dependent 
nucleic acid binding and redox activity. The C-terminal domain is deputed on the 
endonuclease activity. On the right side, amino acids essential for the relative activity 
are reported. (Poletto et al., 2016) b) Cartoon representation of the complex 
APE1:DNA product. APE1 is shown in yellow while the site of cleavage is indicated 
with a red arrow. THF indicates the remaining abasic site. (Freudenthal et al., 2015) 
a) b) 
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APE1 possesses different nuclease activities on DNA as well as RNA. 
Regarding its role in the BER pathway, APE1 is able to cleave the DNA 
phosphodiester backbone to the 5’ side of abasic sites. The cleavage produces 
SSB with a 3’-hydroxyl (OH) and a 5’-deoxyribose phosphate ends (dRP). 
Subsequent BER enzymes are deputed to filling and sealing the gap.  
The active site of the endonuclease activity is defined by several 
residues including His-309, Glu-96, Asp-283, Thr-265, Tyr-171, Asn-68, Asp-
210, Asp-70 and Asn-212, most of them are involved in a hydrogen bonding 
network formation (Beernink et al. 2001; Mol et al. 2000; Freudenthal et al. 
2015a). After the abasic site recognition, APE1 discriminates the lesion, 
excluding any normal dNTP, and stabilizes an extra-helical DNA backbone 
distorted about 35°.  
An important characteristic of APE1 activity is its dependence on 
magnesium ions. Upon formation of the initial recognition APE1-DNA complex, 
an additional rearrangement is needed to allow the efficient execution of the 
hydrolytic reaction. The presence of Mg2+ (or Mn2+), positioned in the active 
site E96 is important to promote this rearrangement (Erzberger and Wilson 
1999). As Figure 8 shows, the cleavage reaction, metal ion-dependent, needs 
also a molecule of water acting as a nucleophile (Freudenthal et al. 2015a).  
Moreover, although replacement of Asp-90, Asp-308 or Glu-96 by 
alanine does not significantly compromise nucleic acid binding, a reduction in 
enzymatic activity is observed (Barzilay et al. 1995).  
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An alternative pathway of BER, in which APE1 has a fundamental role 
as endonuclease, is the Nucleotide Incision Repair (NIR) pathway.  
NIR pathway works as a backup of BER when glycosylases are absent 
or inactive on the damage, thus insuring a correct removal of damaged bases 
as a result of oxidative stress (Gros 2004a; Timofeyeva et al. 2011; Ishchenko 
et al. 2006; Gelin et al. 2010; Daviet et al. 2007a; Redrejo-Rodríguez et al. 
2016). In that pathway, APE1 processes directly at the 5’ of the oxidized base 
without the intervention of a glycosylase leaving fragments with 3’ OH 
extremities (Gros 2004a). After the removal of the dangling damaged 
nucleotide by FEN1 (Kim, Biade, and Matsumoto 1998; Klungland and Lindahl 
1997), the DNA backbone can be efficiently repaired by DNA polymerases. In 
this way, the NIR action avoids the generation of potentially toxic AP-
intermediates (Ischenko and Saparbaev 2002).  
Several works have focused their attention on the NIR activity of APE1, 
by defining the substrates that are efficiently processed by APE1 including 5,6-
dihydro-2’-deoxyuridine (DHU), 5,6-dihydrothymidine (DHT), 5-hydroxy-2’-
deoxyuridine (5OHU) (Gros 2004a; Ischenko and Saparbaev 2002), 5-
hydroxy-2’-deoxycitidine (5OHC) (Daviet et al. 2007a; Gros 2004a; Ischenko 
and Saparbaev 2002), alpha-2’-deoxynucleosides (αdA, αdT and αdC) (Ide et 
al. 1994; Gros 2004a), the majority of which are generated under ionizing 
radiation and certain drugs. This non-canonical activity of APE1 could explain 
how the lack of DNA glycosylases does not render cells or mice more sensitive 
Figure 8 Catalytic mechanism of APE1 processing when an AP site is present in 
DNA 
After a first DNA recognition, APE1 is able to cleave in a Mg2+ dependent reaction the 
abasic site. E96, catalytic site of the protein, is fundamental to promote the cleavage 
reaction. (Erzberger and Wilson, 1999) 
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to oxidative agents and IR (Alseth et al. 1999; Blaisdell and Wallace 2001; 
Friedberg and Meira 2003). This is in contrast to what is observed in APE1 
deficient cells (Ludwig et al. 1998; Ramotar et al. 1991; Cunningham et al. 
1986). In fact, the haploinsufficiency in AP endonuclease activity in mice leads 
to reduced survival associated with an increased cancer susceptibility when 
exposed to oxidative stress (Meira et al. 2001). 
Moreover, what emerged is that the NIR activity of APE1 can be 
observed under environmental conditions dramatically different in terms of 
salts, pH and structural involvement compared to the classical BER activity. 
The optimal conditions for NIR activity are very similar to 3’ → 5’ exonuclease 
APE1 activity, characterized by a pH around 6.4 - 6.8, and a KCl concentration 
of 50 mM (Gros 2004a). Moreover, NIR is more active at 100-fold lower MgCl2 
concentration compared to AP-endonuclease activity (Gros 2004a). 
Interestingly, the N-terminal domain of APE1 deputed to protein-protein 
interaction and indispensable to redox activity but not AP-endonuclease 
activity (Izumi et al. 2005a), is, on the contrary, essential for the NIR activity 
(Gros 2004a). Moreover, Timofeyeva et al. demonstrated that Lysine in 
position 98 contributes significantly in the 5’ - phospodiester bond hydrolysis 
of DNA substrate, but not to the dissociation of the enzyme from the product 
complex (Timofeyeva et al. 2011). The substitution of this amino acid 
influences the NIR activity more than BER, demonstrating that the active site 
of APE1 involved in NIR and BER pathways is the same, but different 
conformations of it are responsible for the incision of unrelated lesions as AP 
sites and DHU, substrate of BER and NIR, respectively (Timofeyeva et al. 
2011). 
APE1 is also active on damaged single stranded DNA suggesting a new 
role in transcription, replication and/or recombination (Marenstein, Wilson III, 
and Teebor 2004). APE1 has DNA 3’-phosphatase and has a 3’-5’ DNA 
exonuclease activity in vitro on mismatched deoxyribonucleotides at the 3’ 
termini of nicked or gapped DNA (Chou and Cheng 2003; Wilson 2003; Izumi 
et al. 2005b). Again, for the exonuclease activity of APE1, specific saline 
conditions are essential (Chou and Cheng 2003). 
Moreover, a lot of data supports the role of APE1 in the RNA 
metabolism (Tell, Wilson, and Lee 2010) including: 
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• APE1 cleaves AP-site containing single stranded RNA in  in vitro assay 
(Berquist, McNeill, and Wilson 2008); 
• APE1 physically associates with ribosomal RNA (rRNA) allowing its 
correct processing (Vascotto et al. 2009); 
• APE1 interacts with a wide variety of proteins involved in rRNA processing, 
including Nucleophosmin (NPM1) (Vascotto et al. 2009).  
It has been proposed that APE1/NPM1 interaction inhibits APE1 binding 
to RNA through direct competition. At the same time, NPM1, binding rRNA, 
is able to mask rRNA from APE1. In tumoral cells, in which APE1 and 
NPM1 levels and the interaction among them are higher than in healthy 
cells, APE1/NPM1 inhibitors, characterized in our laboratory, could be a 
chance in order to impair this interaction (Poletto, Malfatti, et al. 2016). 
Other APE1 interactors involved in RNA metabolism are YB-1 
(Chattopadhyay et al. 2008, 1) and hnRNP-L (Kuninger et al. 2002).  
• As other members of exonuclease III family, APE1 conserves the RNase 
H activity which allows the degradation of the RNA strand of a DNA-RNA 
duplex in vitro. Several residues are essential for this activity, including 
Asp-219, important for RNA and DNA enzymatic activity and binding, and 
Asp-90, Asp-308 and Glu-96 involved in RNA and DNA enzymatic activity 
but not in the binding activity (Barzilay et al. 1995).To date, the biological 
effect of this function is still unknown.  
• The catalytic site of the endonuclease activity of APE1 has an interesting 
endoribonuclease function of APE1 (Barnes et al. 2009; W.-C. Kim et al. 
2011) that preferentially cleaves at UA, UG and CA sites in single-stranded 
regions of RNAs. Amino acids involved in the endoribonuclease activity 
are several including: N68, D70, Y171, D210, F266, D308 and H309.  In 
vitro experiments, obtained by Barnes et al., have demonstrated that this 
function is explicated on the proto-oncogene c-myc RNA, feature of the 
development of several tumors. APE1 is able to cleave, via its 
endoribonuclease activity, a specific coding region of c-myc mRNA in vitro. 
It was demonstrated that APE1 regulates the stability of c-myc mRNA in 
cells. Moreover, upon knockdown of endogenous APE1, c-myc mRNA is 
specifically destabilized demonstrating that APE1 may control c-myc 
mRNA level and half-life in vivo (Barnes et al. 2009). 
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• APE1 has a weak 3’-5’ exoribonuclease activity (Chohan et al. 2015) 
removing a phosphoryl group from the 3’ end of RNA decay products. An 
interesting data on RNA nuclease activities of APE1 is that the protein 
does not require Mg2+. 
• Finally, recently discovered in our laboratory, APE1 has a role in pri-
miRNA processing and stability via association with the DROSHA-
processing complex during genotoxic stress (Antoniali et al. 2017). 
Finally, other important functions of APE1, different from its nuclease 
activities, regard its ability to work as a redox co-activator of several 
transcription factors that regulate gene expression, involved in cancer 
promotion and progression. Indispensable for redox function is the residue of 
cysteine in position 65. APE1 is able to control the transcriptional regulation of 
gene expression by keeping, in a reduced state, critical Cys residues of some 
transcription factors. The redox modulation enhances the DNA binding activity 
of several transcription factors including AP-1, p53, HIF-1alpha, NF-KB, CREB 
and Egr-1 (Tell et al. 2009, 1; Cesaratto et al. 2013; Fantini et al. 2008, 2010).  
Moreover, another still not-well characterized function of APE1 is its 
transcriptional repressor activity through binding to the negative calcium 
responsive elements (nCaRE). This function is promoted by PTH and the 
same APE1 promoters (Antoniali, Lirussi et al. 2014). 
Several clinical studies have observed that APE1, as well as other BER 
proteins, is involved in several types of cancer. For this reason, APE1 
represents a good candidate as chemotherapeutic target (Wilson and 
Simeonov 2010; Poletto, Malfatti, et al. 2016; Rai et al. 2013, 2012).   
As above anticipated, enzymes merely deputed to DNA repair, such as 
APE1, have also a role in RNA metabolism (Antoniali, Malfatti, and Tell 2017). 
For this reason, next paragraphs focus on the description of a relative new 
type of lesion involving RNA underlining the hypothesis of a role of APE1 in its 
processing.  
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4.4 Incorporation of ribonucleotides into DNA 
RNA:DNA hybrids are particular structures in which an RNA molecule is 
paired with a DNA molecule to form a precise configuration. Generation of 
these structures occurs physiologically in cells during processes such as DNA 
replication, DNA transcription, retroviral infection, retro-element mobilization 
and telomere elongation (Förstemann and Lingner 2005). If not properly 
processed, the presence of RNA:DNA hybrids induces harmful consequences 
to the genome integrity causing reducing fork speed with a replication-
transcription collisions and chromosomal break repair (Hamperl and Cimprich 
2014; Brambati et al. 2015).  
At least three types of RNA:DNA hybrids can be found in eukaryotic cells, 
which are represented in Figure 9:  
• ssRNA paired with ssDNA, in which a single strand molecule of 
RNA is complementary to a single molecule of DNA; 
• R-loop, in which the two DNA strands are separated with only 
one hybridized to RNA while the other is single stranded DNA; 
•  rNMPs embedded in DNA, when a single, or more, 
ribonucleotide(s) is/are embedded in a double stranded molecule 
of DNA. 
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Figure 9 Schematic representation of three RNA:DNA hybrids observed in 
eukaryotic cells 
ssRNA paired with ssDNA (upper), R-loop (middle) and single or more rNMPs 
embedded in DNA (bottom) are the best-represented form of RNA:DNA hybrids. 
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Although undesirable, rNMPs incorporation in DNA is a very frequent 
event, so that it is considered the most common type of ‘DNA damage’ 
occurring in normal cells (Williams and Kunkel 2014; Koh, Balachander, et al. 
2015).  
For this reason, in next paragraphs of this Thesis, the attention will be 
mostly focused on the rNMPs incorporation into DNA elucidating causes, 
repair, and inefficient repair-consequences of this phenomenon.  
4.4.1 Causes of rNMPs incorporation within DNA 
Starting from quantification data of the nucleotides rate into the cell, it was 
demonstrated the the rNTPs pool far exceeds the dNTPs pool under basal 
conditions (Koh, Balachander, et al. 2015; McElhinny et al. 2010) (Figure 10). 
Although the dNTP: rNTP ratio is variable, the amount of rNTPs is greater than 
the amount of dNTPs between organisms and tissues (Nick McElhinny et al. 
2010; Kennedy et al. 2010). The amount of rNTPs in S. cerevisiae is generally 
40–300 - fold higher than that of dNTPs in cycling cells (Nick McElhinny et al. 
2010; Crespan et al. 2016; Traut 1994) increasing the probability of incorrect 
rNMP incorporation during DNA replication and repair (Koh, Balachander, et 
al. 2015; Clausen et al. 2013; Nick McElhinny et al. 2010; Crespan et al. 2016). 
The greater amount of rNTPs compared to dNTPs, coupled with an 
imprecise activity of replicative polymerases (Koh, Balachander, et al. 2015; 
Clausen et al. 2013; Nick McElhinny et al. 2010; Crespan et al. 2016), would 
explain its high frequency, about more than 100 million rNMPs in mammalian 
DNA, transiently incorporated during each replication cycle. Replicative DNA 
polymerases carry an active site in which a bulky amino acid residue at the 
entry site discriminates dNTPs from rNTPs (Joyce 1997). DNA polymerases 
possess a 3’-exonucleolytic proofreading activity that, in addition to the DNA 
Mismatch repair (MMR) pathway, ensures a correct discrimination of the four 
different bases lowering the error rate to around 10-10 (Kunkel 2009). In this 
way, DNA replication proceeds with high fidelity.  
Thus, DNA polymerases are able to well discriminate rNTPs. Under 
conditions in which the rNTPs: dNTPs ratio is in favour of rNTPs, DNA 
polymerases can erroneously incorporate rNTPs than dNTPs (Joyce 1997; 
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Brown and Suo 2011). It has been estimated the potential rate of incorporation 
by DNA Polymerase α (around 1’900 rNMPs), DNA Polymerase ε (around 
9’600 rNMPs) and DNA Polymerase δ  (around 2’200 rNMPs) (Nick McElhinny 
et al. 2010; Marasco et al. 2017). Remarkably, the exonuclease activity results 
inefficient versus  this type of error (Figure 10). 
Further, if a damaged or a wrong base is incorporated into DNA, the 
replicative fork is stopped. To counteract the deleterious effects of the 
replicative DNA polymerase stalling, cells possess a specialized system called 
translesion DNA synthesis (TLS) bypass. In this pathway, translesion 
polymerases that have a large active site allow lower base and sugar 
selectivity allowing to bypass the damage. Again, under conditions in which 
the amount of rNTPs is much higher than dNTPs into the cell, the risk of mis-
incorporation increases. This mechanism, if on one hand, contributes to cell 
survival promoting DNA replication, on the other may fix a damage/mutation 
(Sassa et al. 2016).  
One additional source of rNMPs in DNA may derive from the mechanism 
of replication of the DNA lagging strand. In order to initiate, DNA polymerases 
need a 10-ribonucleotides primer, synthetized by a RNA primase. Starting from 
this primer, a DNA fragment of about 200 nucleotides is synthetized, called 
Okazaki fragments (Clausen et al. 2013). Subsequently, RNA primers are duly 
removed to allow the filling of the DNA gap and the generation of a continuous 
DNA strand (Rossi and Bambara 2006). If these primers are not completely 
eliminated, isolated rNMP/s can permanently persist within genomic DNA 
(Figure 10).  
Recently, it has been found that rNMPs are also incorporated by DNA 
polymerase 𝜸 in mitochondrial DNA, in heavy- as well as light-strand DNA. 
Increased levels of embedded ribonucleotides, affecting mtDNA stability and 
impairing new rounds of mtDNA replication, may contribute to a new 
pathogenic mechanism (Berglund et al. 2017). Further studies are needed 
regarding the consequences of the rNMPs incorporation in mtDNA and their 
repair processing. 
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Finally, although not fully explored yet, generation of hydroxyl radicals from 
oxidative stress could be the cause of conversion of the deoxyribose sugar 
into ribose in vitro and in vivo (Randerath et al. 1992). This can happen both 
in the cellular nucleotide pool or directly into the DNA.  
Additional data are needed in support to this hypothesis. 
 
 
4.4.2 Effects of rNMPs incorporation into the DNA 
Being a relative new discover in the DNA repair field, studies regarding 
the consequences of rNMP incorporation in DNA are not abundant and the 
majority of them are conducted only in yeast models.  
Considering that the difference between rNTPs and dNTPs is the 
presence of hydroxyl (OH) group in 2’ position of the sugar, when a rNTP is 
erroneously embedded into DNA, its presence highly destabilizes the DNA 
backbone.  
Several studies were carried on in order to try to better explain the 
effects of this lesion on DNA. It has been demonstrated that the presence of 
one or more rNMPs increases the susceptibility to DNA hydrolysis, and strand 
Figure 10 Major causes of rNMP incorporation within DNA  
Schematic representation of a double helix of DNA (blue dots) in which one or more 
ribonucleotides (red dots) are embedded in DNA. Different are the causes of rNMPs 
incorporation in DNA including, starting from left, high levels of rNMPs compared to 
dNMPs in the cellular nucleotide pool, inefficiency into sugar discrimination by several 
DNA Polymerases (middle), and finally residue rNPMs from RNA primers used to 
generate Okazaki fragments (right). (Modified from Nick McElhinny et al., 2010 and 
Griffiths et al., 2010) 
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cleavage, under basal conditions (Chiu et al. 2014). From data obtained by 
Atomic Force Microscopy (AFM), X-ray crystallography and high-resolution 
NMR solution structures, it was demonstrated that this lesion alters DNA 
elasticity and structure in a sequence dependent manner. Indeed, the lesion 
locally perturbs the structure asymmetrically on the 3’ side of the lesion in both 
the riboguanosine-containing and the complementary strand of the duplex 
(Chiu et al. 2014; Koh, Chiu, et al. 2015; Evich et al. 2016). Moreover, it has 
been reported that the presence of a single rNMP in DNA changes the global 
conformation of DNA from B-form to A-form DNA, although it is dependent on 
the size, sequence and crystallization conditions (Ramakrishnan and 
Sundaralingam 1993a, [b] 1993). Finally, it affects the activity and function of 
several DNA-interacting proteins increasing the DNA fragility and mutability 
(Williams and Kunkel 2014; Caldecott 2014).  
Recently it has also seen that rNMPs in DNA act as template for DNA 
synthesis (Storici et al. 2007; Shen, Nandi, et al. 2011), although the DNA 
polymerases processivity on rNMP tracts is reduced (Storici et al. 2007).  
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4.5 Ribonucleotide Excision Repair pathway 
Since the presence of ribonucleotides into DNA affects genomic 
stability, eukaryotic cell needs the action of enzymatic pathway deputed to 
rNMPs removal called Ribonucleotide Excision Repair (RER) pathway (Reijns 
et al. 2012) (Figure 11).  
The first and main enzyme acting in the RER pathway is RNase H2, a 
nuclear enzyme that cleaves at a single, or more ribonucleotides embedded in 
DNA. RNase H2 incises the DNA backbone on the 5’-side of the 
ribonucleotide. Although RNase H1 is a protein similar to RNase H2, it is not 
active on a single rNMP within DNA and it is not able to promote the starting 
of RER pathway (Sparks et al. 2012). Then, flap endonuclease (Fen1) incises 
3’ side of the rNMP to release it, leaving a gap that will be filled by DNA 
Polymerase δ or ε and ligated by Ligase I (Sparks et al. 2012; Rydberg and 
Game 2002) (Figure 11). 
As happens for the BER, all RER enzymes also work in a coordinate 
way in order to guarantee the correct repair of the damaged DNA. Moreover, 
all of the four enzymes working in RER pathway show interactions with PCNA 
which has a stimulating functional role on these enzymes (Sparks et al. 2012; 
Bubeck et al. 2011). 
Surprisingly, the RER pathway is highly conserved from Eukaria to 
Archea to Bacteria (Heider et al. 2017). An interesting difference is about 
RNase HII, the prokaryotic corresponding protein of the eukaryotic RNase H2. 
RNase HII is in monomeric form in Archea and Bacteria differently from the 
trimeric RNase H2. Although not still well demonstrated, the role of the three 
subunits composing the eukaryotic RNase H2 is associated with other more 
important biological functions of the protein.  
Published data have observed that some effects of the RER inactivity, 
principally due to RNase H2 defects, result in S-phase checkpoint activation 
(Williams et al. 2013) and slow cell growth (McElhinny et al. 2010). Moreover, 
as expected, a lot of rNMPs are left unrepaired into the genome. 
	
	 	
	 	 Introduction 
	40	
 
In next paragraphs, a deeper explanation about the structure and 
function of RNase enzymes will be done with a brief remark about pathologies 
associated to RNase H2. 
 
 
 
 
	 	
Figure 11 Principal steps of Ribonucleotide Excision Repair Pathway 
rNMP is specifically recognized and incised by RNase H2 protein. The synchronized 
work of Polδ or ε, Fen1 and Ligase I allow the complete repair of the damage. (Heider 
et al., 2017) 
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4.5.1 Ribonuclease H enzymes 
Generally, DNA:RNA hybrids are efficiently processed by a class of 
enzymes called RNase H, a family of endoribonucleases able to cleave the 
RNA strand in a sequence-non-specific manner producing short 
oligonucleotides and generating 5’-phosphate and 3’-hydroxy free groups. At 
the same time, a single strand DNA is left and used as a template to 
reconstitute the double strand DNA (Ohtani et al. 1999).  
Eukaryotic RNase H family includes two classes of enzymes: RNase 
H1 (type 1) and RNase H2 (type 2). As will be addressed in the next 
paragraphs, these two proteins differ from each other by amino acids 
sequence and biochemical properties. On the contrary, they partially share the 
substrate specificity. Indeed, they are able to cleave at the 5’ side of RNA 
phosphodiester bonds (Nowotny et al. 2007; Chapados et al. 2001), using 
bivalent cations such as Mg2+ and Mn2+ (Hausen and Stein 1970) (Figure 12). 
 
 
 
 
 
 
 
  
Figure 12 Activity of RNase H enzymes on DNA  
Schematic representation of a double helix of DNA (blue dots) in which one or more 
ribonucleotides (red dots) are embedded in DNA. Scissors indicate RNase H proteins. 
RNase H1 is able to cleave at the 5’side of at least four rNMPs embedded in DNA 
whereas RNase H2 also cleaves at the 5’side of a single rNMP embedded in DNA.  
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4.5.1.1 RNase H1 
Human RNase H1 is a monomeric protein composed of 286 aminoacids 
with a molecular weight (MW) of about 32,200 Da.  
RNase H1 is homologous to the prokaryotic RNase HI and the RNase 
H domain of retroviral reverse transcriptase (Cerritelli and Crouch 2009). Its 
localization is mostly nuclear, although its function, in this compartment, is still 
not understood. Moreover, when localized into the mitochondria, RNase H1 
exerts an essential role in the mtDNA replication.  
The typical organization of eukaryotic RNase H1 consists of different 
domains each having a specific function. First, the most important domain is 
exerted by the H-Domain (RNase H Domain) localized at the C- terminal. 
Through this domain, RNase H1 is able to process different RNA: DNA hybrids 
structures including R-loops and tract composed of at least four 
ribonucleotides embedded in DNA. The prerogative of this function, is the 
recognition of both DNA:RNA hybrid strands (Lima et al. 2007). Its ability to 
bind various nucleic acids is mediated by the HBD (Hybrid Binding Domain), 
localized at the N-terminal. Upstream of the HBD, many, but not all, eukaryotic 
RNase H1 possess an MTS (Mitochondrial Targeting Sequence), required for 
protein localization within mitochondria. RNase H1 works by removing RNA 
primers used for mtDNA replication (Cerritelli et al. 2003). As demonstrated, 
rnaseh1  null mouse embryos arrest development due to a failure into the 
amplification of mitochondrial DNA (mtDNA). Finally, the CD (Connection 
Domain), a linker sequence between the N-terminal HBD and the C-terminal 
RNase H domain allows the N- and C-terminal regions to move rather freely in 
and around the substrates. This region can be variable in length and 
composition, suggesting a putative role in the protein-protein interaction.  
4.5.1.2 RNase H2 
RNase H2, differently from the monomeric prokaryotic RNase HII, is a 
heterotrimeric protein including three subunits, subunit A, around 299 
aminoacids (MW ≈ 33,400), subunit B, around 308 aminoacids (MW ≈ 34,800) 
and subunit C, of 164 aminoacids (MW ≈ 17,800) (Cerritelli and Crouch 2009; 
Jeong 2004) (Figure 13).  
Although sharing with RNase H1 the same endoribonuclease function 
on degrading single stranded RNA in R-loop structures, the function of 
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cleaving the 5’ side of a single mis-incorporated rNMP present in a DNA 
molecule belongs only to RNase H2 (Hiller et al. 2012; Cerritelli and Crouch 
2009).  
The ability of the eukaryotic RNase H2 to cleave mis-incorporated 
rNMPs is attributed to its catalytic domain, i.e. subunit A. It has been 
demonstrated that subunits B and C form a complex that may serve as a 
nucleation site for the subunit A to form the catalytic active protein, or for 
possible interaction with other protein partners to support other functions. 
Thus, although the exact function of the accessory components, subunits B 
and C, are not still fully understood, their presence may confer important roles 
to the whole protein complex. In support of this, published data have 
demonstrated that RNase H2 interacts with PCNA (Meslet-Cladiére et al. 
2007; Chon et al. 2009). Specifically, subunit B possesses a specific motif 
defined by the sequence QxxmxxΦΦ where x is any residue, m is aliphatic 
hydrophobic and Φ is an aromatic called PIP box (PCNA-interacting peptide). 
The PIP box, localized at C-terminus of the protein, is required for the 
interaction of RNase H2 with PCNA, a fundamental protein that clamps around 
double strand DNA during DNA replication allowing the transport of elongating 
polymerases and other factors involved in Okazaki fragment processing to the 
replication fork. The interaction between RNase H2 and PCNA mediated by 
PIP sequence on the subunit B leads to an exclusive RNase H2 localization at 
replication foci (Bubeck et al. 2011). It is not fully known if the interaction with 
PCNA is limited to the RNase H2 localization to the replication foci or involved 
other functions. Moreover, the consequences of this interaction are not still 
completely understood. 
Although it has been demonstrated that this interaction does not affect 
the catalytic activity of RNase H2 in vitro (Bubeck et al. 2011; Chon et al. 2009), 
it opens new issues about the involvement of RNase H2 in replication/repair 
processes.  
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Figure 13 Representation of the subunits A, B and C, components of the 
eukaryotic RNase H2  
The core of the catalytic domain (RNASEH2A; blue) is stacked on the interwoven 
auxiliary RNASEH2B (green) and RNASEH2C (red) subunits (left). RNase H2 
structure colored following the electrostatic surface potential (+9kT/e to −9 kT/e; 
electropositive in blue and electronegative in red) on the solvent accessible surface 
(right). (Reijins et al., 2011) 
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4.5.2 Pathologies associated with RNase H2 protein 
The essential role of RNase H2 in cell viability is demonstrated by data 
in which defects in RNase H2, that abolish the enzymatic activity, result 
embryonically lethal in mice (Reijns et al. 2012; Hiller et al. 2012). For this 
reason, very little is known about a putative association between RNase H2 
defects and disorders/disease.  
From the literature, it is well known that RNase H2-null murine 
embryonic fibroblasts (MEFs) activate a p53-dependent damage response 
(Cerritelli and Crouch 2009). Same results were observed also in humans: 
specifically, when RNase H2 is partially absent or catalytically-inactive, the 
cells arrest in S and G2/M phases activating the DNA damage response 
(DDR). Moreover, a high rate of rNMPs, incorporated into DNA, has been 
detected causing a consequent block of the DNA replication (Lazzaro et al. 
2012; Pizzi et al. 2014).  
Interesting results have underlined the association between biallelic 
mutations in each of the three subunits of RNASE H2 and the onset of an 
inflammatory disorder called Aicardi Goutières syndrome (AGS) (Crow et al. 
2006) (Figure 14).  
AGS is a rare congenital encephalopathy with an autosomal recessive 
hereditary phenotype and symptoms similar to those of congenital viral 
infection (Crow et al. 2006; Rice et al. 2007). The signs observed in patients 
are several, including: cutaneous symptoms, acquired microcephaly, brain 
white matter abnormalities, intracranial calcifications and an elevated number 
of white cells (Crow and Manel 2015). 
It has been well-defined how AGS shares features with the systemic 
lupus erythematosus (SLE), a complex autoimmune pathology characterized 
by the presence of antibody direct against antigens, including nucleic acids. In 
SLE pathologies, including AGS, an increase of antiviral type I IFN levels in 
the cerebrospinal fluid stimulates loss of B cells self-tolerance with a following 
production of autoantibody. After antibody-antigen recognition, immune 
complexes are generated with a consequent deposit in the capillary 
(Pendergraft and Means 2015).  
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Several genes, encoding for nucleic acid repair enzymes, result 
mutated in AGS including TREX1, SAMHD1, ADAR1 and RNASEH2 (Figure 
14). Altered RNase H2 function in AGS patients may result in increased level 
of rNMPs in DNA which induces a innate immune response through the IFN𝜸	
signaling and genomic instability with activation of the DNA damage response 
signaling (Brzostek-Racine et al. 2011; Reijns et al. 2012; Pizzi et al. 2014). 
Moreover, the interesting observation that mutations found in the accessory 
subunits B and C are linked with AGS pathology would explain their 
importance in the protein complex (Chon et al. 2009) (Figure 14). 
Finally, a screening of gastric cancers has found different mutations in 
different genes coding for several proteins involved in protein synthesis, 
genomic stability maintenance, metastasis, metabolic improvement, cell 
signaling pathways and chemoresistance. Among them, mutations in the gene 
coding for the subunit B of RNase H2 has emerged (Mottaghi-Dastjerdi et al. 
2015). The association between mutated RNase H2 and cancer needs further 
study.  
Further studies are ongoing to better understand the multiple roles of 
RNase H2 in DNA replication/repair, and genome integrity. Further studies are 
also needed regarding its pathological implications with the aim of finding 
therapeutic strategies. 
 
Figure 14 RNASEH2 mutations promoting systemic autoimmunity  
Polymorphisms in all the three subunits composing RNase H2 identified in individuals 
with SLE are shown in bold above. Below are indicated the variants occurring in 
control population. (Günther et al., 2015) 
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4.6 Different repair systems of rNMPs embedded in DNA 
A still open question is whether other DNA repair systems, other than 
the RER pathway, may remove rNMPs embedded in DNA (Williams et al. 
2013; Williams, Lujan, and Kunkel 2016).  
Trying to answer to this issue, data published have discovered that 
enzymes belonging to DNA repair pathways can work as a back-up 
mechanism when the RER mechanism is inefficient. Among them, 
Topoisomerase I (Top1) can compensate RNase H2 deficiency (Williams et al. 
2013; Sekiguchi and Shuman 1997). Top1 is an essential enzyme deputed to 
resolve DNA supercoils generated during replication and transcription 
(Capranico, Marinello, and Chillemi 2017). It was demonstrated that Top1 is 
able to cleave at the 5’-side of rNMPs (Williams et al. 2013) generating as DNA 
ends, 5’-OH and cyclic 2’-3’ phosphate termini. Then, the cleavage is followed 
by nick processing by Srs2–Exo1 (Potenski et al. 2014; Kim et al. 2011).  
A role for the Nucleotide Excision Repair (NER) pathway has been also 
hypothesized. This pathway generally excises bulky and non-bulky DNA base 
adducts (Reardon and Sancar 2005). Because of, the rNMPs incorporation 
distorts the DNA backbone, NER enzymes could be a good candidate in 
repairing this type of damage.  
Data obtained from Bacteria show an involvement of NER factors in the 
removal of rNMPs in DNA (Vaisman et al. 2013; Lindsey-Boltz et al. 2015), 
contrarily to what is observed for human NER factors which are not involved 
in rNMPs repair (Lindsey-Boltz et al. 2015). Evidences about this difference 
were not improved. It is hypothetical that NER factors might have been lost 
this function during evolution. 
Differently, data performed in vitro have shown that the mismatch repair 
(MMR) mechanism can target mismatches with rNMPs both in E. coli and S. 
cerevisiae  genomic DNA (Shen, Koh, et al. 2011).  
To date, there is no evidence that the BER mechanism could play any 
role in removing rNMPs from the genome. Increasing the knowledge in this 
field represents a stimulating goal in the DNA repair world and in the 
pathogenesis associated with this type of damage. 
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4.7 Beneficial effects of rNMPs incorporation  
Mis-incorporation of ribonucleotides into DNA has been confirmed as a 
deleterious injury for the cell that, when not repaired, could destroy the genome 
integrity. A new vision has reinterpreted this phenomenon, hypothesizing a 
putative helpful and physiological effect of it for the cell.  
Different are the evidences in support of this hypothesis.  
In fission yeast, two rNMPs, consecutively incorporated in DNA, may 
mark the nascent DNA strand, initiating programmed mating-type switching 
(Sayrac et al. 2011). 
Further, a recent work demonstrated that DNA polymerase mu (Pol µ), 
a member of the X-family of DNA polymerases operating in the repair of double 
strand breaks, possesses an open active site that does not allow a correct 
discrimination of the dNTPs (Brown et al. 2010; Ruiz et al. 2003). In other 
words, Pol µ is not able to discriminate the 2'-OH group of the sugar moiety 
and, for this reason, it will insert rNTPs as well as dNTPs during the NHEJ 
pathway (Martin et al. 2013). Although this could be considered detrimental for 
the cell, actually it might be advantageous. Inserting rNTPs with a higher base 
fidelity compared to dNTPs (Martin et al. 2013), Pol µ stimulates the DNA 
ligase IV and promotes the NHEJ mechanism (Nick McElhinny and Ramsden 
2003).  
Finally, another interesting hypothesis concerns a dual role of RNase 
H2. After the nicking at the 5’ side of rNTPs embedded in DNA by RNase H2, 
the remaining gap may enhance the efficiency of mismatch repair pathway. 
The MMR pathway, stimulated by the work of RNase H2, scans the DNA 
repairing eventual damages (Nick McElhinny et al. 2010; Lujan et al. 2013). 
Thus, the presence of rNTPs, when efficiently repaired by RNase H2, could 
stimulate the MMR initiation.  
To date, data in support of putative beneficial effects of the rNMPs 
incorporation in DNA are few. Thus, further studies are ongoing in order to 
improve this open point. 
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4.8 Innovative tools for mapping rNMPs in DNA 
An open point is understanding how the abundance and the distribution of 
ribonucleotides incorporated into DNA could change in different cells and 
under different stress conditions.  
A step forward to go deeper on this topic, is represented by the 
development of different sophisticated approaches (Jinks-Robertson and Klein 
2015), including Ribose-seq analysis (Koh, Balachander, et al. 2015), 
hydrolytic end-sequencing (HydEn-seq) analysis (Clausen et al. 2015), 
polymerase usage sequencing (PU-seq) analysis (Daigaku et al. 2015) and 
embedded ribose-sequencing (emRibo-seq) (Reijns et al. 2012).  
All these approaches are able to efficiently tag the position of rNMPs within 
duplex DNA. They start with the processing of rNMPs embedded in DNA 
through NaOH treatment, that allows creating a basic environment promoting 
the alkaline cleavage of individual rNMPs present within DNA, thus generating 
fragments with terminal 2’,3’-cycling phosphates or 2’-phosphates (PU-seq, 
HydEn-seq and Ribose-seq), or mediating RNase H2 cleavage at the 5’ termini 
of rNMPs generating 3’ OH termini (EmRibo-seq). Once isolated, these DNA 
products are isolated, amplified, and after that, sequenced with different 
sequencing approaches (Figure 15).  
Use of these high-throughput tools has allowed obtaining more precise 
information about the distribution and abundance of rNMPs into the DNA.  
From data obtained in yeast, it has been observed that rNMPs are 
incorporated into mitochondrial and nuclear DNA to a similar extent in a 
‘hotspot’ manner (Koh, Balachander, et al. 2015). Moreover, in both nuclear 
and mtDNA, rCMP and rGMP are incorporated more frequently than the other 
nucleotides. Finally, the number of rNMPs identified per nuclear chromosome 
was found to be proportional to chromosome size (Koh, Balachander, et al. 
2015). Quantitative approaches have estimated a 600 thousand rNMPs in 
budding yeast genome and over 100 million in mouse genome (Williams, 
Lujan, and Kunkel 2016).  
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Figure 15 Summary of the four approaches developed to map rNMPs in DNA  
In PU-seq, HydEn-seq and ribose-seq, alkaline hydrolysis is used in order to isolate 
rNMPs-containing fragments that will be subsequently sequenced by Illumina 
methods. In EmRibo-seq, RNase H2 is used to cleave rNMPs and isolate the 
fragments with 3’ OH termini that will be later sequenced by Ion torrent sequencing. 
(Jinks-Robertson and Klein, 2015) 
	  Aim of this Study 
5. Aim of this Study 
The oxidation of biological molecules including nucleic acids is a very 
frequent phenomenon due, principally, to oxidative stress from endogenous 
and exogenous sources.  
In particular, oxidation of RNA may have a fundamental significance for cell 
biology. For example, Zhan et al. have been reported that oxidized RNA 
compartmentalizes in cytoplasmic loci distinct from stress granules (Zhan et 
al. 2015). A recent quantitative analysis shows the presence of an atypical 
amount of oxidized RNA in Alzheimer’s disease patients, highlighting a link 
between oxidized RNA and cell pathogenesis. Moreover, studies on 
investigating the biological effect of oxidatively and abasic damaged RNA 
demonstrated that these molecules interfere substantially with mRNA 
transcription (Kamiya et al. 2007) and ribosomal translation (Calabretta, 
Kupfer, and Leumann 2015). Although it was demonstrated that abasic RNA 
is processed by the BER pathway component, APE1 (Vascotto et al. 2009), 
data on the processing of oxidized RNA and the role of a specific glycosylase 
involved are missing.  
Recently, the incorporation of ribonucleotides into the DNA has been 
better described as a new type of damage, caused during several physiological 
processes, such as replication (Williams, Lujan, and Kunkel 2016). The RER 
pathway represents the most important pathway involved in the removal of 
rNMPs embedded in DNA. Published data have demonstrated that well-known 
DNA repair pathways, including the MMR and the NER pathways, are not 
active when the RER does not work, as happens in some disorders.  
To date, one open question is finding which DNA repair mechanisms 
are active as back-up when the RER does not work. 
Moreover, it can be hypothesized that, among many millions rNMPs that 
are introduced in the mammalian genome per cell cycle (Williams, Lujan, and 
Kunkel 2016), damaged rNMPs (such as abasic and oxidized) can also be 
incorporated into the DNA. In fact, RNA molecules, as well as rNMPs present 
in the nucleotide pool, are also susceptible to oxidative insults (Randerath et 
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al. 1992; Moreira et al. 2008). The existence of abasic and oxidized rNMPs 
(such as 7,8-Dihydro-8-oxo-riboguanosine) in DNA and their repair represent 
an intriguing reason for study.  
In this context, there is high likelihood that the BER pathway could be 
the best candidate in the processing of unmodified and modified rNMPs in 
DNA. The BER pathway works in the presence of non-bulky lesions generated 
by several damaging agents including oxidative stressors. Among BER 
enzymes, APE1 has a special role for all its multiple functions in cell biology 
and for its frequent involvement in different human pathologies ranging from 
neurodegenerative disorders to cancer (Li and Wilson 2014). Its role in the 
BER pathway is primarily due to its ability to act as 5’ endonuclease, cleaving 
deoxy- abasic sites in DNA and ribo- abasic sites in RNA (Tell, Wilson, and 
Lee 2010; Vascotto et al. 2009; Berquist, McNeill, and Wilson 2008). But its 
involvement in the RNA world goes over, being able to have 3′-RNA 
phosphatase and a weak 3′-5′ exoribonuclease activities (Chohan et al. 2015). 
Moreover, APE1 is requested in pri-miRNA processing and stability via 
association with the DROSHA-processing complex during genotoxic stress 
(Antoniali et al. 2017). Finally, APE1 is involved in the nucleotide incision repair 
(NIR) pathway on modified bases, such as 5,6-dihydro-2’-deoxyuridine, 5,6-
dihydrothymidine, 5-hydroxy-2’-deoxyuridine, 5-hydroxycytosine, in which, 
bypassing the action of specific glycosylases, directly cleaves the modified 
bases (Gros 2004b; Daviet et al. 2007b; Mazouzi et al. 2013).  
Identifying whether the BER pathway, and especially APE1, may target 
normal and modified (abasic and oxidized) rNMPs in DNA represents a new 
amazing non-canonical role of this multifunctional protein that may help to 
better understand the mechanism of genotoxicity of reactive oxygen species 
as well as the function and the impact of BER defects in the molecular 
mechanism of different human diseases. 
Thus, this Thesis has the purpose to show our data, obtained using 
sophisticated in vitro assay, in which different proteins belonging to the RER 
and the BER pathways were tested on unmodified and modified (abasic and 
oxidized) rNMPs embedded in DNA oligonucleotides, in order to discover the 
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existence of a DNA repair pathway specifically involved in the processing of 
these types of damage. 
	 	 Material and Methods 
6. Materials and Methods 
6.1 Synthetic oligonucleotides description and annealing 
conditions 
All oligonucleotides used in this study are listed in Figure 16a. 
Ribo- 1’OH abasic containing oligonucleotide, ss_rOH, were purchased from 
Dharmacon (GE Healthcare, Lafayette, CO, USA). The 26-mer oligonucleotide 
containing a tetrahydrofuran, ss_dF, and its reverse complementary sequence 
ss_dC, were synthesized from Metabion International AG (Steinkirchen, 
Germany). The 25-mer dG-, rG-, d8oxoG- containing oligonucleotides and 
complementary oligonucleotides were synthesized from Metabion 
International AG (Steinkirchen, Germany) (Figure 16b). 
All oligonucleotides were labelled with either IRDye700, IRDye800 
fluorophores or Cyanine5 at 5’ end, purified through RP-HPLC, checked in 
Mass Check and re-suspended in RNase- and DNase- free water. Synthesis 
of oligonucleotide containing an internal ribose 8-oxo-guanosine (r8oxoG) and 
an IRDye700 fluorophore at 5’ end was in-house carried out by our 
collaborator.  
All oligonucleotides used in the present study were re-suspended in 
RNase- and DNase- free water at 100 µM. 100 pmol of each oligonucleotide 
was annealed with an excess of 150 pmol of its complementary DNA 
oligonucleotide in 10 mM TrisHCl pH 7.4 and 10 mM MgCl2, heated at 95°C 
and cooling down over night in the dark. 
  
	 	 Material and Methods 
	 55	
	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
a) 
b) 
Figure 16 View of the modified oligonucleotides used in the current study 
a) Oligonucleotides list, organized for three subtypes that are: DNA oligo control, 
unmodified rNMP in DNA oligo and modified rNMP in DNA oligo. In the table, all the 
single-stranded oligonucleotides sequences and their complementary sequences are 
specified. Unmodified and modified deoxyribonucleotides are colored in blue whereas 
unmodified and modified ribonucleotides in red.  b) Chemical representation of the 
deoxy- tetrahydrofuran, ribose 1’OH abasic site and ribose 8-Oxo-7,8-dihydro-
guanosine modifications.  
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The r8oxoG synthesis was carried out on an Applied Biosystems 392 
DNA/RNA synthesizer using the phosphoramidite chemistry, associated with 
the phenoxyacetyl protecting group for the nucleobases and the tertio-
butyldimethylsilyle protecting group at the 2’-OH position of the ribonucleoside 
residue (Gasparutto et al. 1992). Upon completion, the oligonucleotide was 
de-protected in concentrated aqueous ammonia for 6 hours at 55°C, followed 
by a desilylation step with triethylamine trihydrofluoride (8 hours at room 
temperature) (Gasparutto et al. 1992) and was finally purified by preparative 
20% denaturing PAGE using UV-shadowing detection. After desalting by size 
exclusion, the r8oxoG oligonucleotide was quantified by UV measurements at 
260 nm and its purity was checked by RP-HPLC analysis together with MALDI-
TOF mass measurements (Figure 17). Sample was then lyophilized and frozen 
at -20°C until use.  
 
 
  
a) 
b) 
Figure 17 r8oxoG- containing DNA oligonucleotide analysis 
a)  MALDI-TOF mass spectrum of the r8oxoG- containing DNA oligonucleotide 
(calculated mass: 8528.9; measured mass: 8527.2) shows an unique fragment with 
two states of charge: Peak [M-H]- : 8526.2 and Peak [M-2H]2- : 4262.8. b) Reversed-
phase chromatography of the labeled modified oligonucleotide (Gradient of 0 to 35% 
of CH3CN in TEAA 10mM in 45min – detection 254nm). (Courtesy of Dr. Gasparutto-
published in Malfatti et al., 2017) 
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6.2 Plasmid and expression of recombinant proteins  
Plasmids and expression of human recombinant OGG1 enzyme was 
purified as described in Audebert et al., (Audebert, Radicella, and Dizdaroglu 
2000). Plasmids and expression of human recombinant APE1 wild type (WT) 
and respective mutants (APE1 N∆33 and APE1 E96A) were produced as 
explained in Fantini et al., (Fantini et al. 2010) and in Erzberger and Wilson 
(Erzberger and Wilson 1999). Plasmid and expression of yeast, mouse and 
human recombinant RNase H2 were produced as explained in Chon et al., 
(Chon et al. 2009; Hyongi Chon et al. 2013).  
6.3 Cell lines and silencing experiments 
HeLa cells (human cervical carcinoma) (ATCC®, Milan, Italy) were grown 
in DMEM (EuroClone, Milan, Italy) supplemented with 10% fetal bovin serum 
(FBS-EuroClone, Milan, Italy), penicillin (100 U/ml), streptomycin (100 mg/ml) 
and l-glutamine (2 mM) (EuroClone, Milan, Italy) and cultured in a humidified 
incubator at 5% CO2 at 37°C. For silencing experiments, 15 × 104 cells were 
seeded and transfected with 5' UACUCCAGUCGUACCAGACCU 3' siAPE1 
(100 pmol) or siGENOME SMART pool siRNase H2A (50 pmol) or 5’ CCA 
UGA GGU CAG CAU GGU CUG UU 3’ scramble control siRNA (100 pmol) 
(GE Dharmacon, Milan, Italy) by using Oligofectamine™ Reagent (GE 
Dharmacon, Milan, Italy) as per manufacturer’s indications. After 72 hours 
upon transfection, cells were harvested by trypsinization and centrifuged at 
250 × g for 5 minutes at 4°C. Supernatant was removed, and pellet was 
washed once with ice-cold phosphate-buffered saline without Calcium and 
Magnesium (PBS-Euroclone, Milan, Italy) and then centrifuged again (250 × g 
for 5 minutes at 4°C).  
6.4 Preparation of nuclear cell extracts (NCE)  
After washing with PBS, cells were collected in cold PBS added with 0.1 M 
DTT and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). Cells were centrifuged 
at 800 × g for 10 minutes at 4°C and the supernatant was removed. Pellet was 
re-suspended in a cold hypotonic solution containing 10 mM HEPES pH 7.9, 
10 mM KCl, 0.1 mM MgCl2, 0.1 mM EDTA pH 8.0 complemented with 0.1 mM 
DTT, 0.5 mM PMSF, 1 mM protease inhibitor (PI), 1 mM NaF, 1 mM Na3VO4. 
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After centrifugation at 800 × g for 10 minutes at 4°C, cytosolic proteins (CCE) 
were collected whereas intact nuclei were pelleted. Pellet was washed to 
discard any contamination from cytosol and it was subsequently re-suspended 
with a cold hypertonic solution 20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 mM 
MgCl2, 0.1 mM EDTA pH 8.0, 5% glycerol complemented with 0.1 mM DTT, 
0.5 mM PMSF, 1 mM PI, 1 mM NaF, 1 mM Na3VO4 and incubated on ice for 
30 minutes. At the end, the sample was centrifuged at 15,000 × g for 20 
minutes at 4°C and collected the supernatant containing nuclear proteins 
(NCE). Quantification of each sample was performed by colorimetric Bradford 
assays (Bio-Rad, Milan, Italy).	
6.5 Preparation of whole cell extracts (WCE)  
After washing with PBS, cells were harvested by trypsinization and 
centrifuged at 250 × g for 5 minutes at 4°C. The supernatant was removed, 
washed once with PBS and centrifuged again. Pellet was re-suspended in a 
lysis solution containing 50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 
1% wt/vol Triton X-100 supplemented with 1 mM PI, 1 mM DTT, 0.5 mM PMSF, 
1 mM NaF and 1 mM Na3VO4. After centrifugation at 15,000 × g for 20 minutes 
at 4°C, the supernatant is considered as whole cell extract (WCE). Proteins of 
each sample were quantified using a colorimetric Bradford assays (Bio-Rad, 
Milan, Italy). 
6.6 SDS-PAGE electrophoresis separation, detection 
with Coomassie staining and Western blot analysis of 
protein samples 
All recombinant proteins were loaded onto a 10 w/vol % sodium dodecyl 
sulphate-polyacrylamide (SDS-PAGE) electrophoresis gel, which was 
subsequently stained using Coomassie Brilliant Blue stain (ThermoFisher, 
Waltham, MA, USA). Each band, corresponding to the protein of interest, was 
quantified and normalized with a BSA (bovine serum albumin) standardization 
curve. The image was finally developed by using NIR Fluorescence technology 
with an Odissey CLx scanner (LI-COR GmbH, Germany). Bands were 
quantified and analyzed using the ImageStudio software (LI-COR GmbH, 
Germany).  
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Cell extracts samples were loaded onto a 12 w/vol % SDS-PAGE 
electrophoresis gel. Proteins were then transferred onto nitrocellulose 
membranes (Schleicher & Schuell, Keene, NH, USA). Monoclonal α-APE1 
was from Novus Biologicals (Littleton, CO, USA-NB 100-116), polyclonal α-
RNase H2 was from Abcam (Cambridge, UK - ab92876). Monoclonal α-tubulin 
from SIGMA-ALDRICH (Milan, Italy - T-9026) and α-Lamin A from Abcam 
(Cambridge, UK - ab8980) antibodies were used to detect the respective 
proteins (i.e. Tubulin and Lamin A) as protein normalizers for 
whole/cytoplasmic and nuclear cell extracts respectively. Membranes were 
incubated with secondary antibodies labeled with IRDye (1:10,000 dilution) in 
5% milk, PBS and Tween 0.1% and finally developed by using NIR 
Fluorescence technology with an Odissey CLx scanner (LI-COR GmbH, 
Germany). Bands were quantified and analyzed using the ImageStudio 
software (LI-COR GmbH, Germany).  
6.7 Endonuclease assay 
To measure enzymatic activity of recombinant proteins and NCE on 
different substrates, each reaction was prepared following doses, time points 
and buffers specified in detail into the legend of each experiment. Final volume 
for each reaction was 10 µl. At the end of all reactions, samples were blocked 
with a stop solution, containing 99.5% v/v Formamide (SIGMA-ALDRICH, 
Milan, Italy) supplemented with 10X Orange Loading Dye (LI-COR 
Biosciences, Milan, Italy) and heated at 95°C for 5 minutes. Then, all samples 
were loaded onto a 7 M denaturing 20% polyacrylamide gel in TBE buffer pH 
8.0 and run at 4°C at 300V for 1 hour. Then, the gel was visualized with an 
Odyssey CLx Infrared Imaging system (LI-COR GmbH, Germany). The signals 
of the non-incised substrate (S) and the incision product (P) bands were 
quantified using Image Studio software (LI-COR GmbH, Germany). In all the 
experiments, we indicated with ‘Free’ term, the oligonucleotide incubated 
without any protein or cell extract. In each relative graph, we plotted the 
percentage of endonuclease activity on  y axis, calculated as the quote of 
product divided for the total of oligonucleotide used. When using the 
ds_rOH:dC and ds_r8oxoG:dC oligonucleotides, a very small amount of 
cleavage product was seen in samples not treated with recombinant proteins 
	 	 Material and Methods 
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and/or cell extracts due to the reactivity of this molecule, which was 
spontaneously degraded. During the analysis, this band has been always 
subtracted from bands obtained following treatment with recombinant proteins 
and/or extracts (Figure 18).  
6.8 Electrophoretic mobility shift assay analysis (EMSA)  
Proteins binding to nucleic acids was assessed by EMSA analysis as 
already described by Fantini et al., (Fantini et al. 2010). Briefly, the indicated 
amounts of recombinant purified proteins or cell extracts were co-incubated 
with 250 fmol of the probe (25 nM) at 37°C for 30 minutes. Reactions were 
prepared in a buffer containing 8 mM HEPES, 10 mM KCl, 400 µM EDTA pH 
8.0, 5 mM DTT and 2% glycerol in a 10 µl final volume. Moreover, salmon 
sperm DNA (SSD) (SIGMA-ALDRICH, Milan, Italy) was added like as DNA 
competitor. Samples were loaded onto an 8% w/vol native polyacrylamide gel 
in Tris-Sodium Acetate-EDTA pH 8.0 (TAE) buffer and run at 4°C at 150V for 
1 hour followed by 3 hours at 250V (Figure 18). Specific proteins belonging to 
the protein complex-DNA were detected using a supershift EMSA analysis that 
couples an EMSA analysis, already explained in Material and Methods, to an 
additional 1 hour of pre-incubation of monoclonal antibody direct versus APE1 
(Novus Biologicals, Littleton, CO, USA-NB 100-116) with the total cell extract 
at 4°C. In all the experiments, we indicated with ‘Free’ term, the oligonucleotide 
incubated without any protein or cell extract. 
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6.9 Data representation and statistical analysis 
All graphs were executed and statistically analyzed by using GraphPad 
software. Statistical analyses were performed by using the Student’s t test. 
P<0.05 and P<0.001 were considered as statistically significant. 
 
 
	
Figure 18 Schematic representation of enzymatic assays  
Upon the reaction between oligonucleotides and proteins is occurred in specific 
buffer, time and doses conditions, the reaction is run or on a denaturing gel in order 
to observe a cleavage activity of the protein on the oligonucleotide, or on a native gel 
in order to discriminate a shift of the signal due to a binding between protein and 
oligonucleotide. 
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7. Results  
7.1 Human RNase H2 does not process a rAP site 
embedded in DNA 
RNase H2 is the principal protein able to process paired and 
mismatched rNMP sites embedded in DNA by generating a nick of their 5′ side 
(Shen, Koh, et al. 2011). To date, whether RNase H2 can cleave a rAP site 
incorporated in a duplex DNA is unknown.  
In order to test this hypothesis, we measured RNase H2 ability to cleave 
a modified 25-mer DNA oligonucleotide, called ds_rOH:dC, in which a 1’-OH 
abasic rNMP was incorporated into a DNA substrate as shown in Figure 16 
and Figure 19. In parallel other three oligonucleotides were used including a 
dG- containing oligonucleotide called ds_dG:dC, as negative control, rG- 
containing oligonucleotides paired with C or A in the complementary strands, 
called ds_rG:dC and ds_rG:dA respectively as positive control, and finally the 
corresponding abasic modification with a deoxyribose instead of a ribose 
sugar, called ds_dF:dC (Figure 16 and Figure 19). 
 
 
  
Figure 19 Scheme of substrates used to test the processing of a rAP site 
embedded in a duplex DNA substrate  
Double-stranded (ds) DNA substrates containing a dGMP, rGMP, dF and 1′ OH 
abasic rNMP (rOH) sites in the 13th position. The ‘IRDye700’ in red indicates IRDye 
700 phosphoramidite dye tagged at the 5’ end. The ‘IRDye800’ in green indicates 
IRDye 800 phosphoramidite dye tagged at the 5’ end. The ‘Cy5’ in red indicates 
cyanine dye tagged at the 5′-end of the top strand of the duplex.  DNA nucleotides are 
in blue, RNA in red. The 5′ and 3′ ends of each DNA strand are indicated. 
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First of all, recombinant human RNase H2, composed of its three 
subunits, was purified as explained in Materials and Methods (Figure 20) and 
its activity was tested on ds_rOH:dC oligonucleotide in parallel with dG- and 
rG- containing oligonucleotides as negative and positive controls, respectively.  
 
 
As reported in Figure 21, the enzyme had no activity on ds_dG:dC and 
ds_dF:dC (containing a tetrahydrofuran residue mimicking the abasic site) 
oligonucleotides, whereas it efficiently cleaved the canonical rG substrate as 
expected. In addition, we tested the mismatched rG- containing 
oligonucleotide, ds_rG:dA, confirming that RNase H2 protein is able to cleave 
rGMP in mismatch with dAMP.  
On the other hand, no activity was detectable on ds_rOH:dC 
demonstrating that recombinant human RNase H2 is not able to process an 
abasic rNMP embedded in DNA.  
 
  
Figure 20 Gel-quantification of human RNase H2 recombinant protein used in 
this study 
Increasing doses (250-500-750 ng) of human recombinant RNase H2 protein was 
separated onto 10% SDS–PAGE gel followed by Coomassie staining. Bands 
corresponding to each protein were quantified and normalized on a standardization 
curve of Bovine Serum Albumin (BSA) protein (250-500-750 ng). The molecular 
weight (Mw) expressed in kilodaltons (kDa) is shown on the right of each panel.  
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Figure 21 Human recombinant RNase H2 protein is not able to process an rAP 
site embedded in a duplex DNA substrate 
a)  Representative denaturing polyacrylamide gel of oligonucleotides (25 nM) incision 
by recombinant human RNase H2 (0.5 nM). The reaction was performed in RNase 
H2-buffer (20 mM Tris-HCl, 25 mM KCl, 0.1% BSA, 0.01% Tween20, 4 mM MgCl2, 
pH 7.4) for different time points, expressed in minutes and shown on the top of the 
figure, at 37°C. ds_dG:dC and ds_dF:dC oligonucleotides were used as negative 
controls whereas paired and mismatched ds_rG oligonucleotides as positive controls. 
S indicates the substrate position while P indicates the product position.  b) Relative 
graph illustrating the time-course kinetics activity of the recombinant protein on 
ds_rG:dC and ds_rG:dA oligonucleotides. Data are expressed as mean + SD of three 
independent technical replicas. Statistical significant differences, calculated through 
t-Test analysis, are indicated as *p<0.05 and **p<0.001. 
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Later, we proceeded to confirm these data in vivo using cell extracts. 
We tested the activity of RNase H2 protein obtained from nuclear cell extracts 
on the same substrates, as above. To this aim, RNase H2 expression was 
downregulated in HeLa cells through specific siRNA and the endoribonuclease 
activities of nuclear extracts from knocked down and control cells were then 
assayed. Western blotting analyses, performed on nuclear extracts from 
control (Scramble) and knocked down (siRNase H2) cells, demonstrated the 
efficiency of RNase H2 downregulation (about 50%) upon transfection with 
specific siRNA sequences (Figure 22). APE1 silencing and double APE1 + 
RNase H2 silencing, shown in the WB panel below, will be explained later.  
 
We incubated Scramble or siRNase H2 cell extracts with different substrates 
for the indicated time points. Following knock-down of RNase H2, we found a 
decreased cleavage of ds_rG:dC, as expected Figure 23. Surprisingly, we 
Figure 22 Western blot silencing analysis on nuclear HeLa cell extracts  
HeLa cells were transfected with specific siRNAs directed versus RNase H2 and 
APE1 proteins and compared to the Scramble control. Nuclear cell extracts were 
separated onto 12% SDS–PAGE, and Western blot analysis was performed by using 
an anti-APE1 antibody and an anti-RNase H2 antibody. Lamin A was used as loading 
control. Expression levels for each condition was normalized to the Scramble and 
indicated under each corresponding lane. The molecular weight (Mw) expressed in 
kilodaltons (kDa) is shown on the right of each panel. 
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found that ds_rOH:dC was also cleaved; however, ds_rOH:dC cleavage was 
completely unaffected by siRNase H2 cell extracts. 
These data suggest that human RNase H2 is inactive on an abasic 
rNMP embedded in DNA, hypothesizing that there may be another enzyme/s 
capable of cleaving it. 
In addition from data not shown, in order to increase the stability of the 
abasic rNMP-containing oligonucleotide, an abasic substrate mimicked by 
tetrahydrofuran (F) residues, similarly to what commonly used for dNMP 
(Wilson 2005; Poletto, Malfatti, et al. 2016) was used. Moreover, a longer DNA 
sequence was chosen (about 40-bp) in order to evaluate a possible role of the 
length of the substrate in determining the inability of RNase H2 to process 
these substrates. Recombinant RNase H2 proteins from yeast S. cerevisiae  or 
mouse were tested on these different substrates and, as expected and 
confirming the previous data, both proteins were unable to cleave abasic rG 
sites in DNA (Malfatti et al. 2017).  
Together, these results demonstrate and confirm that eukaryotic RNase 
H2, either from yeast or mammalian origins, do not process abasic rNMP 
incorporated in DNA, independently from the nature of the abasic site (either 
1’-OH or tetrahydrofuran residue) and the length of the substrate (either 25- or 
40-mers). 
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Figure 23 RNase H2 from cell extracts is unable to cleave rAP sites in DNA  
a)  Representative denaturing polyacrylamide gel of oligonucleotides (0.25 µM) 
incision by nuclear HeLa cell extracts (NCE). In order to discriminate the activity of 
RNase H2, 500 ng of NCE, in which RNase H2 expression was previously knocked 
down through specific siRNA (indicated as siRNase H2), were tested in comparison 
to control cells (Scramble) at different time points, expressed in minutes. rG- 
containing oligonucleotide was used as positive control. Time points, expressed in 
minutes, are shown on the top of the figure. Enzymatic reaction was performed at 
37°C in RNase H2-buffer. S indicates the substrate position, while P indicates the 
product position. b) Graph illustrating the time-course kinetics activity of NCE on 
ds_rG:dC in control and RNase H2-knocked down conditions. Enzymatic reaction was 
performed at 37°C in RNase H2-buffer with 500 ng of NCE. Data are expressed as 
mean + SD of three independent technical replicas. Standard deviation values were 
always less than 10% of the mean of the experimental points. Statistical significant 
differences, calculated through t-Test analysis, are indicated as *p<0.05 and 
**p<0.001.  c) Graph illustrating the time-course kinetics activity of NCE on ds_rOH:dC 
oligonucleotide in control and RNase H2-knocked down conditions. Enzymatic 
reaction was performed at 37°C in RNase H2-buffer with 500 ng of NCE. Data are 
expressed as mean + SD of three independent technical replicas. Standard deviation 
values were always less than 10% of the mean of the experimental points.  
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7.2 Human APE1 is able to process a rAP site embedded 
in DNA through its endonuclease catalytic domain 
Upon demonstration that RNase H2 enzyme was inefficient in the 
processing of abasic ribonucleotides embedded in DNA, we moved our 
attention on APE1, the AP endonuclease deputed on cleave abasic sites in 
DNA during the BER (Tell et al. 2009).  
Therefore, in order to test the ability of APE1 to process rAP sites in DNA, 
we purified human recombinant APE1 protein, as described in Materials and 
Methods section (Figure 24).  
 
 
The endonuclease activity of APE1 on ds_rOH:dC substrate was examined 
through cleavage assays. As a positive control for APE1 endonuclease 
activity, an oligonucleotide substrate containing a tetrahydrofuran residue 
mimicking the abasic site, called ds_dF:dC (Wilson 2005; Poletto, Malfatti, et 
al. 2016), was used (Figure 16 and Figure 19). As reported in Figure 25, and 
measured through kinetics experiments in  
Table 1, APE1 processes the abasic rNMP within DNA as efficiently as the 
canonical abasic dNMP.  
Figure 24 Gel-quantification of recombinant APE1 WT protein used in this study   
Increasing doses (500-750 ng) of human recombinant APE1 WT protein was 
separated onto 10% SDS–PAGE gel followed by Coomassie staining. Bands 
corresponding to each protein were quantified and normalized on a standardization 
curve of Bovine Serum Albumin (BSA) protein (250-500-750 ng). The molecular 
weight (Mw) expressed in kilodaltons (kDa) is shown on the right of each panel. 
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Figure 25 Recombinant human APE1 protein efficiently processes a rAP site 
embedded in DNA  
a)  Representative denaturing polyacrylamide gel of oligonucleotides (0.25 µM) 
incision by recombinant APE1 protein (0.288 nM). The reaction was performed in 
APE1-buffer for different time points, expressed in minutes and shown on the top of 
the figure, at 37°C. ds_dF:dC oligonucleotide was used as positive control. S indicates 
the substrate position while P indicates the product position. b) Relative graph 
illustrating the time-course kinetics activity of the recombinant protein on ds_dF:dC 
and ds_rOH:dC oligonucleotides. Data are expressed as mean ± SD of three 
independent technical replicas. Standard deviation values were always <10% of the 
mean of the experimental points  
a) 
b) 
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Moreover, we clearly found that APE1 was unable to process the rG- 
containing oligonucleotide, which is the preferential substrate of RNase H2 
enzyme (Figure 25), while it is active on the rOH substrate.  
We then measured the specific activity of APE1 on abasic 
ribonucleotide embedded in DNA, through kinetis experiments. The kinetic 
constants were calculated and are reported in  
Table 1. Comparing the values, we observe that APE1 has a lower 
affinity for the ds_rOH:dC than the ds_dF:dC (11-fold increase of the KM) but 
a higher catalytic rate (27-fold increase in the kcat/KM  ratio). 
 
[APE1] 
(×10-3 nM) 
Substrate  KM  
[nM]  
VMAX  
(nM/min)  
kCAT  
(min-1)  
kCAT/KM  
(min*nM)-1  
75 ds_dF:dC 14.2±6.98 0.95±0.33 12.7±4.39 0.95±0.16 
3.125 ds_rOH:dC 158±41.79 12.66±3.71 4054±1191.8 26±1.96 
 
Table 1  Kinetic parameters for APE1 endonuclease activity on different 
substrates   
Kinetic parameters (KM, VMAX and kCAT) were calculated from the measurement of the 
endonucleolytic reaction rates for APE1 on ds_dF:dC and ds_rOH:dC substrates. As 
described in Fantini et al., increasing concentrations of the substrate were incubated 
with a selecting concentration of the protein (see first column) in a time-course 
experiment. Kinetic values were calculated using a Lineweaver-Burk plot analysis and 
represent the mean ± SD of three independent experiments.  
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In order to further characterize the enzymatic activity of APE1, we used 
the purified recombinant mutant APE1 E96A protein, in which an EA 
aminoacid substitution was inserted into the catalytic site. The aminoacid 
substitution causes a decreased enzymatic activity of the protein, due to the 
inability to coordinate the Mg2+ ion in the catalytic site (Wilson 2005; Beernink 
et al. 2001; Izumi et al. 2005b) (Figure 26). In addition, we also used the 
purified recombinant mutant APE1 NΔ33 protein, in which the first 33 N-
terminal residues, responsible for RNA-protein interaction but not affecting its 
enzymatic activity, have been deleted (Lindahl 1993; Tell, Wilson, and Lee 
2010) (Figure 26). 
 
 
 
  
Figure 26 Gel-quantification of mutant APE1 recombinant proteins  
Human recombinant mutants APE1 N∆33 (250-500 ng) and APE1 E96A (250-500-
750 ng) proteins were separated onto 10% SDS–PAGE gel followed by Coomassie 
staining. Bands corresponding to each protein were quantified and normalized on a 
standardization curve of Bovine Serum Albumin (BSA) protein (250-500-750 ng). The 
molecular weight (Mw) expressed in kilodaltons (kDa) is shown on the right of each 
panel.  
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Following incubation of ds_rOH:dC with APE1 E96A mutant, there was barely 
any endonuclease activity, whereas the activity of APE1 NΔ33 mutant was 
comparable with that of the APE1 WT protein (Figure 27).  
These data demonstrate that the catalytic domain of APE1 is 
responsible for recognizing and cleaving a rAP site in dsDNA and that the N-
terminal domain does not play any major role in the enzymatic activity on this 
substrate and that AP endonucleolytic activity on rAP sites is intrinsic to the 
purified protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 27 AP catalytic domain of APE1 is involved in the cleavage of abasic 
rNMPs embedded in DNA  
a)  Representative denaturing polyacrylamide gel of oligonucleotides (2.5 pmol) 
incision by different APE1 mutants N∆33 and E96A (0.288 nM), in comparison to wild 
type APE1 (WT). The reaction was performed in APE1-buffer for different time points, 
expressed in minutes and shown on the top of the figure, at 37°C. ds_dF:dC 
oligonucleotide was used as positive control. S indicates the substrate position while 
P indicates the product position. b) and c)  Graphs illustrating the time-course kinetics 
activity of APE1 mutants on ds_dF:dC and ds_rOH:dC oligonucleotides. Data are 
expressed as mean ± SD of three independent technical replicas. Standard deviation 
values were always <10% of the mean of the experimental points. Statistical 
significant differences, calculated through t-Test analysis, are indicated as **p<0.001. 
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In order to confirm that APE1 is the major enzyme capable of cleaving 
ribo-abasic containing sites in cells, we used nuclear cell extracts in which 
APE1 was knocked-down through specific siRNAs (Figure 22), as explained 
in Material and Methods. As Figure 28 shows, the endonuclease activity of 
APE1-kd (siAPE1) cell extracts, was reduced on both ds_dF:dC and 
ds_rOH:dC as compared to its respective control SCR-treated extracts. 
Moreover, what emerges from the Western blot analysis (Figure 22), the 
expression of APE1 protein did not exert any effect on the expression of 
RNase H2 protein itself, demonstrating that the observed reduction of the 
processing activity of the abasic rNMP-containing substrate, observed with 
APE1-kd cell extracts, was likely due to the reduced expression of the APE1 
protein.  
These data demonstrate that human APE1 is the major enzyme capable 
of specifically cleaving at abasic rNMPs in DNA while being unable to process 
normal rNMPs, which are the preferential substrates of RNase H2.  
 
 
 
 
 
 
 
  
Figure 28 APE1 knock down in human cells impairs the processing of a rAP site 
embedded in a duplex DNA substrate 
a)  Representative denaturing polyacrylamide gel of oligonucleotides (0.25 µM) 
incision by nuclear HeLa cell extracts (NCE). In order to discriminate the activity of 
APE1, 10 ng of NCE, in which APE1 expression was previously knocked down 
through specific siRNA (indicated as siAPE1), were tested in comparison to control 
cells (Scramble) at different time points, expressed in minutes and shown on the top 
of the figure. dF- containing oligonucleotide was used as positive control. Enzymatic 
reaction was performed at 37°C in APE1-buffer. S indicates the substrate position, 
while P indicates the product position.  b) Graph illustrating the time-course kinetics 
activity of NCE on ds_dF:dC in control and APE1-knocked down conditions. 
Enzymatic reaction was performed at 37°C in APE1-buffer with 10 ng of NCE. Data 
are expressed as mean + SD of three independent technical replicas. Statistical 
significant differences, calculated through t-Test analysis, are indicated as *p<0.05 
and **p<0.001. c)  Graph illustrating the time-course kinetics activity of NCE on 
ds_rOH:dC oligonucleotide in control and APE1-knocked down conditions. Enzymatic 
reaction was performed at 37°C in APE1-buffer with 10 ng of NCE. Data are 
expressed as mean + SD of three independent technical replicas. Statistical 
significant differences, calculated through t-Test analysis, are indicated as *p<0.05 
and **p<0.001. 
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Again, as above, the specificity of the enzymatic activity of APE1 was 
tested using the tetrahydrofuran ribonucleotide mimicking an abasic residue 
embedded in a longer DNA sequence. Moreover, a pre-treatment of 
Compound #3 (i.e. N-(3-(benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7-
tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide)), a specific APE1 
endonuclease inhibitor (Poletto, Malfatti, et al. 2016; Rai et al. 2013), was 
used. All these experiments confirmed that the main enzymatic activity on 
abasic ribonucleotides embedded in DNA is due to APE1 (data not shown) 
(Malfatti et al. 2017). 
After demonstration that the ability of APE1 to cleave an abasic 
ribonucleotide embedded in DNA, and discarded the possibility of RNase H2 
can have a role in the processing of this type of lesion, we hypothesized that 
ribonucleotides from DNA or from the nucleotide pool can be hydrolyzed 
spontaneously thus generating an abasic site. Another possibility can be the 
presence of an oxidized rNMP, that once processed by specific enzymes, is 
converted to abasic site, as in the case of the classic d8oxoG.  
For this reason, we decided to focus our attention on r8oxoG removal. 
Experiments carried on this new type of lesion are presented in next 
paragraphs.  
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7.3 Human RNase H2 does not process a r8oxoG 
embedded in a duplex DNA  
Abasic ribo- site can be generated by spontaneous hydrolysis of 
ribonucleotides embedded in DNA. Moreover, the processing of oxidized 
ribonucleotides embedded in DNA might generate abasic ribo- sites.  
Thus, in the second part of the Project, we focused our attention on the 
processing of 8oxoG-rNMPs embedded in DNA.  
The r8oxoG containing oligonucleotide was in-house synthesized and, 
as observed from MALDI-MS analysis and HPLC purification, the undesirable 
presence of secondary products of the chemical synthesis of this substrate 
can be excluded (Figure 17). 
First of all, we investigated whether recombinant human RNase H2 
protein was able to recognize and cleave at r8oxoG site using an 
oligonucleotide containing this type of lesion called ds_r8oxoG:dC (Figure 16 
and Figure 29). In these experiments, we compared the specific enzymatic 
activity of RNase H2 with that exerted on the canonical ds_rG:dC substrate, 
as positive control, and using the ds_d8oxoG:dC oligonucleotide as negative 
control (Figure 29).  
 
 
As Figure 30 shows, the ds_rG:dC oligonucleotide was efficiently 
processed by RNase H2 whereas the same activity was not observed for 
ds_r8oxoG:dC. As expected, the d8oxoG-containing oligonucleotide was not 
Figure 29 Scheme of substrates used to test the processing of a r8oxoG site 
embedded in a duplex DNA substrate  
Scheme of double-stranded (ds) DNA substrates containing a d8oxoGMP and a 
r8oxoGMP sites in the 13th position annealed to ss_dC containing- or ss_dA 
containing-complementary oligonucleotides. The ‘IRDye700’ in red indicate IRDye 
700 phosphoramidite dye tagged at the 5’ end. DNA nucleotides are in blue, RNA in 
red. The 5′ and 3′ ends of each DNA strand are indicated. 
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cleaved by RNase H2. These data confirm that RNase H2 was not able to 
process modified rNMPs embedded in DNA. Further studies are ongoing in 
order to understand if RNase H2 might bind the oxidized rNMP. 
 
Similarly, we confirmed these data using RNase H2-kd nuclear extracts 
from HeLa cells (Figure 22). As expected, control nuclear extracts (Scramble) 
displayed a time-dependent endoribonuclease activity on ds_rG:dC, whereas 
the down regulation of RNase H2 protein expression (siRNase H2) was 
associated with a marked reduction of the endoribonuclease activity on the 
same substrate (Figure 31). On the contrary, once we tested the ability of the 
nuclear extracts on ds_r8oxoG:dC oligonucleotide, we found only a weak 
endoribonuclease activity on it , which was not affected by RNase H2 silencing 
(Figure 31).  
These data support the conclusion that the r8oxoG site in DNA is not 
recognized by human RNase H2.  
  
Figure 30 Recombinant human RNase H2 protein is not able to process a r8oxoG 
site embedded in a duplex DNA substrate 
Representative denaturing polyacrylamide gel of oligonucleotides (25 nM) incision by 
human recombinant RNase H2 (5 fmol). Reaction was performed in RNase H2-buffer 
(20 mM Tris-HCl, 25 mM KCl, 0.1% BSA, 0.01% Tween20, 4 mM MgCl2, pH 7.4) at 
37°C. ds_rG:dC and ds_d8oxoG:dC oligonucleotides were used as positive and 
negative controls, respectively. Time points are shown on the top of the figure. S 
indicates the substrate position, while P indicates the product position.  
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Figure 31 RNase H2 from cell extracts is unable to process a r8oxoG site 
embedded in a duplex DNA substrate 
a) Representative denaturing polyacrylamide gel of ds_rG:dC and b) ds_r8oxoG:dC   
oligonucleotides (0.25 µM) incision by nuclear HeLa cell extracts (NCE). In order to 
discriminate the activity of RNase H2, 500 ng of NCE in which RNase H2 expression 
was previously knocked down through specific siRNA (indicated as siRNase H2) were 
tested in comparison to control cells (Scramble) at different time points (minutes), 
shown on top of the figure. S indicates the substrate position while P indicates the 
product position.  
a) 
b) 
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7.4 OGG1 has neither lyase nor glycosylase activities on 
oxidized rG substrate 
We then investigated whether enzymes of the BER pathway may be 
involved in the processing of the r8oxoG substrate. To this purpose, we tested 
recombinant purified human OGG1 and APE1 proteins (Figure 32 and Figure 
24).  
 
 
As explained in the Introduction section, OGG1 protein belongs to the 
bi-functional glycosylases family having both lyase and glycosylase activities 
on oxidized dG (Boiteux and Radicella, 2000). Thus, we examined the 
processing activity of OGG1 on the r8oxoG substrate in comparison to the 
d8oxoG-containing oligonucleotide, as a positive control (Figure 29). First, we 
tested the ability of OGG1 to recognize an r8oxoG site through electrophoretic 
mobility shift assay (EMSA). As shown in Figure 33, increasing amount of 
recombinant OGG1 formed a stable retarded complex with the r8oxoG 
oligonucleotide in a dose-dependent manner. In addition, as confirmed, OGG1 
binding was specific for the modified r8oxoG- containing oligonucleotide (lanes 
2 and 3). As expected, the shift was observed when recombinant OGG1 was 
incubated with the positive control ds_d8oxoG:dC (lanes 11 and 12) but not 
with the negative controls ds_rG:dC (lanes 5 and 6). A weak signal is detected 
Figure 32 Gel-quantification of recombinant human OGG1 protein  
Increasing doses (250-500 ng) of human recombinant OGG1 protein was  separated 
onto 10% SDS–PAGE gel followed by Coomassie staining. Bands corresponding to 
each protein were quantified and normalized on a standardization curve (250-500-
750 ng) of Bovine Serum Albumin (BSA) protein. The molecular weight (Mw) 
expressed in kilodaltons (kDa) is shown on the right of each panel. 
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when the ds_dG:dC oligonucleotide was used (lanes 8 and 9) and is 
attributable to a low affinity binding of the enzyme to the unmodified DNA 
(Figure 33). 
 
  
Figure 33 Human OGG1 binds r8oxoG- containing oligonucleotide 
Representative native EMSA polyacrylamide gel of OGG1 binding on ds_r8oxoG:dC 
oligonucleotide (25 nM) is shown. ds_dG:dC and ds_rG:dC are used as negative 
controls whereas ds_d8oxoG:dC is used as positive control. The ‘Bound’ arrow 
indicates the retarded complex between OGG1 and the probe whereas the ‘Free’ 
arrow the unbound substrate. Amounts of OGG1 protein, expressed in pico moles, 
are shown on the top of the figure. Reactions were performed as explained in “Material 
and Methods” section.  
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We next tested the lyase activity of OGG1 on different substrates. 
Figure 34 shows that OGG1 was only able to process the canonical substrate 
ds_d8oxoG:dC in a dose response manner. In contrast, no lyase activity was 
apparent for any of the other substrates used, including the ds_r8oxoG:dC and 
the ds_r8oxoG:dA.  
 
 
 
 
  
Figure 34 Human OGG1 has not any lyase activity on r8oxoG-containing 
oligonucleotide  
Representative denaturing polyacrylamide gel of lyase activity of human OGG1 on 
different duplex DNA oligonucleotides (25 nM). Doses of OGG1 protein expressed in 
femto moles are shown on the top of the figure. Reactions were performed in OGG1-
buffer (20 mM Tris-HCl, 100 mM KCl, 0.1% BSA, 0.01% Tween20, pH 7.4) at 37°C 
for 30 minutes. S indicates the substrate position, while P indicates the product 
position.  
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OGG1 is the major glycosylase enzyme in the BER pathway, able to 
convert oxidized bases in abasic sites, subsequently cleaved by the 
endonuclease APE1 (Krokan and Bjoras 2013; Boiteux and Radicella 1999; 
David, O’Shea, and Kundu 2007). In order to measure its glycosylase activity 
on the same substrates, we co-incubated a fixed amount of recombinant 
OGG1 with increasing amounts of recombinant purified APE1 (Figure 35). 
While OGG1 displayed a robust glycosylase activity on the canonical 
ds_d8oxoG:dC substrate, a weak activity on ds_r8oxoG:dC oligonucleotide 
(indicated by a single asterisk) was observed (Figure 35). Moreover, the 
presence of an additional higher mobility band, increasing as a function of 
APE1 concentration (indicated with a double asterisk) was observed only in 
the case of the ds_r8oxoG:dC substrate.  
We conclude that OGG1 has neither lyase nor glycosylase activity on 
the r8oxoG substrate, and that APE1 can weakly process this substrate alone. 
About APE1 activity, a detailed description will be explained in the next 
paragraph.  
 
 
 
 
 
 
  
Figure 35 Human OGG1 does not possess a glycosylase activity on r8oxoG-
containing oligonucleotide  
a)  Representative denaturing polyacrylamide gel of incision by different doses of 
APE1 co-incubated with a fixed amount of OGG1 (3.125 nM) on different duplex DNA 
oligonucleotides (25 nM) in order to investigate glycosylase activity of OGG1. 
Different doses of APE1 protein, expressed in femto moles, are shown on top of the 
figure. Reactions were performed in a buffer containing 20 mM Tris-HCl, 100 mM KCl, 
0.1% BSA, 0.01% Tween20, pH 7.4 at 37°C for 30 minutes. S indicates the substrate 
position while P indicates the product position. Moreover, at the right of the panel, a 
longer product of about 12 nucleotides is indicated by an asterisk whereas a smaller 
one of 11 nucleotides is indicated by a double asterisk. b) Histograms represent the 
dose response of OGG1 glycosylase activity on ds_d8oxoG:dC and paired and 
mismatched ds_r8oxoG oligonucleotides. ds_d8oxoG oligonucleotide was used as a 
positive control whereas ds_dG:dC and ds_rG:dC oligonucleotides were used as 
negative controls. The activity is reported as percentage of substrate converted to 
product. Data are expressed as mean + SD of three independent technical replicas.  
Statistical significant differences, calculated through t-Test analysis, are indicated as 
*p<0.05 and **p<0.001. 
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7.5 APE1 has a weak endo-/exo-nuclease activities on 
the r8oxoG-containing substrate depending on Mg2+ 
concentration and on the presence of its N-terminal 
domain 
Based on the above presented data, we then checked whether APE1 ‘per 
se’ had any endoribonuclease activity on ds_r8oxoG:dC substrate (Figure 36). 
Compared to the ds_dF:dC substrate, APE1 displayed a modest, though 
significant, processing activity on both ds_r8oxoG:dC and ds_r8oxoG:dA 
oligonucleotides, while no activity was observed in the case of the dG- and the 
d8oxoG-containing substrates (Figure 36), as expected. As observed above, 
the appearance of an additional faster migrating cleavage product (indicated 
by a double asterisk corresponding to a 11-nt product) was visible in the case 
of the ds_r8oxoG:dC substrate, which might be associated with a recently 
identified 3’-exonuclease activity by the protein (Chohan et al. 2015).  
In contrast, using the oligonucleotide containing the mismatched 
ds_r8oxoG:dA, most of the fragments produced after incision by the AP 
endonucleolytic activity (indicated with a single asterisk) were not further 
degraded by the exonucleolytic activity. 
 
 
 
 
 
  
Figure 36 Human APE1 shows weak endo- and 3’-exonuclease activities on the 
r8oxoG substrate 
a)  Representative denaturing polyacrylamide gel of APE1 incision on different duplex 
DNA oligonucleotides (25 nM), in which ds_dF:dC oligonucleotide was used as a 
positive control, whereas ds_dG:dC and ds_rG:dC oligonucleotides were used as 
negative controls. The doses of APE1 protein used, expressed in femto moles, are 
shown on the top of the figure. On the right side, a schematic representation of the 
cleavage products, showing the position of the ribonucleotide (red box with R) 
embedded in the DNA oligonucleotide and the APE1 cleavage on it, producing a 
longer product of about 12 nucleotides (*) and a smaller one of 11 nucleotides (**). 
Reactions were performed in APE1-buffer containing 20 mM Tris-HCl, 100 mM KCl, 
0.1% BSA, 0.01% Tween20, pH 7.4 for 30 minutes at 37°C. S indicates the substrate 
position while P indicates the product position.  b) Relative graph indicates a dose-
response APE1 activity on paired and mismatched ds_r8oxoG:dC oligonucleotide in 
comparison to ds_dF:dC positive control. Data are expressed as mean + SD of three 
independent technical replicas. Statistical significant differences, calculated through 
t-Test analysis, are indicated as **p<0.001. 
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Data not shown, in which the missing cleavage on single stranded 
oligonucleotide (ss_r8oxoG) by APE1 was compared to the weak cleaved 
product of the annealed oligonucleotide (ds_r8oxoG:dC), demonstrated the 
requirement for secondary structured oligonucleotide sequences for efficient 
enzymatic activities by APE1. These data thus exclude that the observed 
cleavage product was due to the processing of a residual non-annealed 
oligonucleotide possibly present after the annealing reaction (Malfatti et al. 
2017).	
Together, these data suggest that the APE1 enzymatic activity on the 
r8oxoG substrate requires a dsDNA molecule and the exonuclease activity is 
dependent on the paired nucleotide, possibly as a consequence of a different 
stereo-chemical geometry between the 8oxoG:A and the 8oxoG:C.  
It has been previously demonstrated that the exonuclease activity of 
APE1 strictly depends on salt concentrations (Chou and Cheng 2003). We 
therefore tested whether the 3’-exonuclease activity observed on the 
ds_r8oxodG:dC shared some common features (in terms of dependence on 
the ionic strength conditions) with the 3’-exonuclease activity on mispaired 
DNA, as previously described (Chou and Cheng 2003). Firstly, we determined 
the optimal MgCl2 (Figure 37a-b) and KCl (Figure 37c-d) concentrations 
required for the 3’-exonuclease activity. The 3’-exonuclease activity was 
present up to a concentration of 2 mM MgCl2. An inhibitory effect was apparent 
at MgCl2 concentrations above 4 mM. At the same time, the 3’-exonuclease 
activity was poorly affected at KCl concentration equal to 100 mM.  
These results are in line with previous data on 3’-mispaired DNA (Chou 
and Cheng 2003) and suggest that the observed 3’-exonuclease activity 
strongly depends on the electrostatic interaction of APE1 with the substrate 
during the cleavage reaction and with the role of Mg2+ ions.  
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Figure 37 Human APE1 activities on the r8oxoG substrate depend on mono- and 
di-valent cations 
a) Representative denaturing polyacrylamide gel of APE1 (5 nM) incision on 
ds_r8oxoG:dC oligonucleotide under different MgCl2 concentrations that is expressed 
in mM (top) performing a reaction long 30 minutes in APE1 buffer. S indicates the 
substrate position while P indicates the product position. Moreover, at the right of the 
panel, a longer product of about 12 nucleotides is indicated by an asterisk whereas a 
smaller one of 11 nucleotides is indicated by a double asterisk. b) Relative graph 
shows the ratio between two products obtained as a function of MgCl2 concentration. 
c) Representative denaturing polyacrylamide gel of APE1 (5 nM) incision on 
ds_r8oxoG:dC oligonucleotide under different KCl concentrations in combination with 
two different MgCl2 concentrations, 1 mM and 10 mM (top) performing a reaction long 
30 minutes in a buffer containing 20 mM Tris–HCl, 0.1% BSA, 0.01% Tween20, pH 
7.4. S indicates the substrate position, while P indicates the product position. 
Moreover, at the right of the panel, a longer product of about 12 nucleotides is 
indicated by an asterisk whereas a smaller one of 11 nucleotides is indicated by a 
double asterisk. d)  Relative graph shows product levels in association with different 
salts concentrations. Statistical significant differences, calculated through t-Test 
analysis, are indicated as **p<0.001. 
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After choosing the optimal salts conditions, in which both endo- and 
exo- activities of APE1 (100 mM KCl and 1 mM MgCl2) are present, we 
evaluated whether the enzymatic activity of APE1 on ds_r8oxoG:dC was 
dependent on the same catalytic site responsible for the endonuclease activity 
observed on abasic dsDNA and abasic rNMP within dsDNA (data not shown) 
(Malfatti et al. 2017). To this aim, the enzymatic activity of the E96A mutant 
was compared to that of the WT protein. These data demonstrate that the 
APE1 E96A mutant has a reduced endoribonuclease activity showing no 3’-
exonuclease activity over the ds_r8oxoG:dC substrate. Due to the effect of salt 
concentration on this latter activity, we also tested the enzymatic activity of the 
APE1 NΔ33 deletion mutant. Interestingly, while this protein retained the 
endoribonuclease activity of the WT protein, its 3’-exonuclease activity was 
abolished. Moreover, treatment with APE1 inhibitor Compound #3 confirmed 
that the catalytic site responsible for the endonuclease activity is also 
responsible for the endoribonuclease activity over the r8oxoG substrate (data 
not shown) (Malfatti et al. 2017).  
These results show that APE1 has a weak, though significant, 
endoribonuclease activity on the r8oxoG substrate with an additional specific 
3’-exonuclease activity dependent on:  
i) the kind of base pairing: i.e. ds_r8oxoG:dC or ds_r8oxoG:dA;  
ii) salt concentrations (i.e. Mg2+);  
iii) the presence of the 33 N-terminal domain. 
Overall, our data suggest that BER enzymes, but not RER, are involved in 
the processing of non-canonical rNMPs, such as abasic or oxidized, 
incorporated in DNA. Because the repair pathway catalyzed by APE1 towards 
the oxidized rG is fundamentally different from that of BER, since no bases are 
excised, we can conclude that the observed effect could be ascribed to an 
alternative damage-specific endonuclease initiated repair pathway, previously 
referred to as either alternative excision repair (AER) or nucleotide incision 
repair (NIR) (reviewed by (Yasui 2013) and by (Prorok et al. 2013)).  
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7.6 APE1 and RNase H2 do not biochemically and 
functionally interact in human cells 
In the last part of this Thesis, we performed preliminary experiments to 
support the functional independence between the BER and the RER 
pathways.  
First, we tested whether APE1 and RNase H2 proteins functionally interact. 
We used HeLa cells transfected with siRNAs specific for APE1 and RNase H2 
mRNAs to knock down the corresponding endogenous proteins. Whole cell 
extracts were prepared as explained in Materials and Methods section, and 
Western blotting analysis was used to check the effective protein down 
regulation (Figure 38).  
 
 
Then, we checked the ability of APE1 and RNase H2 from cell extracts to 
recognize the ds_r8oxoG:dC substrate. We performed EMSA analysis with cell 
extracts from control (Scramble) and APE1-kd (siAPE1) or RNase H2-kd 
(siRNase H2) cells. As demonstrated in Figure 39a, incubation of cell extract 
from control cells displayed a shift containing APE1-complex. The intensity of 
the retarded complex was decreased upon APE1-kd (siAPE1) (Figure 39a, 
Figure 38 Western blot analysis of whole cell extracts silenced for APE1 and 
RNase H2 
HeLa cells were transfected with siRNAs directed versus RNase H2 and APE1 
proteins and compared to the Scramble control. Whole cell extracts were separated 
onto 12% SDS–PAGE, and Western blot analysis was performed by using an anti-
APE1 antibody and an anti-RNase H2 antibody. Tubulin was used as loading control. 
The molecular weight (MW) expressed in kilodaltons (kDa) is shown on the right of 
each panel.  
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lane 4) and upon the double APE1/RNase H2-kd (siAPE1 + siRNase H2) 
(Figure 39a, lane 6) but not upon RNase H2 silencing alone (siRNase H2) 
(Figure 39a, lane 5). This suggest that APE1 is involved in a protein complex 
able to recognize r8oxoG damage in which RNase H2 is not present.  
These data were also confirmed by supershift EMSA experiments with anti-
APE1 specific antibody in which the “Bound” signal was supershifted in the 
presence of antibody directed versus APE1, confirming the presence of APE1 
in the binding complex of r8oxoG damage (Figure 39c). 
 
 
(legend on next page) 
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c) 
Figure 39 APE1 is part of the protein complex recognizing r8oxoG damage from 
cell extracts 
a)  Representative native EMSA polyacrylamide gel on ds_r8oxoG:dC oligonucleotide 
incubated with 2.5 µg of whole cell extracts from untreated HeLa cells (lane 2) and 
HeLa cells transfected with control siRNA (lane 3), silenced for APE1 (lane 4), RNase 
H2 (lane 5) and APE1/RNase H2 (lane 6) for 30 minutes at 37°C. Lane 1 corresponds 
to r8oxoG-containing oligonucleotide alone without any cell extract. On the right side 
of the gel, an arrow denotes the retarded complex between cell extract and the probe 
(left). b) Histogram shows the difference of binding between each condition. c)  
Representative native polyacrylamide gel of ds_r8oxoG:dC oligonucleotide incubated 
at 37°C for 30 minutes with the indicated amounts of whole cell extracts (WCE) 
without or with a pre-incubation with the specific monoclonal antibody recognizing 
APE1 protein, at 4°C for 1 hour, before gel separation. Bound complex to the 
oligonucleotide is indicated by an arrow named ‘Bound’, whereas the supershifted 
complex, obtained after incubation with the specific antibody, is indicated by an arrow 
named ‘Supershifted’. Representative native polyacrylamide gel of ds_r8oxoG:dC 
oligonucleotide incubated at 37°C for 30 minutes with the indicated amounts of whole 
cell extracts (WCE) without or with a pre-incubation with increasing amounts of the 
specific monoclonal antibody recognizing APE1 protein, at 4°C for 1 hour, before gel 
separation. Bound complex to the oligonucleotide is indicated by an arrow named 
‘Bound’, whereas the supershifted complex, obtained after incubation with the specific 
antibody, is indicated by an arrow named ‘Supershifted’.   
	 	 Discussion 
8. Discussion 
The incorporation of rNMPs within DNA is a frequent phenomenon 
occurring into the genome of both prokaryotes and eukaryotes (Williams and 
Kunkel 2014; Koh, Balachander, et al. 2015; Hovatter and Martinson 1987; 
Potenski and Klein 2014). The presence of rNMPs into the genome causes 
genomic instability, but the cell responds with a specific pathway, called RER 
pathway, in which RNase H2 works as endonuclease enzyme, able to cleave 
at the 5’ side of the rNMP (Sparks et al. 2012; Heider et al. 2017). That RNase 
H2 functionality is important within the cell is testified by its requirement for the 
embryonic development in mouse (Hiller et al. 2012) and by the fact that, when 
mutated, is causally linked to the onset of AGS, a rare autoimmune 
inflammatory disease (Rice et al. 2013; Pizzi et al. 2014).  
Until now, Topoisomerase I is the only enzyme able to cleave rNMPs 
embedded in DNA, when the RER pathway does not work. Contrarily, studies 
conducted on the MMR and the NER pathways have shown the inefficiency of 
these pathways in the processing of this particular lesion (Williams et al. 2013; 
Lindsey-Boltz et al. 2015). It is still unclear if other known DNA repair pathways 
work as back-up mechanisms of the RER pathway. 
Remarkably, considering several published data, it can be 
hypothesized that, among many millions rNMPs that are introduced in the 
mammalian genome per cell cycle (Williams, Lujan, and Kunkel 2016), 
damaged rNMPs (such as abasic and oxidized) can also be incorporated into 
the DNA. In fact, RNA molecules, as well as rNMPs present in the nucleotide 
pool, are also susceptible to oxidative insults (Randerath et al. 1992; Moreira 
et al. 2008). Moreover, a significant generation of abasic sites formation has 
been demonstrated upon RNA oxidation and alkylation (Loeb and Preston 
1986).  
For this reason, whereas the role of RNase H2-initiated RER 
mechanism of DNA repair in recognizing and cleaving rNMPs embedded in 
DNA is well established (Williams, Lujan, and Kunkel 2016; Cerritelli and 
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Crouch 2009), little is known if the RER pathway, or other DNA repair pathways 
are involved in the removal of damaged rNMPs. 
Describing the repair of this non-canonical lesions could be considered 
a great step forward in the DNA repair field. 
In this context, a role of the Base Excision Repair (BER) pathway has 
not been addressed, yet. BER is the main pathway coping with the repair of 
non-distorting single-base lesions, such as abasic sites and oxidized bases 
(Dianov et al. 2001). For its abilities, BER may represent an interesting 
candidate to work as a back-up mechanism of RER on canonical rNMPs in 
DNA as well as preferable candidate on repairing abasic or oxidized rNMPs 
within DNA. Moreover, this hypothesis is encouraged by new discovered 
functions of the BER pathway in the RNA quality control surveillance and RNA-
decay. Specifically, a role of APE1, the main AP endonuclease working in the 
BER pathway, emerges for its ability to cleave abasic damaged RNA and for 
its involvement in the processing of miRNAs (Tell, Wilson, and Lee 2010; 
Jobert and Nilsen 2014; Antoniali et al. 2017).  
Although great steps forward have been done along this direction, there 
is still no evidence that the BER pathway can be associated to the removal of 
unmodified and/or modified rNMPs embedded in DNA. Characterizing this new 
unexpected ability of BER enzymes could improve our knowledge around the 
genotoxicity mechanism of oxidative stress and the impact of BER defects in 
human disease, cancer mechanisms, and for the development of new 
anticancer strategies.  
In light of this, this Project points on investigating if the RER pathway 
has a role on repairing abasic and oxidized rNMPs within DNA and on 
improving our knowledge about the putative role of BER on unmodified and 
modified rNMPs embedded in DNA. In this context, by different in vitro  assays 
and using different DNA oligonucleotides containing different damaged bases, 
we obtained interesting results that advance important information in this field. 
First, we started from abasic rNMPs (rAP) site embedded in a DNA 
oligonucleotide. We demonstrate that the rAP site is targeted by APE1 rather 
than RNase H2 in eukaryotic systems. Specifically, we have found that 
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eukaryotic RNase H2 enzymes from yeast and mouse (data not shown) and 
human, are unable to process rAP sites in DNA, whereas recombinant human 
APE1 is able to efficiently cleave this type of damage. APE1 processes the 
rAP site as efficiently as the canonical deoxy-abasic site as measured by 
kinetic data. Data using catalytically inactive APE1 mutants (E96A) clearly 
demonstrate that the endonuclease active site of APE1 is required to perform 
the endoribonuclease activity on a ribose abasic site in dsDNA. Differently, the 
cleavage activity of the 33N-terminal truncated mutant, which does not impact 
the catalytic function of the enzyme but is involved in the release of the product 
upon cleavage (Fantini et al. 2010), is comparable to that of wild-type APE1. 
This last result demonstrates that the unstructured N-domain is dispensable 
for the enzymatic reaction on the abasic ribonucleotide site. Moreover, using 
RNase H2 or APE1 depleted HeLa nuclear extracts, we showed that the 
processing activity of the rAP site in DNA depends only on the presence of 
APE1 and not on RNase H2.  
These results highlight a new role of APE1 in processing rAP sites 
embedded in DNA, demonstrating that the catalytic site of APE1 and the 
mechanism of product release is similar to that of the canonical deoxy-
substrate.  
In the second part of this Project, we moved on oxidized rG embedded 
in DNA. A potentially significant, yet poorly characterized, source of rNMPs 
incorporated in DNA may arise from oxidative stress. rNMPs were shown to 
form during oxidative DNA damage both in vitro and in vivo (Randerath et al. 
1992). This means that oxidation can occur not only on the G base but also on 
the deoxyribose converting it in ribose. Moreover, it is be possible that abasic 
and oxidized dNMPs into DNA are converted into abasic or oxidized rNMPs 
embedded in DNA. 
Furthermore, rAP sites embedded in DNA may be generated by 
spontaneous hydrolysis or by the action of an unknown glycosylase on 
oxidized rNMPs, such as r8oxoG.  
Published data have estimated the rate of depurination in DNA under 
physiological conditions that is about 10,000 abasic sites per day in human 
cells (Lindahl and Nyberg 1972). As it happens for DNA, spontaneous 
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depurination also occurs in RNA, although ~ 1,000 times slower than DNA 
(Kochetkov and Budovskii 1972). Considering that rNMPs abundance in DNA 
is very high (around 600,000 rNMPs in budding yeast genomic DNA, and 
therefore a factor of 250 higher in mammalian genomic DNA (150,000,000) 
(Williams, Lujan, and Kunkel 2016)), it is not unrealistic to deduce that cells 
may contain a non-negligible number of rAP sites in DNA as well as oxidized 
rNMPs, caused by oxidative stressors to whom the cell is often exposed, and 
that can increase in cancer cells. 
Interestingly, abasic RNA results significantly more stable than abasic 
DNA, suggesting that specific enzymatic mechanisms should exist in vivo  to 
cope with this lesion (Kupfer and Leumann 2006).  
In support of this, recent studies suggested that r8-oxoGTP is formed 
in vivo under oxidative stress conditions and may be incorporated during 
replication into DNA by S. pombe  and M. smegmatis polymerases (Sastre-
Moreno et al. 2014; Ordonez and Shuman 2014; Cilli et al. 2015), as well as 
by human DNA Polβ. However, concerning this last case, since the level and 
function of Polβ in cells are highly regulated by complex signaling mechanism 
(Parsons et al. 2011), the probability of r8oxoG incorporation into genomic 
DNA by Polβ is still a question under debate, which needs further experimental 
proof.  
Because of the spontaneous formation of rAP sites is a rare event, it is 
a key question to find enzymatic activities able to generate rAPs starting by a 
previous processing of oxidized rNMPs embedded in DNA.  
Although a possible RER and BER involvement in the removal of 
r8oxoG from DNA has been proposed in other reports (Cilli et al. 2015; Sassa 
et al. 2016), further work in our laboratory is ongoing along these lines to 
address these fundamental issues.  
Considering all these observations, we investigated the role of the RER 
pathway in the recognition and cleavage of oxidized rNMPs (r8oxoG) within 
DNA. After demonstrating its inability, we focused on BER proteins. 
First, we tested the RNase H2 activity on r8oxoG in a DNA substrate. 
Similarly to results obtained with the abasic rNMP in DNA, our data clearly 
demonstrate that the RER pathway is not involved in processing of oxidized 
rNMPs embedded in DNA. Eukaryotic RNase H2 is unable to process this 
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lesion in vitro. Interestingly, additional ongoing studies show that the 
prokaryotic counterpart of that protein seems to preserve the ability to process 
this modified rNMPs in DNA. Moreover, although the prokaryotic RNase HII is 
active on oxidized rG, the eukaryotic RNase H2 is completely inactive on this 
lesion, suggesting that the ability to process r8oxoG in DNA might have been 
lost during evolution. 
Based on these observations, we explored a potential role of the BER 
proteins, including OGG1 and APE1. First, we showed that the human OGG1, 
the main glycosylase enzyme able to recognize and repair oxidized dG, has 
neither a glycosylase nor a lyase activity on oxidized rG site embedded in a 
DNA substrate.  
Despite the ability of OGG1 to efficiently bind the oxidized substrate 
was confirmed, in agreement with recent findings (Sassa et al. 2016), it is 
possible to speculate that the enzyme is unable to hydrolyze the N-glycosidic 
bond of the r8oxoG maybe as a consequence of the steric hindrance with the 
2’-OH of the ribose which renders the C1’ unavailable for the nucleophilic 
attack by the catalytic site.  
Interestingly, we discovered that APE1 has a weak endoribonuclease 
activity on r8oxoG site embedded in a DNA substrate, and shows a 3’-
exonuclease activity, similarly to the 3’-exonuclease activity on DNA 
demonstrated previously (Wilson 2005; Beernink et al. 2001). In line with 
previous results, the 3’-exonuclease activity of APE1 is strictly dependent on 
Mg2+ concentration and on the presence of the first 33 aminoacids. The 
importance of the N-terminal domain is explained by different observations: i)  
it bears the majority of the positive charges of APE1; ii)  is the target of the main 
post-translational modifications of the protein (i.e. acetylation, ubiquitination, 
proteolysis); iii)  is involved in modulating the interaction with different protein 
partners, and finally iv) may modulate the catalytic rate, probably acting on the 
koff  of the catalytic reaction due to increased speed of product release 
(Vascotto et al. 2009; Fantini et al. 2010). These unexpected results, which 
suggest that APE1 3’-exonuclease activity strongly depends on the 
electrostatic interaction of APE1, involving its unstructured N-terminal domain, 
with the substrate (Wilson 2005), may be explained on the basis of the 
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previously characterized ability of APE1 to process some particular structured 
RNA species in a specific manner (Poletto et al. 2013). The weak endo- and 
3’-exonuclease activities on r8oxoG- containing substrate and their 
dependence on Mg2+-concentrations and on the presence of the first N-
terminal domain residues of APE1 are fully in agreement with the previously 
described nucleotide incision repair (NIR) function by APE1 on several 
oxidized substrates, such as: 5,6-dihydro-2’-deoxyuridine, 5,6-
dihydrothymidine, 5-hydroxy-2’-deoxyuridine, 5-hydroxycytosine (Mazouzi et 
al. 2013; Gros 2004b; Daviet et al. 2007b). Notably, the limited activity 
obtained in the experimental conditions we used (also after changing the pH 
conditions, data not shown) are in agreement with previous reports on the NIR 
function by APE1 on some particular substrates, such as the αdG:dG and the 
5OH-dC:dG (Daviet et al. 2007b). In addition, the biochemical characterization 
through MALDI-MS and HPLC analyses we performed may be suggestive for 
the existence of an equilibrium between different conformational species of 
r8oxoG dsDNA, excluding any possible bias due to contaminant present in the 
oligonucleotide used for the assays.  
Differently from our results, Sassa et al., found no enzymatic activity by 
APE1. This discrepancy with our results may be due to the different 
experimental conditions for the enzymatic assays, i.e. higher Mg2+ 
concentrations and the use of a small amount of EDTA, both aspects already 
demonstrated to strongly affect the APE1 enzymatic activity on the r8oxoG 
substrate. A comparative experiment, we performed (data not shown), was 
indeed supportive of this hypothesis, reinforcing the importance of the 
experimental conditions when studying the non-canonical functions of APE1 
protein. 
Therefore, these findings underscore the importance of identifying 
which enzyme(s) are responsible for the recognition and the efficient 
processing of the r8oxoG substrate, in order to further extend our studies of 
this hot scientific topic. 
The model structures of DNA with a unmodified rNMP or a rAP site in 
the RNase H2 and APE1 active site, respectively were compared (Figure 40). 
The canonical rNMP base is hydrogen bonded to the complementary DNA 
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strand base (Rychlik et al. 2010). After the recognition of the RNA:DNA 
junction, RNase H2 can incide the damage. On the contrary, the abasic rNMP 
is not bonded to the complementary strand, causing an orphan base on the 
complementary DNA strand. In this case, RNase H2 is not able to recognize 
the RNA:DNA junction and, consequently, cleave the abasic rNMP. We 
hypothesized that the lack of the hydrogen bonding between the abasic rNMP 
and the opposite deoxyribonucleotide interferes with the capacity of RNase H2 
to recognize and cleave an abasic rNMP.  
Differently from RNase H2, APE1 specifically recognizes and cleaves 
an abasic distortion in DNA, and engulfs the sugar-phosphate further distorting 
the DNA (Freudenthal et al. 2015b). We hypothesized that the ribose extra OH 
would have only minor influence on the structure, explaining how APE1 is able 
to cleave deoxy-abasic sites as well as ribo- abasic sites (Figure 40).  
 
  
 
Figure 40 Structural models with the active site of RNase H2 and APE1 in 
presence of a rNMP or a rAP, respectively  
T. maritima (left) and human APE1 (right) is in a complex with DNA having a single 
rNMP or single abasic residue, respectively. DNA is indicated in blue, while the single 
rNMP and the abasic residue are shown in red as sticks. Ribose or G base or abasic 
sites are pointed by arrows. Proteins are shown in green. The part of APE1 that engulf 
the abasic sugar is colored in magenta. PDB for RNase H2 is 303-F; for APE1 as 
1DEW (Courtesy of Professor Crouch-published in Malfatti et al., 2017). 
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In conclusion, we hypothesized a model in which 8oxo-ribonucleotides 
could be generated in the cellular nucleotide pool or even when they are 
already incorporated in DNA, possibly as a result of an oxidation of the sugar 
and/or the base.  
After the evidence that human RNase H2 is not able to process an 
oxidized rNMP embedded in DNA, we found that APE1 shows a weak but 
significant activity on it. Similarly, RNase H2 does not process a rAP 
embedded in DNA, which could be generated spontaneously or by the r8oxoG 
processing, and again APE1 possesses a strong activity on this type of 
damage. Because APE1 activity on 8oxo-ribonucleotides in DNA is low, we 
hypothesize that other proteins (probably a unknown glycosylase) may 
participate in their repair (Figure 41).  
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Figure 41 A model for the repair of oxidized and abasic rNMP sites embedded in 
DNA by APE1 
DNA ( ), when subjected to oxidative stress (yellow flash of lightning) in which 
oxidized damaged bases are generated (yellow dot), is efficiently repaired by Base 
Excision Repair (BER) pathway in which OGG1, the main glycosylase, processes the 
oxidized base leaving a deoxy- abasic site ( ) to APE1, the BER endonuclease, that 
cleaves the abasic site allowing the correct repair of damaged DNA (left side). At the 
same time, ribonucleotides embedded in DNA ( ) can be oxidized following by 
oxidative stress. Although OGG1 is not able to process r8oxoG, APE1 shows a weak 
activity on this damaged rNMP. Probably, an unknown glycosylase might cleave 
r8oxoG generating a ribo-abasic site ( ) that, as we have demonstrated, is efficiently 
processed by APE1 (right side). 
RNase H2, the main enzyme of Ribonucleotide Excision Repair pathway, is not 
involved in the processing of both types of damaged rNMPs embedded in DNA.  
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Although important discoveries have been done in this direction, 
several unresolved questions still remain open.  
As previously demonstrated in our lab, APE1-defective cells show 
increased oxidized rRNA content upon oxidative stress (Vascotto et al. 2009). 
Now, this observation seems to have a molecular explanation in the detected 
endoribonuclease activity of APE1 over r8oxoG- containing oligonucleotides 
and will deserve further attention in our future studies.  
Confirming the inability of OGG1 in the processing of r8oxoG site in 
DNA, experiments are underway in order to address if other glycosylases may 
process oxidized rNMPs to generate rAP sites, which surprisingly are 
processed by APE1 in a very efficient way.  
Thus, the first aim for the further development of this work is the 
identification of which enzyme(s) is recruited to cleave oxidized base of rNMPs 
incorporated in DNA generating an abasic rNMP site which may be 
subsequently processed by APE1.  
For instance, a role for the YB-1 protein in recognizing oxidized 
ribonucleotides sites in RNA has also been hypothesized (Hayakawa et al. 
2002), but no specific enzymatic mechanisms able to remove this oxidized 
base has been described, yet.  
As mentioned before, the accumulation of the oxidized RNA upon 
silencing of APE1 expression, may be explained by the assumption that 
enzymatic removal of oxidized rNMPs may represent the limiting step in the 
process. In addition, since APE1 is overexpressed in different types of cancer, 
such as ovarian, gastro-esophageal, pancreatico-biliary, lung and breast 
cancers (Woo et al. 2014; Al-Attar et al. 2010), it would be interesting to 
determine whether any correlation exists between its expression level and 
presence of modified rNMPs in cancers. Additional studies are ongoing along 
this direction.  
By starting from ribo-Seq analysis, we would like to re-adapt this 
technique in order to have the possibility to distinguish damaged, including 
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abasic and oxidized, rNMPs among the unmodified rNMPs embedded in DNA. 
Then, we will expand our knowledge about the formation of abasic 
ribonucleotides in DNA, that is still a matter of debate. Although, the existence 
of specific N-ribohydrolases, including the toxin ricin, has been already 
documented (Schramm 1997) to be able to generate abasic rNMPs in RNA 
molecules, besides spontaneous generation (Loeb and Preston 1986), more 
specific information are needed in this context. 
Then, we will investigate how the mis-incorporation of undamaged 
rNMPs changes under oxidative stress and/or silencing of APE1.  
Besides the weak direct activity of APE1 on r8oxoG, APE1 could be 
stimulated by a glycosylase activity allowing a faster turnover as demonstrated 
for DNA substrates (Vidal et al. 2001). Again, work is in progress along these 
lines to better inspect this mechanism and the putative glycosylase enzymes 
involved.  
The activity of APE1 on r8oxoG and rAP sites embedded in DNA does 
not hide the possibility that a similar activity could be exerted on RNA 
molecules too. This finding could represent the first demonstration of an 
enzyme able to recognize and process oxidized RNA (Vascotto et al. 2009). 
Since RNA oxidation has been shown to exert detrimental physiological 
effects, and to be a common feature in different human pathologies ranging 
from aging to neurodegenerative and cancer diseases (Simms and Zaher 
2016). This is testified by the fact that oxidized RNA (Rhee, Valentine, and 
Termini 1995) or RNA containing abasic sites (Kupfer and Leumann 2006) 
show inhibitory effects on reverse transcriptase activity, whereas oxidized 
mRNA (Shan, Chang, and Lin 2007; Tanaka, Chock, and Stadtman 2007) or 
mRNA with abasic sites (Hudak, Bauman, and Tumer 2002) exhibit 
compromised translation activity as well as translation fidelity (Calabretta, 
Kupfer, and Leumann 2015). Finding an enzyme involved in the processing of 
oxidized RNA could represent an amazing discovery in the DNA repair world 
that will open the way for the discovery of new molecular mechanisms 
underlying different pathogenesis and will set the basis for the creation of new 
drugs.	
	 	 Acknowledgments 
10. Acknowledgments  
Giunta a questo punto, la fine del mio percorso di Dottorato segna la fine 
di un periodo iniziato otto anni fa quando, non avendo superato il test per 
Medicina, decisi di intraprendere il corso in Biotecnologie.  
E da lì è iniziato tutto…  
Durante questo tortuoso meraviglioso percorso, mi sento in dovere di 
ringraziare tutte quelle persone che mi sono state vicine e che mi hanno 
lasciato un pezzo di loro.  
Innanzitutto, un grande Grazie a tutta la mia Famiglia... ai miei Genitori, che 
mi hanno permesso di studiare ciò che più mi piaceva elogiando ogni mio 
minuscolo passo in avanti e supportando ogni mia scelta. Certo in questi otto 
anni, non avete ancora superato la distanza, ma ci lavoreremo… ☺ Vi voglio 
bene. Un Grazie a mia sorella, la persona che è tanto diversa quanto simile a 
me e per questo, ti adoro con tutto il mio cuore. Grazie a Enrico, compagno di 
ogni singola avventura da nove anni. Tu solo sai quanto sia cambiata in questi 
anni e il tuo sguardo me lo dice quando mi sussurri quanto sei fiero di 
me…come sono è soprattutto grazie a Te che ascolti e plachi ogni mio lamento 
e ogni mia paura, e che ti emozioni quando io mi emoziono (perché dopotutto 
sei felice pure tu che APE1 taglia ☺). Ti voglio bene! Ma soprattutto Grazie 
all’ultima arrivata (per poco) della Famiglia, la mia piccola Nuty, che riesce a 
rendere spensierate anche le giornate più uggiose. 
Un enorme Grazie a Gianluca. Sei anni fa mi hai accolta nel tuo laboratorio 
nel quale, in punta di piedi, ho cercato di fare mio tutto ciò che potevi offrirmi. 
Non ti ringrazierò mai abbastanza per l’aiuto che mi hai offerto, per tutto ciò 
che mi hai insegnato e per tutto ciò che ancora mi devi insegnare, per tutte le 
volte che mi hai “sgridato” e per tutte le volte che mi hai detto che avevo 
sbagliato. Grazie per la maturità, lavorativa e non, che mi hai insegnato ad 
avere, per la forza che mi hai trasmesso quando mi vedevi a terra, per il sorriso 
sincero che mi hai donato quando mi hai visto crescere. Grazie per la mano 
che mi hai teso quando non sapevo come andare avanti, per tutti i “Brava” che 
mi hai detto (perché so che erano tutti sinceri), per tutte le volte che, vedendo 
la mia fragilità, mi hai trattato come una figlia. Senza di Te questo percorso 
non sarebbe stato lo stesso… per me sarai sempre il capo numero 1 ☺. 
Grazie alle mie fantastiche colleghe Giulia, Silvia, Giovanna e Marta… 
lavorare sarebbe molto più stancante senza i sorrisi e le risate che mi 
strappate ☺.  
Un enorme Grazie a Mattia, il mio primo e unico tutor. Ti ringrazio per tutto 
l’aiuto che mi hai dato quando ancora non sapevo che cosa significasse fare 
scienza ☺. 
Grazie a Lisa che sebbene sia lontano si ricorda di me e dei bei tempi in lab. 
Grazie a Lorenzo e alle sue luuuunghe chiacchierate sui massimi sistemi ☺. 
	 	 Acknowledgments 
	 107	
Grazie a Erika, che rende la vita di laboratorio un po’ più “magica” (tu sai a 
cosa mi riferisco ☺). 
Grazie a Rhena, Arianna e Giulia, compagne di Università e di quei bellissimi 
5 anni insieme che rimpiango spesso. 
Grazie a Francesca, Havva, Sathya e Chance che mi hanno permesso di 
lavorare nel loro laboratorio ad Atlanta e di condire la mia vita con una delle 
esperienze più belle e al tempo stesso sconvolgenti della mia vita.  
	
Spero che voi tutti condividiate questo mio meraviglioso percorso nel mondo 
della Biologia. 
	
“ 	.	.	.
		…”	
	
	
	
	
	
	
	  List of Publications 
11.  List of Publications (2014-2017) 
 “Inhibitors of the Apurinic/Apyrimidinic Endonuclease 1 
(APE1)/Nucleophosmin (NPM1) Interaction That Display Anti-Tumor 
Properties”, Mattia Poletto, Matilde Clarissa Malfatti,  Dorjbal Dorjsuren, Pasqualina 
L. Scognamiglio, Daniela Marasco, Carlo Vascotto, Ajit Jadhav, David J. Maloney, 
David M. Wilson III, Anton Simeonov, and Gianluca Tell, Molecular Carcinogenesis, 
2016. 10.1002/mc.22313  
 
 “Unveiling the non-repair face of the Base Excision Repair pathway in RNA 
processing: A missing link between DNA repair and gene expression?”, Giulia 
Antoniali, Matilde Clarissa Malfatti, Gianluca Tell, DNA Repair, 2017. 
10.1016/j.dnarep.2017.06.008  
 
 “Abasic and oxidized ribonucleotides embedded in DNA are processed by 
human APE1 and not by RNase H2”, Matilde Clarissa Malfatti, Sathya 
Balachander, Giulia Antoniali, Kyung Duk Koh, Christine Saint-Pierre, Didier 
Gasparutto, Hyongi Chon, Robert J. Crouch, Francesca Storici, and Gianluca Tell.
10.1093/nar/gkx723  
 
 “Human AP endonuclease activity on telomeric G4 structures is dependent on 
acetylatable Lysine residues on the N-terminal domain”, Silvia Burra, Daniela 
Marasco, Matilde Clarissa Malfatti, Giulia Antoniali, Bruce Demple, Antonella 
Virgilio, Veronica Esposito, Aldo Galeone, Gianluca Tell, in preparation.  
 
 “APE1/NPM1 axis in Triple Negative Breast Cancer”, Matilde Clarissa Malfatti, 
Lorenzo Gerratana, Carla Di Loreto, Fabio Puglisi, Gianluca Tell, in preparation.   
 
	 	 References 
12. References 
• Al-Attar, A., L. Gossage, K. R. Fareed, M. Shehata, M. Mohammed, A. M. 
Zaitoun, I. Soomro, et al. 2010. “Human Apurinic/apyrimidinic Endonuclease 
(APE1) Is a Prognostic Factor in Ovarian, Gastro-Oesophageal and 
Pancreatico-Biliary Cancers.” British Journal of Cancer 102 (4): 704–9. 
https://doi.org/10.1038/sj.bjc.6605541. 
• Allinson, Sarah L, Kate M Sleeth, Gemma E Matthewman, and Grigory L 
Dianov. 2004. “Orchestration of Base Excision Repair by Controlling the Rates 
of Enzymatic Activities.” DNA Repair 3 (1): 23–31. 
https://doi.org/10.1016/j.dnarep.2003.09.002. 
• Almeida, Karen H., and Robert W. Sobol. 2007. “A Unified View of Base 
Excision Repair: Lesion-Dependent Protein Complexes Regulated by Post-
Translational Modification.” DNA Repair 6 (6): 695–711. 
https://doi.org/10.1016/j.dnarep.2007.01.009. 
• Alseth, Ingrun, Lars Eide, Manuela Pirovano, Torbjørn Rognes, Erling 
Seeberg, and Magnar Bjør\a as. 1999. “The Saccharomyces Cerevisiae 
Homologues of Endonuclease III from Escherichia Coli, Ntg1 and Ntg2, Are 
Both Required for Efficient Repair of Spontaneous and Induced Oxidative 
DNA Damage in Yeast.” Molecular and Cellular Biology 19 (5): 3779–87. 
• An, Qian, Peter Robins, Tomas Lindahl, and Deborah E. Barnes. 2007. “5-
Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA 
Glycosylase to Reduce Drug Cytotoxicity.” Cancer Research 67 (3): 940–45. 
• Antoniali, Giulia, Lisa Lirussi, Chiara D’Ambrosio, Fabrizio Dal Piaz, Carlo 
Vascotto, Elena Casarano, Daniela Marasco, Andrea Scaloni, Federico 
Fogolari, and Gianluca Tell. 2014. “SIRT1 Gene Expression upon Genotoxic 
Damage Is Regulated by APE1 through nCaRE-Promoter Elements.” 
Molecular Biology of the Cell 25 (4): 532–47. 
https://doi.org/10.1091/mbc.E13-05-0286. 
• Antoniali, Giulia, Lisa Lirussi, Mattia Poletto, and Gianluca Tell. 2014. 
“Emerging Roles of the Nucleolus in Regulating the DNA Damage Response: 
The Noncanonical DNA Repair Enzyme APE1/Ref-1 as a Paradigmatical 
Example.” Antioxidants & Redox Signaling 20 (4): 621–39. 
https://doi.org/10.1089/ars.2013.5491. 
• Antoniali, Giulia, Matilde Clarissa Malfatti, and Gianluca Tell. 2017. 
“Unveiling the Non-Repair Face of the Base Excision Repair Pathway in RNA 
Processing: A Missing Link between DNA Repair and Gene Expression?” 
DNA Repair 56 (August): 65–74. 
https://doi.org/10.1016/j.dnarep.2017.06.008. 
• Antoniali, Giulia, Fabrizio Serra, Lisa Lirussi, Mikiei Tanaka, Chiara 
D’Ambrosio, Shiheng Zhang, Slobodanka Radovic, et al. 2017. “Mammalian 
APE1 Controls miRNA Processing and Its Interactome Is Linked to Cancer 
RNA Metabolism.” Nature Communications 8 (1): 797. 
https://doi.org/10.1038/s41467-017-00842-8. 
• Audebert, M., J. P. Radicella, and M. Dizdaroglu. 2000. “Effect of Single 
Mutations in the OGG1 Gene Found in Human Tumors on the Substrate 
Specificity of the Ogg1 Protein.” Nucleic Acids Research 28 (14): 2672–78. 
• Bailly, V., and W. G. Verly. 1988. “Possible Roles of Beta-Elimination and 
Delta-Elimination Reactions in the Repair of DNA Containing AP 
	 	 References 
	110
(apurinic/apyrimidinic) Sites in Mammalian Cells.” The Biochemical Journal 
253 (2): 553–59. 
• Balazy, Michael, and Santosh Nigam. 2003. “Aging, Lipid Modifications and 
Phospholipases--New Concepts.” Ageing Research Reviews 2 (2): 191–209. 
• Barnes, T., W.-C. Kim, A. K. Mantha, S.-E. Kim, T. Izumi, S. Mitra, and C. 
H. Lee. 2009. “Identification of Apurinic/apyrimidinic Endonuclease 1 (APE1) 
as the Endoribonuclease That Cleaves c-Myc mRNA.” Nucleic Acids Research 
37 (12): 3946–58. https://doi.org/10.1093/nar/gkp275. 
• Barzilay, Gil, Lisa J. Walker, Craig N. Robson, and Ian D. Hickson. 1995. 
“Site-Directed Mutagenesis of the Human DNA Repair Enzyme HAP1: 
Identification of Residues Important for AP Endonuclease and RNase H 
Activity.” Nucleic Acids Research 23 (9): 1544–50. 
• Bauer, Nicholas C., Anita H. Corbett, and Paul W. Doetsch. 2015. “The 
Current State of Eukaryotic DNA Base Damage and Repair.” Nucleic Acids 
Research, October, gkv1136. https://doi.org/10.1093/nar/gkv1136. 
• Beernink, Peter T, Brent W Segelke, Masood Z Hadi, Jan P Erzberger, David 
M Wilson, and Bernhard Rupp. 2001. “Two Divalent Metal Ions in the Active 
Site of a New Crystal Form of Human Apurinic/apyrimidinic Endonuclease, 
ape1: Implications for the Catalytic Mechanism.” Journal of Molecular 
Biology 307 (4): 1023–34. https://doi.org/10.1006/jmbi.2001.4529. 
• Berglund, Anna-Karin, Clara Navarrete, Martin K. M. Engqvist, Emily 
Hoberg, Zsolt Szilagyi, Robert W. Taylor, Claes M. Gustafsson, Maria 
Falkenberg, and Anders R. Clausen. 2017. “Nucleotide Pools Dictate the 
Identity and Frequency of Ribonucleotide Incorporation in Mitochondrial 
DNA.” PLoS Genetics 13 (2): e1006628. 
https://doi.org/10.1371/journal.pgen.1006628. 
• Berquist, Brian R., Daniel R. McNeill, and David M. Wilson. 2008. 
“Characterization of Abasic Endonuclease Activity of Human Ape1 on 
Alternative Substrates, as Well as Effects of ATP and Sequence Context on AP 
Site Incision.” Journal of Molecular Biology 379 (1): 17–27. 
https://doi.org/10.1016/j.jmb.2008.03.053. 
• Blaisdell, J. O., and S. S. Wallace. 2001. “Abortive Base-Excision Repair of 
Radiation-Induced Clustered DNA Lesions in Escherichia Coli.” Proceedings 
of the National Academy of Sciences 98 (13): 7426–30. 
https://doi.org/10.1073/pnas.131077798. 
• Boiteux, Serge, and J. Pablo Radicella. 1999. “Base Excision Repair of 8-
Hydroxyguanine Protects DNA from Endogenous Oxidative Stress.” 
Biochimie 81 (1): 59–67. 
• Boiteux, Serge, and J.Pablo Radicella. 2000. “The Human OGG1 Gene: 
Structure, Functions, and Its Implication in the Process of Carcinogenesis.” 
Archives of Biochemistry and Biophysics 377 (1): 1–8. 
https://doi.org/10.1006/abbi.2000.1773. 
• Boveris, A., and E. Cadenas. 2000. “Mitochondrial Production of Hydrogen 
Peroxide Regulation by Nitric Oxide and the Role of Ubisemiquinone.” 
IUBMB Life 50 (4-5): 245–50. https://doi.org/10.1080/713803732. 
• Boveris, A., L. E. Costa, J. J. Poderoso, M. C. Carreras, and E. Cadenas. 2000. 
“Regulation of Mitochondrial Respiration by Oxygen and Nitric Oxide.” 
Annals of the New York Academy of Sciences 899: 121–35. 
• Brambati, Alessandra, Arianna Colosio, Luca Zardoni, Lorenzo Galanti, and 
Giordano Liberi. 2015. “Replication and Transcription on a Collision Course: 
	 	 References 
	 111	
Eukaryotic Regulation Mechanisms and Implications for DNA Stability.” 
Frontiers in Genetics 6: 166. https://doi.org/10.3389/fgene.2015.00166. 
• Breen, A. P., and J. A. Murphy. 1995. “Reactions of Oxyl Radicals with DNA.” 
Free Radical Biology & Medicine 18 (6): 1033–77. 
• Brown, Jessica A., Kevin A. Fiala, Jason D. Fowler, Shanen M. Sherrer, Sean 
A. Newmister, Wade W. Duym, and Zucai Suo. 2010. “A Novel Mechanism 
of Sugar Selection Utilized by a Human X-Family DNA Polymerase.” Journal 
of Molecular Biology 395 (2): 282–90. 
https://doi.org/10.1016/j.jmb.2009.11.003. 
• Brown, Jessica A., and Zucai Suo. 2011. “Unlocking the Sugar ‘Steric Gate’ 
of DNA Polymerases.” Biochemistry 50 (7): 1135–42. 
https://doi.org/10.1021/bi101915z. 
• Brzostek-Racine, S., C. Gordon, S. Van Scoy, and N. C. Reich. 2011. “The 
DNA Damage Response Induces IFN.” The Journal of Immunology 187 (10): 
5336–45. https://doi.org/10.4049/jimmunol.1100040. 
• Bubeck, D., M. A. M. Reijns, S. C. Graham, K. R. Astell, E. Y. Jones, and A. 
P. Jackson. 2011. “PCNA Directs Type 2 RNase H Activity on DNA 
Replication and Repair Substrates.” Nucleic Acids Research 39 (9): 3652–66. 
https://doi.org/10.1093/nar/gkq980. 
• Busso, Carlos S., Michael W. Lake, and Tadahide Izumi. 2010. 
“Posttranslational Modification of Mammalian AP Endonuclease (APE1).” 
Cellular and Molecular Life Sciences 67 (21): 3609–20. 
https://doi.org/10.1007/s00018-010-0487-3. 
• Bustamante, J., G. Bersier, M. Romero, R. A. Badin, and A. Boveris. 2000. 
“Nitric Oxide Production and Mitochondrial Dysfunction during Rat 
Thymocyte Apoptosis.” Archives of Biochemistry and Biophysics 376 (2): 
239–47. https://doi.org/10.1006/abbi.2000.1716. 
• Cadenas, E., J. J. Poderoso, F. Antunes, and A. Boveris. 2000. “Analysis of the 
Pathways of Nitric Oxide Utilization in Mitochondria.” Free Radical Research 
33 (6): 747–56. 
• Cadet, Jean. 2014. “Oxidative Degradation Pathways of Cellular DNA: 
Product Formation and Mechanistic Insights.” Free Radical Biology & 
Medicine 75 Suppl 1 (October): S2. 
https://doi.org/10.1016/j.freeradbiomed.2014.10.598. 
• Cadet, Jean, Kelvin J.A. Davies, Marisa HG Medeiros, Paolo Di Mascio, and 
J. Richard Wagner. 2017. “Formation and Repair of Oxidatively Generated 
Damage in Cellular DNA.” Free Radical Biology and Medicine 107 (June): 
13–34. https://doi.org/10.1016/j.freeradbiomed.2016.12.049. 
• Calabretta, A., P. A. Kupfer, and C. J. Leumann. 2015. “The Effect of RNA 
Base Lesions on mRNA Translation.” Nucleic Acids Research, April. 
https://doi.org/10.1093/nar/gkv377. 
• Caldecott, Keith W. 2014. “Molecular Biology. Ribose--an Internal Threat to 
DNA.” Science (New York, N.Y.) 343 (6168): 260–61. 
https://doi.org/10.1126/science.1248234. 
• Capranico, Giovanni, Jessica Marinello, and Giovanni Chillemi. 2017. “Type 
I DNA Topoisomerases.” Journal of Medicinal Chemistry 60 (6): 2169–92. 
https://doi.org/10.1021/acs.jmedchem.6b00966. 
• Cerritelli, Susana M., and Robert J. Crouch. 2009. “Ribonuclease H: The 
Enzymes in Eukaryotes: Ribonucleases H of Eukaryotes.” FEBS Journal 276 
(6): 1494–1505. https://doi.org/10.1111/j.1742-4658.2009.06908.x. 
	 	 References 
	112
• Cerritelli, Susana M., Ella G. Frolova, Chiguang Feng, Alexander Grinberg, 
Paul E. Love, and Robert J. Crouch. 2003. “Failure to Produce Mitochondrial 
DNA Results in Embryonic Lethality in Rnaseh1 Null Mice.” Molecular Cell 
11 (3): 807–15. 
• Cesaratto, Laura, Erika Codarin, Carlo Vascotto, Antonio Leonardi, Mark R. 
Kelley, Claudio Tiribelli, and Gianluca Tell. 2013. “Specific Inhibition of the 
Redox Activity of Ape1/Ref-1 by E3330 Blocks Tnf-Α-Induced Activation of 
Il-8 Production in Liver Cancer Cell Lines.” Edited by Gordon Langsley. PLoS 
ONE 8 (8): e70909. https://doi.org/10.1371/journal.pone.0070909. 
• Chan, Simon Wan, and Peter C. Dedon. 2010. “The Biological and Metabolic 
Fates of Endogenous DNA Damage Products.” Journal of Nucleic Acids 2010 
(December): 929047. https://doi.org/10.4061/2010/929047. 
• Chapados, Brian R, Qing Chai, David J Hosfield, Junzhuan Qiu, Binghui Shen, 
and John A Tainer. 2001. “Structural Biochemistry of a Type 2 RNase H: RNA 
Primer Recognition and Removal during DNA replication11Edited by K. 
Morikawa.” Journal of Molecular Biology 307 (2): 541–56. 
https://doi.org/10.1006/jmbi.2001.4494. 
• Chatterjee, Nimrat, and Graham C. Walker. 2017. “Mechanisms of DNA 
Damage, Repair, and Mutagenesis: DNA Damage and Repair.” Environmental 
and Molecular Mutagenesis 58 (5): 235–63. https://doi.org/10.1002/em.22087. 
• Chattopadhyay, Ranajoy, Soumita Das, Amit K. Maiti, Istvan Boldogh, Jingwu 
Xie, Tapas K. Hazra, Kimitoshi Kohno, Sankar Mitra, and Kishor K. Bhakat. 
2008. “Regulatory Role of Human AP-Endonuclease (APE1/Ref-1) in YB-1-
Mediated Activation of the Multidrug Resistance Gene MDR1.” Molecular 
and Cellular Biology 28 (23): 7066–80. https://doi.org/10.1128/MCB.00244-
08. 
• Chiu, Hsiang-Chih, Kyung Duk Koh, Marina Evich, Annie L. Lesiak, Markus 
W. Germann, Angelo Bongiorno, Elisa Riedo, and Francesca Storici. 2014. 
“RNA Intrusions Change DNA Elastic Properties and Structure.” Nanoscale 6 
(17): 10009. https://doi.org/10.1039/C4NR01794C. 
• Chohan, Manbir, Sebastian Mackedenski, Wai-Ming Li, and Chow H. Lee. 
2015. “Human Apurinic/Apyrimidinic Endonuclease 1 (APE1) Has 3′ RNA 
Phosphatase and 3′ Exoribonuclease Activities.” Journal of Molecular Biology 
427 (2): 298–311. https://doi.org/10.1016/j.jmb.2014.12.001. 
• Chon, H., A. Vassilev, M. L. DePamphilis, Y. Zhao, J. Zhang, P. M. Burgers, 
R. J. Crouch, and S. M. Cerritelli. 2009. “Contributions of the Two Accessory 
Subunits, RNASEH2B and RNASEH2C, to the Activity and Properties of the 
Human RNase H2 Complex.” Nucleic Acids Research 37 (1): 96–110. 
https://doi.org/10.1093/nar/gkn913. 
• Chon, Hyongi, Justin L. Sparks, Monika Rychlik, Marcin Nowotny, Peter M. 
Burgers, Robert J. Crouch, and Susana M. Cerritelli. 2013. “RNase H2 Roles 
in Genome Integrity Revealed by Unlinking Its Activities.” Nucleic Acids 
Research 41 (5): 3130–43. https://doi.org/10.1093/nar/gkt027. 
• Chou, K.-m., and Y.-c. Cheng. 2003. “The Exonuclease Activity of Human 
Apurinic/Apyrimidinic Endonuclease (APE1): BIOCHEMICAL 
PROPERTIES AND INHIBITION BY THE NATURAL DINUCLEOTIDE 
Gp4G.” Journal of Biological Chemistry 278 (20): 18289–96. 
https://doi.org/10.1074/jbc.M212143200. 
• Cilli, Piera, Anna Minoprio, Cecilia Bossa, Margherita Bignami, and Filomena 
Mazzei. 2015. “Formation and Repair of Mismatches Containing 
Ribonucleotides and Oxidized Bases at Repeated DNA Sequences.” Journal 
	 	 References 
	 113	
of Biological Chemistry 290 (43): 26259–69. 
https://doi.org/10.1074/jbc.M115.679209. 
• Clausen, Anders R, Scott A Lujan, Adam B Burkholder, Clinton D Orebaugh, 
Jessica S Williams, Maryam F Clausen, Ewa P Malc, et al. 2015. “Tracking 
Replication Enzymology in Vivo by Genome-Wide Mapping of 
Ribonucleotide Incorporation.” Nature Structural & Molecular Biology, 
January. https://doi.org/10.1038/nsmb.2957. 
• Clausen, Anders R., Sufang Zhang, Peter M. Burgers, Marietta Y. Lee, and 
Thomas A. Kunkel. 2013. “Ribonucleotide Incorporation, Proofreading and 
Bypass by Human DNA Polymerase δ.” DNA Repair 12 (2): 121–27. 
https://doi.org/10.1016/j.dnarep.2012.11.006. 
• Collins, A. R., M. Dusinská, C. M. Gedik, and R. Stĕtina. 1996. “Oxidative 
Damage to DNA: Do We Have a Reliable Biomarker?” Environmental Health 
Perspectives 104 Suppl 3 (May): 465–69. 
• Crespan, Emmanuele, Antonia Furrer, Marcel Rösinger, Federica Bertoletti, 
Elisa Mentegari, Giulia Chiapparini, Ralph Imhof, et al. 2016. “Impact of 
Ribonucleotide Incorporation by DNA Polymerases β and λ on Oxidative Base 
Excision Repair.” Nature Communications 7 (February): 10805. 
https://doi.org/10.1038/ncomms10805. 
• Crow, Yanick J, Andrea Leitch, Bruce E Hayward, Anna Garner, Rekha 
Parmar, Elen Griffith, Manir Ali, et al. 2006. “Mutations in Genes Encoding 
Ribonuclease H2 Subunits Cause Aicardi-Goutières Syndrome and Mimic 
Congenital Viral Brain Infection.” Nature Genetics 38 (8): 910–16. 
https://doi.org/10.1038/ng1842. 
• Crow, Yanick J., and Nicolas Manel. 2015. “Aicardi–Goutières Syndrome and 
the Type I Interferonopathies.” Nature Reviews Immunology 15 (7): 429–40. 
https://doi.org/10.1038/nri3850. 
• Cunningham, R. P., S. M. Saporito, S. G. Spitzer, and B. Weiss. 1986. 
“Endonuclease IV (nfo) Mutant of Escherichia Coli.” Journal of Bacteriology 
168 (3): 1120–27. 
• Daigaku, Yasukazu, Andrea Keszthelyi, Carolin A Müller, Izumi Miyabe, 
Tony Brooks, Renata Retkute, Mike Hubank, Conrad A Nieduszynski, and 
Antony M Carr. 2015. “A Global Profile of Replicative Polymerase Usage.” 
Nature Structural & Molecular Biology 22 (3): 192–98. 
https://doi.org/10.1038/nsmb.2962. 
• David, Sheila S., Valerie L. O’Shea, and Sucharita Kundu. 2007. “Base-
Excision Repair of Oxidative DNA Damage.” Nature 447 (7147): 941–50. 
https://doi.org/10.1038/nature05978. 
• Daviet, Stéphane, Sophie Couvé-Privat, Laurent Gros, Kazuo Shinozuka, 
Hiroshi Ide, Murat Saparbaev, and Alexander A. Ishchenko. 2007a. “Major 
Oxidative Products of Cytosine Are Substrates for the Nucleotide Incision 
Repair Pathway.” DNA Repair 6 (1): 8–18. 
https://doi.org/10.1016/j.dnarep.2006.08.001. 
• ———. 2007b. “Major Oxidative Products of Cytosine Are Substrates for the 
Nucleotide Incision Repair Pathway.” DNA Repair 6 (1): 8–18. 
https://doi.org/10.1016/j.dnarep.2006.08.001. 
• Demple, B., T. Herman, and D. S. Chen. 1991. “Cloning and Expression of 
APE, the cDNA Encoding the Major Human Apurinic Endonuclease: 
Definition of a Family of DNA Repair Enzymes.” Proceedings of the National 
Academy of Sciences of the United States of America 88 (24): 11450–54. 
	 	 References 
	114
• Déry, Ugo, and Jean-Yves Masson. 2007. “Twists and Turns in the Function 
of DNA Damage Signaling and Repair Proteins by Post-Translational 
Modifications.” DNA Repair 6 (5): 561–77. 
https://doi.org/10.1016/j.dnarep.2006.12.009. 
• Dianov, G. L., N. Souza-Pinto, S. G. Nyaga, T. Thybo, T. Stevnsner, and V. 
A. Bohr. 2001. “Base Excision Repair in Nuclear and Mitochondrial DNA.” 
Progress in Nucleic Acid Research and Molecular Biology 68: 285–97. 
• Dianov, Grigory L., and Ulrich Hübscher. 2013. “Mammalian Base Excision 
Repair: The Forgotten Archangel.” Nucleic Acids Research 41 (6): 3483–90. 
https://doi.org/10.1093/nar/gkt076. 
• Dizdaroglu, M., E. Holwitt, M. P. Hagan, and W. F. Blakely. 1986. “Formation 
of Cytosine Glycol and 5,6-Dihydroxycytosine in Deoxyribonucleic Acid on 
Treatment with Osmium Tetroxide.” The Biochemical Journal 235 (2): 531–
36. 
• Dizdaroglu, Miral. 2012. “Oxidatively Induced DNA Damage: Mechanisms, 
Repair and Disease.” Cancer Letters 327 (1-2): 26–47. 
https://doi.org/10.1016/j.canlet.2012.01.016. 
• Donley, Nathan, Pawel Jaruga, Erdem Coskun, Miral Dizdaroglu, Amanda K. 
McCullough, and R. Stephen Lloyd. 2015. “Small Molecule Inhibitors of 8-
Oxoguanine DNA Glycosylase-1 (OGG1).” ACS Chemical Biology 10 (10): 
2334–43. https://doi.org/10.1021/acschembio.5b00452. 
• Drohat, Alexander C., and Christopher T. Coey. 2016. “Role of Base Excision 
‘Repair’ Enzymes in Erasing Epigenetic Marks from DNA.” Chemical 
Reviews 116 (20): 12711–29. https://doi.org/10.1021/acs.chemrev.6b00191. 
• Erzberger, Jan P., and David M. Wilson. 1999. “The Role of Mg 2+ and 
Specific Amino Acid Residues in the Catalytic Reaction of the Major Human 
Abasic Endonuclease: New Insights from EDTA-Resistant Incision of Acyclic 
Abasic Site Analogs and Site-Directed Mutagenesis.” Journal of Molecular 
Biology 290 (2): 447–57. 
• Evich, Marina, Alexander M. Spring-Connell, Francesca Storici, and Markus 
W. Germann. 2016. “Structural Impact of Single Ribonucleotide Residues in 
DNA.” ChemBioChem 17 (20): 1968–77. 
https://doi.org/10.1002/cbic.201600385. 
• Fan, Jinshui, and David M. Wilson. 2005. “Protein-Protein Interactions and 
Posttranslational Modifications in Mammalian Base Excision Repair.” Free 
Radical Biology & Medicine 38 (9): 1121–38. 
https://doi.org/10.1016/j.freeradbiomed.2005.01.012. 
• Fantini, Damiano, Damiano Fantini, Carlo Vascotto, Marta Deganuto, 
Nicoletta Bivi, Stefano Gustincich, Gabriella Marcon, et al. 2008. “APE1/Ref-
1 Regulates PTEN Expression Mediated by Egr-1.” Free Radical Research 42 
(1): 20–29. https://doi.org/10.1080/10715760701765616. 
• Fantini, Damiano, Carlo Vascotto, Daniela Marasco, Chiara D’Ambrosio, 
Milena Romanello, Luigi Vitagliano, Carlo Pedone, et al. 2010. “Critical 
Lysine Residues within the Overlooked N-Terminal Domain of Human APE1 
Regulate Its Biological Functions.” Nucleic Acids Research 38 (22): 8239–56. 
https://doi.org/10.1093/nar/gkq691. 
• Fleming, Aaron M., and Cynthia J. Burrows. 2017. “8-Oxo-7,8-
Dihydroguanine, Friend and Foe: Epigenetic-like Regulator versus Initiator of 
Mutagenesis.” DNA Repair 56 (August): 75–83. 
https://doi.org/10.1016/j.dnarep.2017.06.009. 
	 	 References 
	 115	
• Fleming, Aaron M., Yun Ding, and Cynthia J. Burrows. 2017. “Oxidative 
DNA Damage Is Epigenetic by Regulating Gene Transcription via Base 
Excision Repair.” Proceedings of the National Academy of Sciences, January, 
201619809. https://doi.org/10.1073/pnas.1619809114. 
• Förstemann, Klaus, and Joachim Lingner. 2005. “Telomerase Limits the 
Extent of Base Pairing between Template RNA and Telomeric DNA.” EMBO 
Reports 6 (4): 361–66. https://doi.org/10.1038/sj.embor.7400374. 
• Freudenthal, Bret D, William A Beard, Matthew J Cuneo, Nadezhda S 
Dyrkheeva, and Samuel H Wilson. 2015a. “Capturing Snapshots of APE1 
Processing DNA Damage.” Nature Structural & Molecular Biology, October. 
https://doi.org/10.1038/nsmb.3105. 
• Freudenthal, Bret D., William A. Beard, Matthew J. Cuneo, Nadezhda S. 
Dyrkheeva, and Samuel H. Wilson. 2015b. “Capturing Snapshots of APE1 
Processing DNA Damage.” Nature Structural & Molecular Biology 22 (11): 
924–31. https://doi.org/10.1038/nsmb.3105. 
• Friedberg, Errol C., and Lisiane B. Meira. 2003. “Database of Mouse Strains 
Carrying Targeted Mutations in Genes Affecting Biological Responses to 
DNA Damage. Version 5.” DNA Repair 2 (5): 501–30. 
• Fromme, J. Christopher, Steven D. Bruner, Wei Yang, Martin Karplus, and 
Gregory L. Verdine. 2003. “Product-Assisted Catalysis in Base-Excision DNA 
Repair.” Nature Structural Biology 10 (3): 204–11. 
https://doi.org/10.1038/nsb902. 
• Gasparutto, D., T. Livache, H. Bazin, A. M. Duplaa, A. Guy, A. Khorlin, D. 
Molko, A. Roget, and R. Téoule. 1992. “Chemical Synthesis of a Biologically 
Active Natural tRNA with Its Minor Bases.” Nucleic Acids Research 20 (19): 
5159–66. 
• Gebicki, Janusz M. 2016. “Oxidative Stress, Free Radicals and Protein 
Peroxides.” Archives of Biochemistry and Biophysics 595 (April): 33–39. 
https://doi.org/10.1016/j.abb.2015.10.021. 
• Gelin, Aurore, Modesto Redrejo-Rodríguez, Jacques Laval, Olga S. Fedorova, 
Murat Saparbaev, and Alexander A. Ishchenko. 2010. “Genetic and 
Biochemical Characterization of Human AP Endonuclease 1 Mutants 
Deficient in Nucleotide Incision Repair Activity.” Edited by Martin G. 
Marinus. PLoS ONE 5 (8): e12241. 
https://doi.org/10.1371/journal.pone.0012241. 
• Gorman, Michael A., Solange Morera, Dominic G. Rothwell, Eric de La 
Fortelle, Clifford D. Mol, John A. Tainer, Ian D. Hickson, and Paul S. 
Freemont. 1997. “The Crystal Structure of the Human DNA Repair 
Endonuclease HAP1 Suggests the Recognition of Extra-Helical Deoxyribose 
at DNA Abasic Sites.” The EMBO Journal 16 (21): 6548–58. 
• Gros, L. 2004a. “The Major Human AP Endonuclease (Ape1) Is Involved in 
the Nucleotide Incision Repair Pathway.” Nucleic Acids Research 32 (1): 73–
81. https://doi.org/10.1093/nar/gkh165. 
• ———. 2004b. “The Major Human AP Endonuclease (Ape1) Is Involved in 
the Nucleotide Incision Repair Pathway.” Nucleic Acids Research 32 (1): 73–
81. https://doi.org/10.1093/nar/gkh165. 
• Guikema, J. E. J., R. M. Gerstein, E. K. Linehan, E. K. Cloherty, E. Evan-
Browning, D. Tsuchimoto, Y. Nakabeppu, and C. E. Schrader. 2011. 
“Apurinic/Apyrimidinic Endonuclease 2 Is Necessary for Normal B Cell 
Development and Recovery of Lymphoid Progenitors after Chemotherapeutic 
	 	 References 
	116
Challenge.” The Journal of Immunology 186 (4): 1943–50. 
https://doi.org/10.4049/jimmunol.1002422. 
• Guikema, Jeroen E. J., Erin K. Linehan, Nada Esa, Daisuke Tsuchimoto, 
Yusaku Nakabeppu, Robert T. Woodland, and Carol E. Schrader. 2014. 
“Apurinic/apyrimidinic Endonuclease 2 Regulates the Expansion of Germinal 
Centers by Protecting against Activation-Induced Cytidine Deaminase-
Independent DNA Damage in B Cells.” Journal of Immunology (Baltimore, 
Md.: 1950) 193 (2): 931–39. https://doi.org/10.4049/jimmunol.1400002. 
• Hadi, Masood Z., Krzysztof Ginalski, Lam H. Nguyen, and David M. Wilson. 
2002. “Determinants in Nuclease Specificity of Ape1 and Ape2, Human 
Homologues of Escherichia Coli Exonuclease III.” Journal of Molecular 
Biology 316 (3): 853–66. https://doi.org/10.1006/jmbi.2001.5382. 
• Hamperl, Stephan, and Karlene A. Cimprich. 2014. “The Contribution of Co-
Transcriptional RNA:DNA Hybrid Structures to DNA Damage and Genome 
Instability.” DNA Repair 19 (July): 84–94. 
https://doi.org/10.1016/j.dnarep.2014.03.023. 
• Hausen, P., and H. Stein. 1970. “Ribonuclease H. An Enzyme Degrading the 
RNA Moiety of DNA-RNA Hybrids.” European Journal of Biochemistry 14 
(2): 278–83. 
• Hayakawa, Hiroshi, Takeshi Uchiumi, Takao Fukuda, Megumi Ashizuka, 
Kimitoshi Kohno, Michihiko Kuwano, and Mutsuo Sekiguchi. 2002. “Binding 
Capacity of Human YB-1 Protein for RNA Containing 8-Oxoguanine †.” 
Biochemistry 41 (42): 12739–44. https://doi.org/10.1021/bi0201872. 
• Heider, Margaret R., Brett W. Burkhart, Thomas J. Santangelo, and Andrew F. 
Gardner. 2017. “Defining the RNaseH2 Enzyme-Initiated Ribonucleotide 
Excision Repair Pathway in Archaea.” The Journal of Biological Chemistry 
292 (21): 8835–45. https://doi.org/10.1074/jbc.M117.783472. 
• Hiller, B., M. Achleitner, S. Glage, R. Naumann, R. Behrendt, and A. Roers. 
2012. “Mammalian RNase H2 Removes Ribonucleotides from DNA to 
Maintain Genome Integrity.” Journal of Experimental Medicine 209 (8): 
1419–26. https://doi.org/10.1084/jem.20120876. 
• Hoeijmakers, Jan HJ. 2001. “Genome Maintenance Mechanisms for 
Preventing Cancer.” Nature 411 (6835): 366–74. 
• ———. 2009. “DNA Damage, Aging, and Cancer.” New England Journal of 
Medicine 361 (15): 1475–85. 
• Hoeijmakers, J. H. J. 2001. “DNA Repair Mechanisms.” Maturitas 38 (1): 17–
22. 
• Hovatter, Kenneth R., and Harold G. Martinson. 1987. “Ribonucleotide-
Induced Helical Alteration in DNA Prevents Nucleosome Formation.” 
Proceedings of the National Academy of Sciences 84 (5): 1162–66. 
• Howard, Michael J., and Samuel H. Wilson. 2017. “Processive Searching 
Ability Varies among Members of the Gap-Filling DNA Polymerase X 
Family.” The Journal of Biological Chemistry, September. 
https://doi.org/10.1074/jbc.M117.801860. 
• Howes, Timothy R. L., and Alan E. Tomkinson. 2012. “DNA Ligase I, the 
Replicative DNA Ligase.” Sub-Cellular Biochemistry 62: 327–41. 
https://doi.org/10.1007/978-94-007-4572-8_17. 
• Huang, En, Dianbo Qu, Yi Zhang, Katerina Venderova, M. Emdadul Haque, 
Maxime W. C. Rousseaux, Ruth S. Slack, John M. Woulfe, and David S. Park. 
2010. “The Role of Cdk5-Mediated Apurinic/apyrimidinic Endonuclease 1 
	 	 References 
	 117	
Phosphorylation in Neuronal Death.” Nature Cell Biology 12 (6): 563–71. 
https://doi.org/10.1038/ncb2058. 
• Hudak, Katalin A., Joseph D. Bauman, and Nilgun E. Tumer. 2002. “Pokeweed 
Antiviral Protein Binds to the Cap Structure of Eukaryotic mRNA and 
Depurinates the mRNA Downstream of the Cap.” RNA (New York, N.Y.) 8 (9): 
1148–59. 
• Ide, H., K. Tedzuka, H. Shimzu, Y. Kimura, A. A. Purmal, S. S. Wallace, and 
Y. W. Kow. 1994. “Alpha-Deoxyadenosine, a Major Anoxic Radiolysis 
Product of Adenine in DNA, Is a Substrate for Escherichia Coli Endonuclease 
IV.” Biochemistry 33 (25): 7842–47. 
• Ischenko, Alexander A., and Murat K. Saparbaev. 2002. “Alternative 
Nucleotide Incision Repair Pathway for Oxidative DNA Damage.” Nature 415 
(6868): 183–87. https://doi.org/10.1038/415183a. 
• Ishchenko, Alexander A., Eric Deprez, Andrei Maksimenko, Jean-Claude 
Brochon, Patrick Tauc, and Murat K. Saparbaev. 2006. “Uncoupling of the 
Base Excision and Nucleotide Incision Repair Pathways Reveals Their 
Respective Biological Roles.” Proceedings of the National Academy of 
Sciences of the United States of America 103 (8): 2564–69. 
• Islam, Md Torequl. 2017. “Oxidative Stress and Mitochondrial Dysfunction-
Linked Neurodegenerative Disorders.” Neurological Research 39 (1): 73–82. 
https://doi.org/10.1080/01616412.2016.1251711. 
• Iyama, Teruaki, and David M. Wilson. 2013. “DNA Repair Mechanisms in 
Dividing and Non-Dividing Cells.” DNA Repair 12 (8): 620–36. 
https://doi.org/10.1016/j.dnarep.2013.04.015. 
• Izumi, Tadahide, David B. Brown, C. V. Naidu, Kishor K. Bhakat, Mark A. 
MacInnes, Hiroshi Saito, David J. Chen, and Sankar Mitra. 2005a. “Two 
Essential but Distinct Functions of the Mammalian Abasic Endonuclease.” 
Proceedings of the National Academy of Sciences of the United States of 
America 102 (16): 5739–43. 
• ———. 2005b. “Two Essential but Distinct Functions of the Mammalian 
Abasic Endonuclease.” Proceedings of the National Academy of Sciences of 
the United States of America 102 (16): 5739–43. 
• Jeong, H.-S. 2004. “RNase H2 of Saccharomyces Cerevisiae Is a Complex of 
Three Proteins.” Nucleic Acids Research 32 (2): 407–14. 
https://doi.org/10.1093/nar/gkh209. 
• Jinks-Robertson, Sue, and Hannah L. Klein. 2015. “Ribonucleotides in DNA: 
Hidden in Plain Sight.” Nature Structural & Molecular Biology 22 (3): 176–
78. 
• Jobert, Laure, and Hilde Nilsen. 2014. “Regulatory Mechanisms of RNA 
Function: Emerging Roles of DNA Repair Enzymes.” Cellular and Molecular 
Life Sciences, February. https://doi.org/10.1007/s00018-014-1562-y. 
• Joyce, C. M. 1997. “Choosing the Right Sugar: How Polymerases Select a 
Nucleotide Substrate.” Proceedings of the National Academy of Sciences of the 
United States of America 94 (5): 1619–22. 
• Kalyanaraman, Balaraman. 2013. “Teaching the Basics of Redox Biology to 
Medical and Graduate Students: Oxidants, Antioxidants and Disease 
Mechanisms.” Redox Biology 1 (1): 244–57. 
https://doi.org/10.1016/j.redox.2013.01.014. 
• Kamiya, Hiroyuki, Akihiro Suzuki, Kazuaki Kawai, Hiroshi Kasai, and 
Hideyoshi Harashima. 2007. “Effects of 8-Hydroxy-GTP and 2-Hydroxy-ATP 
	 	 References 
	118
on in Vitro Transcription.” Free Radical Biology & Medicine 43 (5): 837–43. 
https://doi.org/10.1016/j.freeradbiomed.2007.05.034. 
• Kennedy, Edward M., Christina Gavegnano, Laura Nguyen, Rebecca Slater, 
Amanda Lucas, Emilie Fromentin, Raymond F. Schinazi, and Baek Kim. 2010. 
“Ribonucleoside Triphosphates as Substrate of Human Immunodeficiency 
Virus Type 1 Reverse Transcriptase in Human Macrophages.” Journal of 
Biological Chemistry 285 (50): 39380–91. 
https://doi.org/10.1074/jbc.M110.178582. 
• Kim, K., S. Biade, and Y. Matsumoto. 1998. “Involvement of Flap 
Endonuclease 1 in Base Excision DNA Repair.” The Journal of Biological 
Chemistry 273 (15): 8842–48. 
• Kim, N., S.-y. N. Huang, J. S. Williams, Y. C. Li, A. B. Clark, J.-E. Cho, T. A. 
Kunkel, Y. Pommier, and S. Jinks-Robertson. 2011. “Mutagenic Processing of 
Ribonucleotides in DNA by Yeast Topoisomerase I.” Science 332 (6037): 
1561–64. https://doi.org/10.1126/science.1205016. 
• Kim, Wan-Cheol, Brian R. Berquist, Manbir Chohan, Christopher Uy, David 
M. Wilson, and Chow H. Lee. 2011. “Characterization of the 
Endoribonuclease Active Site of Human Apurinic/Apyrimidinic Endonuclease 
1.” Journal of Molecular Biology 411 (5): 960–71. 
https://doi.org/10.1016/j.jmb.2011.06.050. 
• Klungland, A., and T. Lindahl. 1997. “Second Pathway for Completion of 
Human DNA Base Excision-Repair: Reconstitution with Purified Proteins and 
Requirement for DNase IV (FEN1).” The EMBO Journal 16 (11): 3341–48. 
https://doi.org/10.1093/emboj/16.11.3341. 
• Kochetkov, N. K., and E. I. Budovskii. 1972. “Hydrolysis of N-Glycosidic 
Bonds in Nucleosides, Nucleotides, and Their Derivatives.” In Organic 
Chemistry of Nucleic Acids, edited by N. K. Kochetkov and E. I. Budovskii, 
425–48. Boston, MA: Springer US. http://link.springer.com/10.1007/978-1-
4684-2973-2_4. 
• Koh, Kyung Duk, Sathya Balachander, Jay R Hesselberth, and Francesca 
Storici. 2015. “Ribose-Seq: Global Mapping of Ribonucleotides Embedded in 
Genomic DNA.” Nature Methods, January. 
https://doi.org/10.1038/nmeth.3259. 
• Koh, Kyung Duk, Hsiang-Chih Chiu, Elisa Riedo, and Francesca Storici. 2015. 
“Measuring the Elasticity of Ribonucleotide(s)-Containing DNA Molecules 
Using AFM.” Methods in Molecular Biology (Clifton, N.J.) 1297: 43–57. 
https://doi.org/10.1007/978-1-4939-2562-9_3. 
• Krishnamurthy, Nirmala, Xiaobei Zhao, Cynthia J. Burrows, and Sheila S. 
David. 2008. “Superior Removal of Hydantoin Lesions Relative to Other 
Oxidized Bases by the Human DNA Glycosylase hNEIL1.” Biochemistry 47 
(27): 7137–46. https://doi.org/10.1021/bi800160s. 
• Krokan, H. E., and M. Bjoras. 2013. “Base Excision Repair.” Cold Spring 
Harbor Perspectives in Biology 5 (4): a012583–a012583. 
https://doi.org/10.1101/cshperspect.a012583. 
• Kuninger, David T., Tadahide Izumi, John Papaconstantinou, and Sankar 
Mitra. 2002. “Human AP-Endonuclease 1 and hnRNP-L Interact with a 
nCaRE-like Repressor Element in the AP-Endonuclease 1 Promoter.” Nucleic 
Acids Research 30 (3): 823–29. 
• Kunkel, T. A. 2009. “Evolving Views of DNA Replication (In)Fidelity.” Cold 
Spring Harbor Symposia on Quantitative Biology 74 (0): 91–101. 
https://doi.org/10.1101/sqb.2009.74.027. 
	 	 References 
	 119	
• Kupfer, P. A., and C. J. Leumann. 2006. “The Chemical Stability of Abasic 
RNA Compared to Abasic DNA.” Nucleic Acids Research 35 (1): 58–68. 
https://doi.org/10.1093/nar/gkl948. 
• Kuznetsov, Nikita A., Vladimir V. Koval, Dmitry O. Zharkov, Georgy A. 
Nevinsky, Kenneth T. Douglas, and Olga S. Fedorova. 2005. “Kinetics of 
Substrate Recognition and Cleavage by Human 8-Oxoguanine-DNA 
Glycosylase.” Nucleic Acids Research 33 (12): 3919–31. 
https://doi.org/10.1093/nar/gki694. 
• Kuznetsov, Nikita A., Alexandra A. Kuznetsova, Yuri N. Vorobjev, Lev N. 
Krasnoperov, and Olga S. Fedorova. 2014. “Thermodynamics of the DNA 
Damage Repair Steps of Human 8-Oxoguanine DNA Glycosylase.” PloS One 
9 (6): e98495. https://doi.org/10.1371/journal.pone.0098495. 
• Lazzaro, Federico, Daniele Novarina, Flavio Amara, Danielle L. Watt, Jana E. 
Stone, Vincenzo Costanzo, Peter M. Burgers, Thomas A. Kunkel, Paolo 
Plevani, and Marco Muzi-Falconi. 2012. “RNase H and Postreplication Repair 
Protect Cells from Ribonucleotides Incorporated in DNA.” Molecular Cell 45 
(1): 99–110. https://doi.org/10.1016/j.molcel.2011.12.019. 
• Lima, Walt F., John B. Rose, Josh G. Nichols, Hongjiang Wu, Michael T. 
Migawa, Tadeusz K. Wyrzykiewicz, Andrew M. Siwkowski, and Stanley T. 
Crooke. 2007. “Human RNase H1 Discriminates between Subtle Variations in 
the Structure of the Heteroduplex Substrate.” Molecular Pharmacology 71 (1): 
83–91. https://doi.org/10.1124/mol.106.025015. 
• Li, Mengxia, and David M. Wilson. 2014. “Human Apurinic/Apyrimidinic 
Endonuclease 1.” Antioxidants & Redox Signaling 20 (4): 678–707. 
https://doi.org/10.1089/ars.2013.5492. 
• Lindahl, T. 1993. “Instability and Decay of the Primary Structure of DNA.” 
Nature 362 (6422): 709–15. https://doi.org/10.1038/362709a0. 
• Lindahl, T., and B. Nyberg. 1972. “Rate of Depurination of Native 
Deoxyribonucleic Acid.” Biochemistry 11 (19): 3610–18. 
• Lindsey-Boltz, Laura A., Michael G. Kemp, Jinchuan Hu, and Aziz Sancar. 
2015. “Analysis of Ribonucleotide Removal from DNA by Human Nucleotide 
Excision Repair.” Journal of Biological Chemistry 290 (50): 29801–7. 
https://doi.org/10.1074/jbc.M115.695254. 
• Lirussi, Lisa, Giulia Antoniali, Carlo Vascotto, Chiara D’Ambrosio, Mattia 
Poletto, Milena Romanello, Daniela Marasco, Marilisa Leone, Franco 
Quadrifoglio, and Kishor K. Bhakat. 2012. “Nucleolar Accumulation of APE1 
Depends on Charged Lysine Residues That Undergo Acetylation upon 
Genotoxic Stress and Modulate Its BER Activity in Cells.” Molecular Biology 
of the Cell 23 (20): 4079–96. 
• Loeb, L. A., and B. D. Preston. 1986. “Mutagenesis by Apurinic/apyrimidinic 
Sites.” Annual Review of Genetics 20: 201–30. 
https://doi.org/10.1146/annurev.ge.20.120186.001221. 
• Lonkar, Pallavi, and Peter C. Dedon. 2011. “Reactive Species and DNA 
Damage in Chronic Inflammation: Reconciling Chemical Mechanisms and 
Biological Fates.” International Journal of Cancer 128 (9): 1999–2009. 
https://doi.org/10.1002/ijc.25815. 
• Ludwig, D. L., M. A. MacInnes, Y. Takiguchi, P. E. Purtymun, M. Henrie, M. 
Flannery, J. Meneses, R. A. Pedersen, and D. J. Chen. 1998. “A Murine AP-
Endonuclease Gene-Targeted Deficiency with Post-Implantation Embryonic 
Progression and Ionizing Radiation Sensitivity.” Mutation Research 409 (1): 
	 	 References 
	120
17–29. 
• Lujan, Scott A., Jessica S. Williams, Anders R. Clausen, Alan B. Clark, and 
Thomas A. Kunkel. 2013. “Ribonucleotides Are Signals for Mismatch Repair 
of Leading-Strand Replication Errors.” Molecular Cell 50 (3): 437–43. 
https://doi.org/10.1016/j.molcel.2013.03.017. 
• Malfatti, Matilde Clarissa, Sathya Balachander, Giulia Antoniali, Kyung Duk 
Koh, Christine Saint-Pierre, Didier Gasparutto, Hyongi Chon, Robert J. 
Crouch, Francesca Storici, and Gianluca Tell. 2017. “Abasic and Oxidized 
Ribonucleotides Embedded in DNA Are Processed by Human APE1 and Not 
by RNase H2.” Nucleic Acids Research 45 (19): 11193–212. 
https://doi.org/10.1093/nar/gkx723. 
• Marasco, Michelle, Weiyi Li, Michael Lynch, and Craig S. Pikaard. 2017. 
“Catalytic Properties of RNA Polymerases IV and V: Accuracy, Nucleotide 
Incorporation and rNTP/dNTP Discrimination.” Nucleic Acids Research, 
September. https://doi.org/10.1093/nar/gkx794. 
• Marenstein, Dina R., David M. Wilson III, and George W. Teebor. 2004. 
“Human AP Endonuclease (APE1) Demonstrates Endonucleolytic Activity 
against AP Sites in Single-Stranded DNA.” DNA Repair 3 (5): 527–33. 
https://doi.org/10.1016/j.dnarep.2004.01.010. 
• Markkanen, Enni. 2017. “Not Breathing Is Not an Option: How to Deal with 
Oxidative DNA Damage.” DNA Repair 59 (September): 82–105. 
https://doi.org/10.1016/j.dnarep.2017.09.007. 
• Martin, M. J., M. V. Garcia-Ortiz, V. Esteban, and L. Blanco. 2013. 
“Ribonucleotides and Manganese Ions Improve Non-Homologous End Joining 
by Human Pol.” Nucleic Acids Research 41 (4): 2428–36. 
https://doi.org/10.1093/nar/gks1444. 
• Mazouzi, A., A. Vigouroux, B. Aikeshev, P. J. Brooks, M. K. Saparbaev, S. 
Morera, and A. A. Ishchenko. 2013. “Insight into Mechanisms of 3’-5’ 
Exonuclease Activity and Removal of Bulky 8,5’-Cyclopurine Adducts by 
Apurinic/apyrimidinic Endonucleases.” Proceedings of the National Academy 
of Sciences 110 (33): E3071–80. https://doi.org/10.1073/pnas.1305281110. 
• McElhinny, Stephanie A Nick, Dinesh Kumar, Alan B Clark, Danielle L Watt, 
Brian E Watts, Else-Britt Lundström, Erik Johansson, Andrei Chabes, and 
Thomas A Kunkel. 2010. “Genome Instability due to Ribonucleotide 
Incorporation into DNA.” Nature Chemical Biology 6 (10): 774–81. 
https://doi.org/10.1038/nchembio.424. 
• Meira, L. B., S. Devaraj, G. E. Kisby, D. K. Burns, R. L. Daniel, R. E. Hammer, 
S. Grundy, I. Jialal, and E. C. Friedberg. 2001. “Heterozygosity for the Mouse 
Apex Gene Results in Phenotypes Associated with Oxidative Stress.” Cancer 
Research 61 (14): 5552–57. 
• Meslet-Cladiére, Laurence, Cédric Norais, Joëlle Kuhn, Julien Briffotaux, 
Jerry W. Sloostra, Elena Ferrari, Ulrich Hübscher, Didier Flament, and Hannu 
Myllykallio. 2007. “A Novel Proteomic Approach Identifies New Interaction 
Partners for Proliferating Cell Nuclear Antigen.” Journal of Molecular Biology 
372 (5): 1137–48. https://doi.org/10.1016/j.jmb.2007.06.056. 
• Mol, C. D., T. Izumi, S. Mitra, and J. A. Tainer. 2000. “DNA-Bound Structures 
and Mutants Reveal Abasic DNA Binding by APE1 and DNA Repair 
Coordination [corrected].” Nature 403 (6768): 451–56. 
https://doi.org/10.1038/35000249. 
• Moreira, Paula I., Akihiko Nunomura, Masao Nakamura, Atsushi Takeda, 
Justin C. Shenk, Gjumrakch Aliev, Mark A. Smith, and George Perry. 2008. 
	 	 References 
	 121	
“Nucleic Acid Oxidation in Alzheimer Disease.” Free Radical Biology and 
Medicine 44 (8): 1493–1505. 
https://doi.org/10.1016/j.freeradbiomed.2008.01.002. 
• Mottaghi-Dastjerdi, N., M. Soltany-Rezaee-Rad, Z. Sepehrizadeh, G. 
Roshandel, F. Ebrahimifard, and N. Setayesh. 2015. “Identification of Novel 
Genes Involved in Gastric Carcinogenesis by Suppression Subtractive 
Hybridization.” Human & Experimental Toxicology 34 (1): 3–11. 
https://doi.org/10.1177/0960327114532386. 
• Nakabeppu, Yusaku. 2014. “Cellular Levels of 8-Oxoguanine in Either DNA 
or the Nucleotide Pool Play Pivotal Roles in Carcinogenesis and Survival of 
Cancer Cells.” International Journal of Molecular Sciences 15 (7): 12543–57. 
https://doi.org/10.3390/ijms150712543. 
• Neeley, William L., and John M. Essigmann. 2006. “Mechanisms of 
Formation, Genotoxicity, and Mutation of Guanine Oxidation Products.” 
Chemical Research in Toxicology 19 (4): 491–505. 
https://doi.org/10.1021/tx0600043. 
• Nick McElhinny, S. A., and D. A. Ramsden. 2003. “Polymerase Mu Is a DNA-
Directed DNA/RNA Polymerase.” Molecular and Cellular Biology 23 (7): 
2309–15. https://doi.org/10.1128/MCB.23.7.2309-2315.2003. 
• Nick McElhinny, S. A., B. E. Watts, D. Kumar, D. L. Watt, E.-B. Lundstrom, 
P. M. J. Burgers, E. Johansson, A. Chabes, and T. A. Kunkel. 2010. “Abundant 
Ribonucleotide Incorporation into DNA by Yeast Replicative Polymerases.” 
Proceedings of the National Academy of Sciences 107 (11): 4949–54. 
https://doi.org/10.1073/pnas.0914857107. 
• Nowotny, Marcin, Sergei A. Gaidamakov, Rodolfo Ghirlando, Susana M. 
Cerritelli, Robert J. Crouch, and Wei Yang. 2007. “Structure of Human RNase 
H1 Complexed with an RNA/DNA Hybrid: Insight into HIV Reverse 
Transcription.” Molecular Cell 28 (2): 264–76. 
https://doi.org/10.1016/j.molcel.2007.08.015. 
• Ogawa, L. M., and S. J. Baserga. 2017. “Crosstalk between the Nucleolus and 
the DNA Damage Response.” Molecular bioSystems, January. 
https://doi.org/10.1039/c6mb00740f. 
• Ohtani, Naoto, Mitsuru Haruki, Masaaki Morikawa, Robert J. Crouch, 
Mitsuhiro Itaya, and Shigenori Kanaya. 1999. “Identification of the Genes 
Encoding Mn 2+ -Dependent RNase HII and Mg 2+ -Dependent RNase HIII 
from Bacillus Subtilis : Classification of RNases H into Three Families †.” 
Biochemistry 38 (2): 605–18. https://doi.org/10.1021/bi982207z. 
• Ordonez, H., and S. Shuman. 2014. “Mycobacterium Smegmatis DinB2 
Misincorporates Deoxyribonucleotides and Ribonucleotides during Templated 
Synthesis and Lesion Bypass.” Nucleic Acids Research 42 (20): 12722–34. 
https://doi.org/10.1093/nar/gku1027. 
• Parsons, Jason L., Irina I. Dianova, Svetlana V. Khoronenkova, Mariola J. 
Edelmann, Benedikt M. Kessler, and Grigory L. Dianov. 2011. “USP47 Is a 
Deubiquitylating Enzyme That Regulates Base Excision Repair by Controlling 
Steady-State Levels of DNA Polymerase β.” Molecular Cell 41 (5): 609–15. 
https://doi.org/10.1016/j.molcel.2011.02.016. 
• Pendergraft, William F., and Terry K. Means. 2015. “AGS, SLE, and 
RNASEH2 Mutations: Translating Insights into Therapeutic Advances.” 
Journal of Clinical Investigation 125 (1): 102–4. 
https://doi.org/10.1172/JCI78533. 
• Pizzi, S., S. Sertic, S. Orcesi, C. Cereda, M. Bianchi, A. P. Jackson, F. Lazzaro, 
	 	 References 
	122
P. Plevani, and M. Muzi-Falconi. 2014. “Reduction of hRNase H2 Activity in 
Aicardi-Goutieres Syndrome Cells Leads to Replication Stress and Genome 
Instability.” Human Molecular Genetics, September. 
https://doi.org/10.1093/hmg/ddu485. 
• Poletto, Mattia, Arnaud J. Legrand, Sally C. Fletcher, and Grigory L. Dianov. 
2016. “p53 Coordinates Base Excision Repair to Prevent Genomic Instability.” 
Nucleic Acids Research, January, gkw015. 
https://doi.org/10.1093/nar/gkw015. 
• Poletto, Mattia, Carla Di Loreto, Daniela Marasco, Elena Poletto, Fabio 
Puglisi, Giuseppe Damante, and Gianluca Tell. 2012. “Acetylation on Critical 
Lysine Residues of Apurinic/apyrimidinic Endonuclease 1 (APE1) in Triple 
Negative Breast Cancers.” Biochemical and Biophysical Research 
Communications 424 (1): 34–39. https://doi.org/10.1016/j.bbrc.2012.06.039. 
• Poletto, Mattia, Matilde C. Malfatti, Dorjbal Dorjsuren, Pasqualina L. 
Scognamiglio, Daniela Marasco, Carlo Vascotto, Ajit Jadhav, et al. 2016. 
“Inhibitors of the Apurinic/apyrimidinic Endonuclease 1 
(APE1)/nucleophosmin (NPM1) Interaction That Display Anti-Tumor 
Properties.” Molecular Carcinogenesis 55 (5): 688–704. 
https://doi.org/10.1002/mc.22313. 
• Poletto, Mattia, Carlo Vascotto, Pasqualina L Scognamiglio, Lisa Lirussi, 
Daniela Marasco, and Gianluca Tell. 2013. “Role of the Unstructured N-
Terminal Domain of the hAPE1 (human Apurinic/apyrimidinic Endonuclease 
1) in the Modulation of Its Interaction with Nucleic Acids and NPM1 
(nucleophosmin).” The Biochemical Journal 452 (3): 545–57. 
https://doi.org/10.1042/BJ20121277. 
• Potenski, Catherine J., Hengyao Niu, Patrick Sung, and Hannah L. Klein. 2014. 
“Avoidance of Ribonucleotide-Induced Mutations by RNase H2 and Srs2-
Exo1 Mechanisms.” Nature 511 (7508): 251–54. 
https://doi.org/10.1038/nature13292. 
• Potenski, C. J., and H. L. Klein. 2014. “How the Misincorporation of 
Ribonucleotides into Genomic DNA Can Be Both Harmful and Helpful to 
Cells.” Nucleic Acids Research, August. https://doi.org/10.1093/nar/gku773. 
• Prakash, Aishwarya, Sylvie Doublié, and Susan S. Wallace. 2012. “The 
Fpg/Nei Family of DNA Glycosylases: Substrates, Structures, and Search for 
Damage.” Progress in Molecular Biology and Translational Science 110: 71–
91. https://doi.org/10.1016/B978-0-12-387665-2.00004-3. 
• Prorok, P., D. Alili, C. Saint-Pierre, D. Gasparutto, D. O. Zharkov, A. A. 
Ishchenko, B. Tudek, and M. K. Saparbaev. 2013. “Uracil in Duplex DNA Is 
a Substrate for the Nucleotide Incision Repair Pathway in Human Cells.” 
Proceedings of the National Academy of Sciences 110 (39): E3695–3703. 
https://doi.org/10.1073/pnas.1305624110. 
• Radman, Miroslav. 2016. “Protein Damage, Radiation Sensitivity and Aging.” 
DNA Repair 44 (August): 186–92. 
https://doi.org/10.1016/j.dnarep.2016.05.025. 
• Rai, Ganesha, Vaddadi N. Vyjayanti, Dorjbal Dorjsuren, Anton Simeonov, 
Ajit Jadhav, David M. Wilson, and David J. Maloney. 2012. “Synthesis, 
Biological Evaluation, and Structure–Activity Relationships of a Novel Class 
of Apurinic/Apyrimidinic Endonuclease 1 Inhibitors.” Journal of Medicinal 
Chemistry 55 (7): 3101–12. https://doi.org/10.1021/jm201537d. 
• ———. 2013. “Small Molecule Inhibitors of the Human 
Apurinic/apyrimidinic Endonuclease 1 (APE1).” 
	 	 References 
	 123	
http://www.ncbi.nlm.nih.gov/books/NBK133448/. 
• Ramakrishnan, B., and M. Sundaralingam. 1993a. “High Resolution Crystal 
Structure of the A-DNA Decamer d(CCCGGCCGGG). Novel Intermolecular 
Base-Paired G*(G.C) Triplets.” Journal of Molecular Biology 231 (2): 431–
44. 
• ———. 1993b. “Evidence for Crystal Environment Dominating Base 
Sequence Effects on DNA Conformation: Crystal Structures of the 
Orthorhombic and Hexagonal Polymorphs of the A-DNA Decamer 
d(GCGGGCCCGC) and Comparison with Their Isomorphous Crystal 
Structures.” Biochemistry 32 (42): 11458–68. 
• Ramotar, D., S. C. Popoff, E. B. Gralla, and B. Demple. 1991. “Cellular Role 
of Yeast Apn1 Apurinic endonuclease/3’-Diesterase: Repair of Oxidative and 
Alkylation DNA Damage and Control of Spontaneous Mutation.” Molecular 
and Cellular Biology 11 (9): 4537–44. 
• Randerath, K., R. Reddy, T. F. Danna, W. P. Watson, A. E. Crane, and E. 
Randerath. 1992. “Formation of Ribonucleotides in DNA Modified by 
Oxidative Damage in Vitro and in Vivo. Characterization by 32P-
Postlabeling.” Mutation Research 275 (3-6): 355–66. 
• Reardon, Joyce T., and Aziz Sancar. 2005. “Nucleotide Excision Repair.” 
Progress in Nucleic Acid Research and Molecular Biology 79: 183–235. 
https://doi.org/10.1016/S0079-6603(04)79004-2. 
• Redrejo-Rodríguez, Modesto, Armelle Vigouroux, Aibek Mursalimov, Inga 
Grin, Doria Alili, Zhanat Koshenov, Zhiger Akishev, et al. 2016. “Structural 
Comparison of AP Endonucleases from the Exonuclease III Family Reveals 
New Amino Acid Residues in Human AP Endonuclease 1 That Are Involved 
in Incision of Damaged DNA.” Biochimie 128-129 (September): 20–33. 
https://doi.org/10.1016/j.biochi.2016.06.011. 
• Reijns, Martin A.M., Björn Rabe, Rachel E. Rigby, Pleasantine Mill, Katy R. 
Astell, Laura A. Lettice, Shelagh Boyle, et al. 2012. “Enzymatic Removal of 
Ribonucleotides from DNA Is Essential for Mammalian Genome Integrity and 
Development.” Cell 149 (5): 1008–22. 
https://doi.org/10.1016/j.cell.2012.04.011. 
• Rhee, Y., M. R. Valentine, and J. Termini. 1995. “Oxidative Base Damage in 
RNA Detected by Reverse Transcriptase.” Nucleic Acids Research 23 (16): 
3275–82. 
• Rice, Gillian I., Martin A.M. Reijns, Stephanie R. Coffin, Gabriella M.A. 
Forte, Beverley H. Anderson, Marcin Szynkiewicz, Hannah Gornall, et al. 
2013. “Synonymous Mutations in RNASEH2A Create Cryptic Splice Sites 
Impairing RNase H2 Enzyme Function in Aicardi-Goutières Syndrome.” 
Human Mutation 34 (8): 1066–70. https://doi.org/10.1002/humu.22336. 
• Rice, Gillian, Teresa Patrick, Rekha Parmar, Claire F. Taylor, Alec Aeby, Jean 
Aicardi, Rafael Artuch, et al. 2007. “Clinical and Molecular Phenotype of 
Aicardi-Goutières Syndrome.” The American Journal of Human Genetics 81 
(4): 713–25. https://doi.org/10.1086/521373. 
• Rivkees, S. A., and M. R. Kelley. 1994. “Expression of a Multifunctional DNA 
Repair Enzyme Gene, Apurinic/apyrimidinic Endonuclease (APE; Ref-1) in 
the Suprachiasmatic, Supraoptic and Paraventricular Nuclei.” Brain Research 
666 (1): 137–42. 
• Robson, C. N., D. Hochhauser, R. Craig, K. Rack, V. J. Buckle, and I. D. 
Hickson. 1992. “Structure of the Human DNA Repair Gene HAP1 and Its 
Localisation to Chromosome 14q 11.2-12.” Nucleic Acids Research 20 (17): 
	 	 References 
	124
4417–21. 
• Rossi, Marie L., and Robert A. Bambara. 2006. “Reconstituted Okazaki 
Fragment Processing Indicates Two Pathways of Primer Removal.” Journal of 
Biological Chemistry 281 (36): 26051–61. 
https://doi.org/10.1074/jbc.M604805200. 
• Rowland, Meng M., Joseph D. Schonhoft, Paige L. McKibbin, Sheila S. David, 
and James T. Stivers. 2014. “Microscopic Mechanism of DNA Damage 
Searching by hOGG1.” Nucleic Acids Research 42 (14): 9295–9303. 
https://doi.org/10.1093/nar/gku621. 
• Roychoudhury, Shrabasti, Somsubhra Nath, Heyu Song, Muralidhar L. Hegde, 
Larry J. Bellot, Anil K. Mantha, Shiladitya Sengupta, Sutapa Ray, Amarnath 
Natarajan, and Kishor K. Bhakat. 2017. “Human Apurinic/Apyrimidinic 
Endonuclease (APE1) Is Acetylated at DNA Damage Sites in Chromatin, and 
Acetylation Modulates Its DNA Repair Activity.” Molecular and Cellular 
Biology 37 (6). https://doi.org/10.1128/MCB.00401-16. 
• Ruiz, José F., Raquel Juárez, Miguel García-Díaz, Gloria Terrados, Angel J. 
Picher, Sergio González-Barrera, Antonio R. Fernández de Henestrosa, and 
Luis Blanco. 2003. “Lack of Sugar Discrimination by Human Pol Mu Requires 
a Single Glycine Residue.” Nucleic Acids Research 31 (15): 4441–49. 
• Rychlik, Monika P., Hyongi Chon, Susana M. Cerritelli, Paulina Klimek, 
Robert J. Crouch, and Marcin Nowotny. 2010. “Crystal Structures of RNase 
H2 in Complex with Nucleic Acid Reveal the Mechanism of RNA-DNA 
Junction Recognition and Cleavage.” Molecular Cell 40 (4): 658–70. 
https://doi.org/10.1016/j.molcel.2010.11.001. 
• Rydberg, Bjorn, and John Game. 2002. “Excision of Misincorporated 
Ribonucleotides in DNA by RNase H (type 2) and FEN-1 in Cell-Free 
Extracts.” Proceedings of the National Academy of Sciences 99 (26): 16654–
59. 
• Sassa, Akira, Melike Ҫağlayan, Yesenia Rodriguez, William A. Beard, Samuel 
H. Wilson, Takehiko Nohmi, Masamitsu Honma, and Manabu Yasui. 2016. 
“Impact of Ribonucleotide Backbone on Translesion Synthesis and Repair of 
7,8-Dihydro-8-Oxoguanine.” Journal of Biological Chemistry, September, 
jbc.M116.738732. https://doi.org/10.1074/jbc.M116.738732. 
• Sastre-Moreno, G., A. Sanchez, V. Esteban, and L. Blanco. 2014. “ATP 
Insertion Opposite 8-Oxo-Deoxyguanosine by Pol4 Mediates Error-Free 
Tolerance in Schizosaccharomyces Pombe.” Nucleic Acids Research 42 (15): 
9821–37. https://doi.org/10.1093/nar/gku711. 
• Sayrac, Suha, Sonya Vengrova, Emma L. Godfrey, and Jacob Z. Dalgaard. 
2011. “Identification of a Novel Type of Spacer Element Required for 
Imprinting in Fission Yeast.” PLoS Genetics 7 (3): e1001328. 
https://doi.org/10.1371/journal.pgen.1001328. 
• Schramm, V. L. 1997. “Enzymatic N-Riboside Scission in RNA and RNA 
Precursors.” Current Opinion in Chemical Biology 1 (3): 323–31. 
• Šebera, Jakub, Lukáš Trantírek, Yoshiyuki Tanaka, and Vladimír Sychrovský. 
2012. “Pyramidalization of the Glycosidic Nitrogen Provides the Way for 
Efficient Cleavage of the N-Glycosidic Bond of 8-OxoG with the hOGG1 
DNA Repair Protein.” The Journal of Physical Chemistry. B 116 (41): 12535–
44. https://doi.org/10.1021/jp309098d. 
• Sekiguchi, J., and S. Shuman. 1997. “Site-Specific Ribonuclease Activity of 
Eukaryotic DNA Topoisomerase I.” Molecular Cell 1 (1): 89–97. 
	 	 References 
	 125	
• Shan, X., Y. Chang, and C.-l. G. Lin. 2007. “Messenger RNA Oxidation Is an 
Early Event Preceding Cell Death and Causes Reduced Protein Expression.” 
The FASEB Journal 21 (11): 2753–64. https://doi.org/10.1096/fj.07-8200com. 
• Shen, Ying, Kyung Duk Koh, Bernard Weiss, and Francesca Storici. 2011. 
“Mispaired rNMPs in DNA Are Mutagenic and Are Targets of Mismatch 
Repair and RNases H.” Nature Structural & Molecular Biology 19 (1): 98–
104. https://doi.org/10.1038/nsmb.2176. 
• Shen, Ying, Pavan Nandi, Matthew B. Taylor, Samantha Stuckey, Hershel P. 
Bhadsavle, Bernard Weiss, and Francesca Storici. 2011. “RNA-Driven Genetic 
Changes in Bacteria and in Human Cells.” Mutation Research/Fundamental 
and Molecular Mechanisms of Mutagenesis 717 (1-2): 91–98. 
https://doi.org/10.1016/j.mrfmmm.2011.03.016. 
• Sidorenko, Victoria S., Georgy A. Nevinsky, and Dmitry O. Zharkov. 2007. 
“Mechanism of Interaction between Human 8-Oxoguanine-DNA Glycosylase 
and AP Endonuclease.” DNA Repair 6 (3): 317–28. 
https://doi.org/10.1016/j.dnarep.2006.10.022. 
• Sidorenko, V. S., and D. O. Zharkov. 2008. “[The role of glycosylases of the 
base excision DNA repair in pathogenesis of hereditary and infectious human 
diseases].” Molekuliarnaia Biologiia 42 (5): 891–903. 
• Simms, Carrie L., and Hani S. Zaher. 2016. “Quality Control of Chemically 
Damaged RNA.” Cellular and Molecular Life Sciences 73 (19): 3639–53. 
https://doi.org/10.1007/s00018-016-2261-7. 
• Sobol, R. W., J. K. Horton, R. Kühn, H. Gu, R. K. Singhal, R. Prasad, K. 
Rajewsky, and S. H. Wilson. 1996. “Requirement of Mammalian DNA 
Polymerase-Beta in Base-Excision Repair.” Nature 379 (6561): 183–86. 
https://doi.org/10.1038/379183a0. 
• Sparks, Justin L., Hyongi Chon, Susana M. Cerritelli, Thomas A. Kunkel, Erik 
Johansson, Robert J. Crouch, and Peter M. Burgers. 2012. “RNase H2-Initiated 
Ribonucleotide Excision Repair.” Molecular Cell 47 (6): 980–86. 
https://doi.org/10.1016/j.molcel.2012.06.035. 
• Storici, Francesca, Katarzyna Bebenek, Thomas A. Kunkel, Dmitry A. 
Gordenin, and Michael A. Resnick. 2007. “RNA-Templated DNA Repair.” 
Nature 447 (7142): 338–41. https://doi.org/10.1038/nature05720. 
• Sung, Jung-Suk, Michael S. DeMott, and Bruce Demple. 2005. “Long-Patch 
Base Excision DNA Repair of 2-Deoxyribonolactone Prevents the Formation 
of DNA-Protein Cross-Links with DNA Polymerase Beta.” The Journal of 
Biological Chemistry 280 (47): 39095–103. 
https://doi.org/10.1074/jbc.M506480200. 
• Svilar, David, Eva M. Goellner, Karen H. Almeida, and Robert W. Sobol. 
2011. “Base Excision Repair and Lesion-Dependent Subpathways for Repair 
of Oxidative DNA Damage.” Antioxidants & Redox Signaling 14 (12): 2491–
2507. https://doi.org/10.1089/ars.2010.3466. 
• Takao, M., Q. M. Zhang, S. Yonei, and A. Yasui. 1999. “Differential 
Subcellular Localization of Human MutY Homolog (hMYH) and the 
Functional Activity of adenine:8-Oxoguanine DNA Glycosylase.” Nucleic 
Acids Research 27 (18): 3638–44. 
• Tanaka, Mikiei, P. Boon Chock, and Earl R. Stadtman. 2007. “Oxidized 
Messenger RNA Induces Translation Errors.” Proceedings of the National 
Academy of Sciences 104 (1): 66–71. 
• Tell, Gianluca, Franco Quadrifoglio, Claudio Tiribelli, and Mark R. Kelley. 
	 	 References 
	126
2009. “The Many Functions of APE1/Ref-1: Not Only a DNA Repair 
Enzyme.” Antioxidants & Redox Signaling 11 (3): 601–19. 
https://doi.org/10.1089/ars.2008.2194. 
• Tell, G., D. M. Wilson, and C. H. Lee. 2010. “Intrusion of a DNA Repair 
Protein in the RNome World: Is This the Beginning of a New Era?” Molecular 
and Cellular Biology 30 (2): 366–71. https://doi.org/10.1128/MCB.01174-09. 
• Timofeyeva, Nadezhda A., Vladimir V. Koval, Alexander A. Ishchenko, Murat 
K. Saparbaev, and Olga S. Fedorova. 2011. “Lys98 Substitution in Human AP 
Endonuclease 1 Affects the Kinetic Mechanism of Enzyme Action in Base 
Excision and Nucleotide Incision Repair Pathways.” Edited by Vladimir N. 
Uversky. PLoS ONE 6 (9): e24063. 
https://doi.org/10.1371/journal.pone.0024063. 
• Traut, T. W. 1994. “Physiological Concentrations of Purines and Pyrimidines.” 
Molecular and Cellular Biochemistry 140 (1): 1–22. 
• Vaisman, Alexandra, John P. McDonald, Donald Huston, Wojciech Kuban, 
Lili Liu, Bennett Van Houten, and Roger Woodgate. 2013. “Removal of 
Misincorporated Ribonucleotides from Prokaryotic Genomes: An Unexpected 
Role for Nucleotide Excision Repair.” Edited by Sue Jinks-Robertson. PLoS 
Genetics 9 (11): e1003878. https://doi.org/10.1371/journal.pgen.1003878. 
• Valdez, L. B., S. Lores Arnaiz, J. Bustamante, S. Alvarez, L. E. Costa, and A. 
Boveris. 2000. “Free Radical Chemistry in Biological Systems.” Biological 
Research 33 (2): 65–70. 
• Vascotto, Carlo, Laura Cesaratto, Leo A. H. Zeef, Marta Deganuto, Chiara 
D’Ambrosio, Andrea Scaloni, Milena Romanello, et al. 2009. “Genome-Wide 
Analysis and Proteomic Studies Reveal APE1/Ref-1 Multifunctional Role in 
Mammalian Cells.” PROTEOMICS 9 (4): 1058–74. 
https://doi.org/10.1002/pmic.200800638. 
• Vascotto, C., D. Fantini, M. Romanello, L. Cesaratto, M. Deganuto, A. 
Leonardi, J. P. Radicella, et al. 2009. “APE1/Ref-1 Interacts with NPM1 within 
Nucleoli and Plays a Role in the rRNA Quality Control Process.” Molecular 
and Cellular Biology 29 (7): 1834–54. https://doi.org/10.1128/MCB.01337-
08. 
• Vidal, A. E., I. D. Hickson, S. Boiteux, and J. P. Radicella. 2001. “Mechanism 
of Stimulation of the DNA Glycosylase Activity of hOGG1 by the Major 
Human AP Endonuclease: Bypass of the AP Lyase Activity Step.” Nucleic 
Acids Research 29 (6): 1285–92. 
• Wallace, Susan S. 2013. “DNA Glycosylases Search for and Remove Oxidized 
DNA Bases.” Environmental and Molecular Mutagenesis 54 (9): 691–704. 
https://doi.org/10.1002/em.21820. 
• Williams, Jessica S., and Thomas A. Kunkel. 2014. “Ribonucleotides in DNA: 
Origins, Repair and Consequences.” DNA Repair 19 (July): 27–37. 
https://doi.org/10.1016/j.dnarep.2014.03.029. 
• Williams, Jessica S., Scott A. Lujan, and Thomas A. Kunkel. 2016. 
“Processing Ribonucleotides Incorporated during Eukaryotic DNA 
Replication.” Nature Reviews Molecular Cell Biology 17 (6): 350–63. 
https://doi.org/10.1038/nrm.2016.37. 
• Williams, Jessica S., Dana J. Smith, Lisette Marjavaara, Scott A. Lujan, Andrei 
Chabes, and Thomas A. Kunkel. 2013. “Topoisomerase 1-Mediated Removal 
of Ribonucleotides from Nascent Leading-Strand DNA.” Molecular Cell 49 
(5): 1010–15. https://doi.org/10.1016/j.molcel.2012.12.021. 
	 	 References 
	 127	
• Wilson, David M. 2003. “Properties of and Substrate Determinants for the 
Exonuclease Activity of Human Apurinic Endonuclease Ape1.” Journal of 
Molecular Biology 330 (5): 1027–37. https://doi.org/10.1016/S0022-
2836(03)00712-5. 
• Wilson, David M. 2005. “Ape1 Abasic Endonuclease Activity Is Regulated by 
Magnesium and Potassium Concentrations and Is Robust on Alternative DNA 
Structures.” Journal of Molecular Biology 345 (5): 1003–14. 
https://doi.org/10.1016/j.jmb.2004.11.028. 
• Wilson, David M., and Vilhelm A. Bohr. 2007. “The Mechanics of Base 
Excision Repair, and Its Relationship to Aging and Disease.” DNA Repair 6 
(4): 544–59. https://doi.org/10.1016/j.dnarep.2006.10.017. 
• Wilson, David M., and Anton Simeonov. 2010. “Small Molecule Inhibitors of 
DNA Repair Nuclease Activities of APE1.” Cellular and Molecular Life 
Sciences 67 (21): 3621–31. https://doi.org/10.1007/s00018-010-0488-2. 
• Wilson, S. H., and T. A. Kunkel. 2000. “Passing the Baton in Base Excision 
Repair.” Nature Structural Biology 7 (3): 176–78. 
https://doi.org/10.1038/73260. 
• Woo, Joohyun, Heejung Park, Sun Hee Sung, Byung-In Moon, Hyunsuk Suh, 
and Woosung Lim. 2014. “Prognostic Value of Human Apurinic/Apyrimidinic 
Endonuclease 1 (APE1) Expression in Breast Cancer.” Edited by Chad 
Creighton. PLoS ONE 9 (6): e99528. 
https://doi.org/10.1371/journal.pone.0099528. 
• Yamagata, Y. 2001. “[Structural basis for the recognition and removal of 
damaged bases from DNA by members of a DNA glycosylase superfamily].” 
Tanpakushitsu Kakusan Koso. Protein, Nucleic Acid, Enzyme 46 (8 Suppl): 
976–85. 
• Yasui, Akira. 2013. “Alternative Excision Repair Pathways.” Cold Spring 
Harbor Perspectives in Biology 5 (6). 
https://doi.org/10.1101/cshperspect.a012617. 
• Yoshida, A., Y. Urasaki, M. Waltham, A.-C. Bergman, P. Pourquier, D. G. 
Rothwell, M. Inuzuka, et al. 2003. “Human Apurinic/Apyrimidinic 
Endonuclease (Ape1) and Its N-Terminal Truncated Form (AN34) Are 
Involved in DNA Fragmentation during Apoptosis.” Journal of Biological 
Chemistry 278 (39): 37768–76. https://doi.org/10.1074/jbc.M304914200. 
• Zhan, Yu, James S. Dhaliwal, Pauline Adjibade, James Uniacke, Rachid 
Mazroui, and William Zerges. 2015. “Localized Control of Oxidized RNA.” 
Journal of Cell Science 128 (22): 4210–19. https://doi.org/10.1242/jcs.175232. 
 
 
 
 
 
	 	 Published Papers 
13. Published papers 
This Thesis discusses the most part of experiments collected in the 
published paper entitled: 
“Abasic and oxidized ribonucleotides embedded in DNA are processed 
by human APE1 and not by RNase H2”. 
Following this, other two papers are in attachment, published during my PhD 
program, entitled: 
“Inhibitors of the Apurinic/Apyrimidinic Endonuclease 1 
(APE1)/Nucleophosmin (NPM1) Interaction That Display Anti-Tumor 
Properties”; 
“Unveiling the non-repair face of the Base Excision Repair pathway in 
RNA processing: A missing link between DNA repair and gene 
expression?”. 
Nucleic Acids Research, 2017 1
doi: 10.1093/nar/gkx723
Abasic and oxidized ribonucleotides embedded in
DNA are processed by human APE1 and not by RNase
H2
Matilde Clarissa Malfatti1,†, Sathya Balachander2,†, Giulia Antoniali1, Kyung Duk Koh2,3,
Christine Saint-Pierre4, Didier Gasparutto4, Hyongi Chon5, Robert J. Crouch5,
Francesca Storici2,* and Gianluca Tell1,*
1Laboratory of Molecular Biology and DNA repair, Department of Medicine, University of Udine, Udine, Italy, 2School
of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA, 3Currently at the University of California,
San Francisco, UCSF, School of Medicine, San Francisco, CA, USA, 4Chimie Reconnaissance & Etude Assemblages
Biologiques, Universite´ Grenoble Alpes, SPrAM UMR5819 CEA CNRS UGA, INAC/CEA, Grenoble, France and
5Developmental Biology Division, Eunice Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health, Bethesda, MD, USA
Received November 01, 2016; Revised July 31, 2017; Editorial Decision August 06, 2017; Accepted August 11, 2017
ABSTRACT
Ribonucleoside 5′-monophosphates (rNMPs) are the
most common non-standard nucleotides found in
DNA of eukaryotic cells, with over 100 million rNMPs
transiently incorporated in the mammalian genome
per cell cycle. Human ribonuclease (RNase) H2 is
the principal enzyme able to cleave rNMPs in DNA.
Whether RNase H2 may process abasic or oxidized
rNMPs incorporated in DNA is unknown. The base
excision repair (BER) pathway is mainly responsible
for repairing oxidized and abasic sites into DNA. Here
we show that human RNase H2 is unable to process
an abasic rNMP (rAP site) or a ribose 8oxoG (r8oxoG)
site embedded in DNA. On the contrary, we found that
recombinant purified human apurinic/apyrimidinic
endonuclease-1 (APE1) and APE1 from human cell
extracts efficiently process an rAP site in DNA and
have weak endoribonuclease and 3′-exonuclease ac-
tivities on r8oxoG substrate. Using biochemical as-
says, our results provide evidence of a human en-
zyme able to recognize and process abasic and oxi-
dized ribonucleotides embedded in DNA.
INTRODUCTION
Incorporation of ribonucleotidesmonophosphate (rNMPs)
in DNA is a frequent phenomenon, which is considered the
most common type of ‘DNA damage’ occurring in normal
cells (1,2). Ribose-seq and other approaches recently de-
veloped for mapping sites of rNMPs in DNA have shown
widespread but not random distribution of rNMPs in chro-
mosomal DNA of budding and fission yeast (2) (and ref-
erences therein). The number of rNMPs identified per nu-
clear chromosomewas found to be proportional to chromo-
some size (2), and quantitation approaches have estimated
a 600,000 rNMPs in budding yeast genome and over 100
millions in mouse genome (3).
The incorporation of rNMPs in genomic DNA may be
due to: (i) the disequilibrium in the cellular pool of deoxyri-
bonucleotides (dNTPs) and ribonucleotides (rNTPs) (2),
(ii) an incomplete elimination of RNA primers used in the
generation of Okazaki fragments (4), (iii) an oxidation of
the deoxyribose sugar into ribose (5) and last but not least,
(iv) an imprecise 3′-exonucleolytic proofreading activity of
replicative DNA polymerases, which do not discriminate
rNMPs from dNMPs pool (2,4,6,7). Furthermore, taking
into consideration all rNMPs that are synthesized during
lagging strand synthesis, more than 100 million rNMPs are
introduced into themammalian genome per cell cycle (3). In
addition, it has been estimated that the amount of rNTPs is
generally 40–350-fold higher than that of dNTPs in cycling
cells (6–8) increasing the probability of incorrect rNMP in-
corporation during DNA replication and repair (2,4,6,7).
The effects of the 2′-hydroxyl group of the ribose sugar
within an rNMP embedded in DNA are numerous: it
mainly altersDNA elasticity and structure in a sequence de-
pendentmanner (9–11) and affects the activity and function
of several DNA-interacting proteins, in addition to increase
the DNA fragility and mutability (1,12). Moreover, rNMPs
in DNA can be template for DNA synthesis (13,14), al-
though the DNA polymerases processivity on rNMP tracts
is reduced (13).
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The main pathway deputed to rNMPs removal is ribonu-
cleotide excision repair (RER), in which the principal en-
zyme is RNase H2. It was demonstrated that RNase H2
deficiency in mammalian cells is associated to DNA dam-
age repair activation and, in humans, to pathology. RNase
H2-null murine embryonic fibroblasts (MEFs) activate a
p53-dependent damage response, whereas null-RNase H2
are embryonic lethal (15). In humans, mutations in each
of the three subunits of RNase H2 are associated with the
neurological syndrome of Aicardi-Goutie`res (AGS), which
causes severe brain dysfunction (16–18). Altered RNase H2
function in AGS patients may result in increased level of
rNMPs in DNA, which could in turn activate DNA dam-
age response signaling and induce innate immune response
(19,20).
Besides RER, other different DNA repair mechanisms
are active to remove rNMPs embedded in DNA (3,21). In
the absence of RNase H2, topoisomerase I cleavage (21),
followed by nick processing by Srs2–Exo1, can remove some
rNMPs (22,23). rNMPs in DNA can be also targeted by
the nucleotide excision repair (NER) factors in bacteria
(24). However, in vitro experiments showed that human
NERproteins are not active to remove rNMPs embedded in
DNA (25). Differently, the mismatch repair (MMR) mech-
anism targets mismatches with rNMPs both in Escherichia
coli and Saccharomyces cerevisiae genomicDNA (26). Until
now, there is no proof that the base excision repair (BER)
mechanism plays any role in removing rNMPs from DNA.
BER is known to repair a wide spectrum of oxidative le-
sions in nuclear and mitochondrial DNA (27,28), and pre-
venting cancer (29,30). Abasic sites, which form by sponta-
neous hydrolysis of the N-glycosidic bond in DNA or fol-
lowing removal of a damaged base by BER glycosylases, are
major targets or intermediate substrates in the BER path-
way of DNA repair (31). It has been estimated that up to
10,000 abasic sites are formed per human genome per day
(32). Despite the fact that spontaneous depurination oc-
curs ∼1,000 times slower in RNA than DNA (33), due to
the high abundance of rNMPs in genomes, with >100 mil-
lion rNMPs transiently present inmammalianDNAduring
one replication cycle, considering rNMP incorporation by
DNA polymerases during DNA replication and repair, and
RNA primers of Okazaki fragments (3), the possibility that
abasic and oxidized rNMPs (such as 7,8-dihydro-8-oxo-
riboguanosine) are present in DNA and are targets of BER
is quite real and worth careful study. These data, together
with other recent findings about the ability of Schizosaccha-
romyces pombe Pol 4,Mycobacterium smegmatisDinB2 and
human Pol! to insert and elongate oxidized rGMP when
paired with dA during DNA replication (34–36), under-
score the necessity to determine how cells can target and
remove oxidized rNMPs or rAP sites from DNA.
Because recent studies point toward a new function of
BER in RNA surveillance (37,38), there is high likelihood
that BER could be involved in the processing of rNMPs
in DNA, particularly in the case of chemically modified
rNMPs, such as abasic and oxidized rNMPs. Identifying
whether BER may target normal and modified rNMPs in
DNA is important to better understanding the mechanism
of genotoxicity of reactive oxygen species, the function and
the impact of BER defects in human disease and cancer
mechanisms. In the absence of proper repair mechanisms
to cope with these kind of lesions, even a single or a few
modified rNMPs present in a genome per cell cycle could
lead to mutations and/or genomic rearrangements.
Findings from our and other laboratories have revealed
an important involvement of the apurinic/apyrimidinic en-
donuclease 1 (APE1) in RNA metabolism and RNA-decay
(37–40). APE1 is by far one of the most studied enzymes
in the BER pathway for its altered expression in different
human pathologies ranging from neurodegenerative to can-
cer disorders (41). Its role in DNA repair is primarily due
to its ability to act as an endonuclease, specifically able to
cleave 5′ to deoxy- abasic sites, which results in a strand
break with 3′-hydroxyl and 5′-phosphodeoxyribose termini.
APE1 also has redox activity needed to modulate the DNA
binding ability of several transcription factors (41). As re-
cently demonstrated, APE1 can endonucleolytically cleave
abasic single-strandedRNA (37,38,40), has a 3′-RNAphos-
phatase activity, and a weak 3′-5′ exoribonuclease activity
(42). Moreover, it has been demonstrated that APE1 has
nucleotide incision repair (NIR) activity on modified bases,
such as 5,6-dihydro-2′-deoxyuridine, 5,6-dihydrothymidine,
5-hydroxy-2′-deoxyuridine, 5-hydroxycytosine, which are
directly repaired by APE1 bypassing the action of specific
glycosylases (43–45). Therefore, we hypothesized thatAPE1
can be involved in processing rNMPs in DNA, particularly
in the case of abasic and oxidized rNMPs.
Here, we found that eukaryotic RNase H2 from yeast,
mouse and human is inactive on an rAP site in DNA in
different assays. We discovered and characterized an un-
known APE1 activity on abasic ribonucleotide embedded
in DNA. We then compared the ability of human RNase
H2 to cleave at an oxidized ribonucleotide (r8oxoG) incor-
porated in a DNA substrate and analyzed the activities of
8-oxoguanine DNA glycosylase (OGG1) and APE1 to rec-
ognize and cleave this particular type of damage. Our data
demonstrate that APE1, but not human RNase H2 and
OGG1, has a weak endoribonuclease activity on the oxi-
dized substrate.
MATERIALS AND METHODS
Double strand synthetic oligonucleotides description and an-
nealing conditions
All oligonucleotides and their complementary sequences
used in this study are listed in Supplementary Table S1
(see also Supplementary Figure S1). ss dG 40 oligonu-
cleotide and its reverse complementary sequence, ss dC 40,
were purchased from Invitrogen (Grand Island, NY, USA).
ss rG 40 oligonucleotide and the DNA oligo containing a
tetrahydrofuran abasic deoxyribonucleotide, ss dF 40, or
tetrahydrofuran abasic ribonucleotide, ss rF 40, as well as
ribo- 1′OH abasic containing oligonucleotide, ss rOH, were
purchased from Dharmacon (GE Healthcare, Lafayette,
CO, USA). The 26-mer oligonucleotide containing a
tetrahydrofuran, ss dF, and its reverse complementary se-
quence ss dC, were synthesized from Metabion Interna-
tional AG (Steinkirchen, Germany). The 25-mer dG-, rG-,
d8oxoG-containing oligonucleotides and complementary
oligonucleotides were synthesized from Metabion Interna-
tional AG (Steinkirchen, Germany).
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ss dG 40, ss rG 40, ss dF 40 and ss rF 40 oligonu-
cleotides were 5′ end-labeled with [! -32P] ATP
(PerkinElmer, Boston, MA, USA) by T4 polynucleotide
kinase (PNK) (New England BioLabs, Ipswich, MA,
USA) in a reaction mixture containing 10 "M ATP using
10X PNK buffer (New England BioLabs, Ipswich, MA,
USA). This labeling reaction was incubated at 37◦C for 1 h,
followed by inactivation at 65◦C for 20 min. The reactions
were purified by using Illustra MicroSpin G-25 column
(GE Healthcare, Buckinghamshire, UK).
The remaining oligonucleotides were labelled with either
IRDye700, IRDye800 fluorophores or Cyanine5 at 5′ end,
as specified in Supplementary Table S1, purified through
RP-HPLC, checked in Mass Check and re-suspended in
RNase- and DNase- free water.
Synthesis of oligonucleotide containing an internal ri-
bose 8-oxo-guanosine (r8oxoG) and an IRDye700 fluo-
rophore at 5′ end was in-house carried out on an Ap-
plied Biosystems 392 DNA/RNA synthesizer using the
phosphoramidite chemistry, associated with the phenoxy-
acetyl protecting group for the nucleobases and the tertio-
butyldimethylsilyle protecting group at the 2′-OH position
of the ribonucleoside residue (46). Upon completion, the
oligonucleotide was de-protected in concentrated aqueous
ammonia for 6 h at 55◦C, followed by a desilylation step
with triethylamine trihydrofluoride (8 h at room tempera-
ture) (46) and was finally purified by preparative 20% de-
naturing PAGE using UV-shadowing detection. After de-
salting by size exclusion, the r8oxoG oligonucleotide was
quantified by UV measurements at 260 nm and its purity
was checked by RP-HPLC analysis together with MALDI-
TOF mass measurements (Supplementary Figure S5, pan-
els A and B). Sample was then lyophilized and frozen at –
20◦C until use.
All oligonucleotides used in the present study were re-
suspended in RNase- andDNase-free water at 100"M. 100
pmol of each oligonucleotidewas annealedwith an excess of
150 pmol of its complementaryDNAoligonucleotide (as in-
dicated in Supplementary Table S1) in 10 mMTris–HCl pH
7.4 and 10 mM MgCl2, heated at 95◦C and cooling down
over night in the dark.
Plasmid and expression of recombinant proteins
Plasmids and expression of human recombinant OGG1 en-
zyme was purified as described by Audebert et al. (47). Plas-
mids and expression of human recombinant APE1 wild
type (WT) and respective mutants (APE1 N!33 and APE1
E96A) were produced as explained by Fantini et al. (48) and
Erzberger andWilson (49). Plasmid and expression of yeast,
mouse and human recombinant RNase H2 were produced
as explained by Chon et al. (50,51).
Cell lines and silencing experiments
HeLa cells (human cervical carcinoma) (ATCC®, Milan,
Italy) were grown inDMEM(EuroClone,Milan, Italy) sup-
plemented with 10% fetal bovin serum (FBS-EuroClone,
Milan, Italy), penicillin (100 U/ml), streptomycin (100
mg/ml) and L-glutamine (2 mM) (EuroClone, Milan, Italy)
and cultured in a humidified incubator at 5% CO2 at 37◦C.
For silencing experiments, 15 × 104 cells were seeded and
transfected with 5′ UACUCCAGUCGUACCAGACCU 3′
siAPE1 (100 pmol) or siGENOME SMART pool siR-
Nase H2A (50 pmol) or 5′ CCA UGA GGU CAG CAU
GGU CUG UU 3′ scramble control siRNA (100 pmol)
(GE Dharmacon, Milan, Italy) by using Oligofectamine™
Reagent (GE Dharmacon, Milan, Italy) as per manufac-
turer’s indications. After 72 h upon transfection, cells were
harvested by trypsinization and centrifuged at 250 × g
for 5 min at 4◦C. Supernatant was removed, and pellet
was washed once with ice-cold phosphate-buffered saline
without Calcium and Magnesium (PBS-Euroclone, Milan,
Italy) and then centrifuged again (250× g for 5 min at 4◦C).
Preparation of nuclear cell extracts (NCE)
After washing with PBS, cells were collected in cold PBS
added with 0.1 M DTT and 0.5 mM phenylmethylsulfonyl
fluoride (PMSF). Cells were centrifuged at 800 × g for 10
min at 4◦C and the supernatant was removed. Pellet was
re-suspended in a cold hypotonic solution containing 10
mMHEPES pH 7.9, 10 mMKCl, 0.1 mMMgCl2, 0.1 mM
EDTA pH 8.0 complemented with 0.1 mM DTT, 0.5 mM
PMSF, 1 mM protease inhibitor (PI), 1 mM NaF, 1 mM
Na3VO4. After centrifugation at 800 × g for 10 min at 4◦C,
cytosolic proteins (CCE) were collected whereas intact nu-
clei were pelleted. Pellet was washed to discard any contam-
ination from cytosol and it was subsequently re-suspended
with a cold hypertonic solution 20 mMHEPES pH 7.9, 420
mMNaCl, 1.5mMMgCl2, 0.1mMEDTApH8.0, 5% glyc-
erol complemented with 0.1 mM DTT, 0.5 mM PMSF, 1
mM PI, 1 mM NaF, 1 mM Na3VO4 and incubated on ice
for 30 min. At the end, the sample was centrifuged at 15,000
× g for 20min at 4◦Cand collected the supernatant contain-
ing nuclear proteins (NCE). Quantification of each sample
was performed by colorimetric Bradford assays (Bio-Rad,
Milan, Italy).
Preparation of whole cell extracts (WCE)
After washing with PBS, cells were harvested by trypsiniza-
tion and centrifuged at 250× g for 5 min at 4◦C. The super-
natant was removed, washed oncewith PBS and centrifuged
again. Pellet was re-suspended in a lysis solution containing
50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA,
1% (w/v) Triton X-100 supplemented with 1 mM PI, 1 mM
DTT, 0.5 mMPMSF, 1mMNaF and 1mMNa3VO4. After
centrifugation at 15 000 × g for 20 min at 4◦C, the super-
natant is considered as whole cell extract (WCE). Proteins
of each sample were quantified using a colorimetric Brad-
ford assays (Bio-Rad, Milan, Italy).
Enzymatic activity assays
Tomeasure enzymatic activity of recombinant proteins and
NCE on different substrates, each reaction was prepared
following doses, time points and buffers specified in detail
into the legend of each experiment. Final volume for each
reaction was 10 "l. At the end of all reactions, samples were
blocked with a stop solution, containing 99.5% (v/v) for-
mamide (Sigma-Aldrich, Milan, Italy) supplemented with
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10× Orange Loading Dye (Li-Cor Biosciences, Milan,
Italy) and heated at 95◦C for 5 min. Then, all samples were
loaded onto a 7 M denaturing 20% polyacrylamide gel in
TBE buffer pH 8.0 and run at 4◦Cat 300V for 1 h. Then, the
gel was visualized with an Odyssey CLx Infrared Imaging
system (LI-CORGmbH,Germany). The signals of the non-
incised substrate (S) and the incision product (P) bandswere
quantified using Image Studio software (LI-COR GmbH,
Germany). When using the ds rOH:dC and ds r8oxoG:dC
oligonucleotides, a very small amount of cleavage product
was seen in samples not treated with recombinant proteins
and/or cell extracts due to the reactivity of this molecule,
which was spontaneously degraded. During the analysis,
this band has been always subtracted from bands obtained
following treatment with recombinant proteins and/or ex-
tracts.
For radioactive experiments, reactions were stopped by
adding 2× denaturing PAGE gel buffer (0.01% bromophe-
nol blue, 95% formamide and 20 mM EDTA pH 8.0) and
heating to 95◦C for 5min. After dilutions, the products were
analyzed by 15% (w/v) polyacrylamide, 8 M urea gel elec-
trophoresis (urea–PAGE). 20–100 Oligonucleotide Length
Standard (Integrated Device Technology, Coralville, IA,
USA) was used as a ladder (M). After electrophoresis, gels
were exposed to phosphor screen overnight. Images were
taken with Typhoon Trio+ (GE Healthcare, Lafayette, CO,
USA) and obtained with ImageQuant (GE Healthcare).
Band intensities were quantified by Multi Gauge V3.0 (Fu-
jifilm).
Electrophoretic mobility shift assay analysis (EMSA)
Proteins binding to nucleic acids was assessed by EMSA
analysis as already described by Fantini et al. (48). Briefly,
the indicated amounts of recombinant purified proteins or
cell extracts were co-incubated with 250 fmol of the probe
(25 nM) at 37◦C for 30 min. Reactions were prepared in
a buffer containing 8 mM HEPES, 10 mM KCl, 400 !M
EDTA pH 8.0, 5 mM DTT and 2% glycerol in a 10 !l fi-
nal volume. Moreover, salmon sperm DNA (SSD) (Sigma-
Aldrich, Milan, Italy) was added like as DNA competi-
tor. Samples were loaded onto an 8% (w/v) native poly-
acrylamide gel in tris-sodium acetate–EDTA pH 8.0 (TAE)
buffer and run at 4◦C at 150 V for 1 h followed by 3 hat 250
V.
Statistical analysis
Statistical analyses were performed by using the Student’s t
test. P < 0.05 was considered as statistically significant.
RESULTS
Human, yeast or mouse RNase H2 does not process an rAP
site embedded in DNA
RNaseH2 is the principal protein able to process paired and
mismatched rNMP sites embedded in DNA by generating a
nick to their 5′ side (26) (and references therein). Up to now,
whether RNase H2 can cleave an rAP site incorporated in
a duplex DNA is unknown. In order to test this hypoth-
esis, we measured RNase H2 ability to cleave a modified
Figure 1. Scheme of substrates used to test cleavage of an rAP site inDNA.
DNA nucleotides are in blue, RNA in red. The 5′ and 3′ ends of eachDNA
strand are indicated. (A) Scheme of double strand (ds) DNA 25-mer sub-
strates (single strand (ss) oligonucleotide annealed to ss dC containing-
complementary oligonucleotide) containing a dGMP, rGMP, dF and 1′
OHabasic rNMP (rOH) site in the 13th position. The ‘IRD700’ in green in-
dicate IRDye 700 phosphoramidite dye tagged at the 5′ end. The ‘IRD800’
in green indicate IRDye 800 phosphoramidite dye tagged at the 5′ end. The
‘Cy5’ in green indicates cyanine dye tagged at the 5′-end of the top strand
of the duplex. (B) Scheme of the ds DNA 40-mer substrate (ss oligonu-
cleotide annealed to its ss complementary oligonucleotide) containing a
dGMP, rGMP, dF and rF site in the 20th position. The P in purple indi-
cates radiolabelled 32P at the 5′-end of the top strand of the duplex. The
red arrow indicates the cleavage position by RNaseH2 5′ to the rGMP site.
25-mer DNA oligonucleotide, called ds rOH:dC, in which
a 1′-OH abasic rNMP was incorporated into a DNA sub-
strate as shown in Figure 1A (see also Supplementary Table
S1 and Supplementary Figure S1). First of all, recombinant
human RNase H2, composed of its three subunits, was pu-
rified as explained in Materials and Methods (Supplemen-
tary Figure S2) and its activity was tested on ds rOH:dC
oligonucleotide in parallel with dG- and rG- containing
oligonucleotides as negative and positive controls, respec-
tively. As reported in Figure 2, the enzyme had no activ-
ity on ds dG:dC and ds dF:dC (containing a tetrahydro-
furan residue mimicking the abasic site) oligonucleotides,
whereas it efficiently cleaved the canonical rG substrate as
expected. In addition, we tested the mismatched rG- con-
taining oligonucleotide, ds rG:dA, confirming that RNase
H2 protein is also active on this type of substrate (Fig-
ure 2A). On the other hand, no activity was detectable on
ds rOH:dCdemonstrating that recombinant humanRNase
H2 is not able to process an abasic rNMP embedded in
DNA. To confirm these data in cells, we tested the activity
of RNase H2 protein obtained from nuclear cell extracts on
the same substrates, as above (Figure 2). To this aim, RNase
H2 expression was downregulated in HeLa cells through
specific siRNA and the endoribonuclease activities of nu-
clear extracts from knocked down and control cells were
then assayed. Western blotting analyses performed on nu-
clear extracts from control (Scramble) and knocked down
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Figure 2. Human RNase H2 is not able to process an rAP site embedded in a duplex DNA substrate. (A) Representative denaturing polyacrylamide gel
of oligonucleotides (25 nM) incision by recombinant human RNase H2 (0.5 nM). The reaction was performed in RNase H2-buffer (20 mM Tris–HCl, 25
mM KCl, 0.1% BSA, 0.01% Tween20, 4 mMMgCl2, pH 7.4) for different time points, expressed in minutes and shown on the top of the figure, at 37◦C.
ds dG:dC and ds dF:dC oligonucleotides were used as negative controls whereas paired and mismatched ds rG oligonucleotides as positive controls. S
indicates the substrate position while P indicates the product position (left). Relative graph illustrating the time-course kinetics activity of the recombinant
protein on ds rG:dC and ds rG:dA oligonucleotides. Data are expressed asmean± SDof three independent technical replicas (right). (B) Graph illustrating
the time-course kinetics activity of NCE on ds rG:dC in control and RNase H2-knocked down conditions. Enzymatic reaction was performed at 37◦C in
RNase H2-buffer with 500 ng of NCE. Data are expressed as mean ± SD of three independent technical replicas. Standard deviation values were always
less than 10% of the mean of the experimental points. (C) Graph illustrating the time-course kinetics activity of NCE on ds rOH:dC oligonucleotide in
control and RNase H2-knocked down conditions. Enzymatic reaction was performed at 37◦C in RNase H2-buffer with 500 ng of NCE. Data are expressed
as mean ± SD of three independent technical replicas. Standard deviation values were always less than 10% of the mean of the experimental points.
(siRNase H2) cells demonstrated the efficiency of RNase
H2 downregulation (∼50%) upon transfection with spe-
cific siRNA sequences (Supplementary Figure S3A). We
incubated Scramble or siRNase H2 cell extracts with dif-
ferent substrates for the indicated time points. Following
knock-down of RNase H2, we found a decreased cleavage
of ds rG:dC, as expected (Figure 2B and Supplementary
Figure S3B). Surprisingly, we found that ds rOH:dC was
also cleaved; however, ds rOH:dC cleavage was completely
unaffected by siRNase H2 cell extracts (Figure 2C and Sup-
plementary Figure S3B). These data suggest that while hu-
man RNase H2 is inactive on an abasic rNMP embedded
in DNA, there is another enzyme/s capable of cleaving it in
human cells.
To increase the stability of the abasic rNMP-containing
oligonucleotide, we also used abasic substrates mimicked by
tetrahydrofuran (F) residues, similarly to what commonly
used for dNMP (52,53). We then tested whether RNase H2
from yeast or mouse may process an abasic rNMP, mim-
icked by a tetrahydrofuran ribonucleotide residue, embed-
ded in a longer DNA sequence composed of 40-bp to eval-
uate a possible role of the length of the substrate in de-
termining the inability of RNase H2 to process these sub-
strates (Figure 1B). We used single-stranded (ss) or double-
stranded (ds) DNA substrates containing an abasic rNMP
site (rF), an rGMP (rG), an abasic dNMP (dF) or a dGMP
as internal controls (Supplementary Table S1). As expected,
S. cerevisiae and mouse RNase H2 cleaved at the single rG
in a DNA duplex substrate (lane 9 in Figure 3, panels A and
B, respectively) and had no activity on the rG embedded in
the ss substrate (lanes 7 and 8 in Figure 3, panels A and
B). Importantly, as we found for human RNase H2, also S.
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Figure 3. Mouse and yeast RNase H2 are not able to process an rAP site
embedded in a duplex DNA substrate. (A and B) Denaturing PAGE gels
showing cleavage result using 10 nM of 40-mer radioactive substrate con-
taining an rG or an rF site, without (lanes 1–6) or with (lanes 7–12) 10 nM
of yeast RNase H2 protein (A) or 10 nM of mouse RNase H2 protein (B).
All reactions were carried out at 37◦C for 1 h in yeast/mouse reaction 1×
buffer (15 mM Tris–HCl pH 8.0, 50 mM NaCl, 10 mM MgCl2, 5% glyc-
erol, 1 mM DTT and 0.1 mg/mL BSA). M indicates the DNA ladder and
the black arrows on the left of each panel show specific band sizes. Lanes
1,7 have ss-substrate containing rG (ss rG 40), lanes 2,8 have ss-substrate
containing ss rG 40 that is cooled slowly at room temperature to demon-
strate the absence of any self-annealing structures, and lanes 3,9 show the
ds-substrate containing rG (ds rG dC). Lanes 4,10 have ss-substrate con-
taining abasic ribo site (ss rF 40), lanes 5,11 have ss rF 40 that is cooled
slowly in room temperature to observe any self-annealing; and lanes 6,12
have ds substrate containing abasic ribo site (ds rF:dC). The percentages
of cleavage of each reaction are displayed below the images as enzymatic
activity (%).
cerevisiae andmouse RNase H2 complexes were inactive on
the abasic rNMP, ds rF:dC (lane 12 in Figure 3, panels A
and B). Together these results demonstrate the inability of
eukaryotic RNaseH2, both from yeast andmammalian ori-
gins, to process an abasic rNMP incorporated in DNA in-
dependently from the nature of the abasic site (either 1′-OH
or tetrahydrofuran residue) and the length of the substrate
(either 25- or 40-mers).
Human APE1 is able to process an rAP site embedded in
DNA through its endonuclease catalytic domain
To test the ability of APE1 to process rAP sites in DNA,
we purified human recombinant APE1 protein, as de-
scribed in Materials and Methods section (Supplemen-
tary Figure S4A). The endonuclease activity of APE1 on
ds rOH:dC substrate was examined through cleavage as-
says. As a positive control for APE1 endonuclease activ-
ity, an oligonucleotide substrate containing a tetrahydro-
furan residue mimicking the abasic site, called ds dF:dC
(52,53), was used. As reported in Figure 4A, and mea-
sured through kinetics experiments in Table 1, APE1 pro-
cesses the abasic rNMPas efficiently as the canonical deoxy-
abasic site having a lower affinity for the ds rOH:dC than
the ds dF:dC (11-fold increase of the KM) but a higher cat-
alytic rate (27-fold increase in the kcat/KM ratio) (Table 1).
Moreover, APE1 was unable to process the rG- contain-
ing oligonucleotide, which is the preferential substrate of
RNase H2 enzyme. To further characterize the enzymatic
activity of APE1, we used the purified recombinant mutant
APE1 E96A protein, in which the missense mutation of the
residue in the catalytic site, characterized by the substitution
of the glutamic acid in position 96 with alanine, causes a de-
creased enzymatic activity of the protein, lacking the ability
to coordinate the Mg2+ ion in the catalytic site (52,54,55)
(Supplementary Figure S4B). In addition, we used the puri-
fied recombinant mutant APE1N!33 protein, in which the
first 33 N-terminal residues, responsible for RNA-protein
interaction but not affecting its enzymatic activity, have
been deleted (32,38) (Supplementary Figure S4B). Follow-
ing incubation of ds rOH:dC with APE1 E96A mutant,
there was barely any endonuclease activity, whereas the ac-
tivity of APE1 N!33 mutant was comparable with that of
the APE1 WT protein (Figure 4, panels B and C and Sup-
plementary Figure S4C). These data demonstrate that the
catalytic domain of APE1 is responsible for recognizing and
cleaving a rAP site in dsDNA and that the N-terminal do-
main does not play any major role in the enzymatic activity
on this substrate and that AP endonucleolytic activity on
rAP sites is intrinsic to the purified protein.
Kinetic parameters (KM, VMAX and kCAT) were calcu-
lated from the measurement of the endonucleolytic reaction
rates for APE1 on ds dF:dC and ds rOH:dC substrates. As
described by Fantini et al. (48), increasing concentrations
of the substrate were incubated with a selecting concentra-
tion of the protein (see first column) in a time-course exper-
iment. Kinetic values were calculated using a Lineweaver–
Burk plot analysis and represent the mean ± SD of three
independent experiments.
To confirm that APE1 is the major enzyme capable
of cleaving ribo-abasic containing sites in cells, we used
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Figure 4. Human APE1 efficiently processes an rAP site embedded in a duplex DNA substrate. (A) Representative denaturing polyacrylamide gel of
oligonucleotides (0.25 !M) incision by recombinant human APE1 (0.288 nM). The reaction was performed in APE1-buffer (20 mM Tris–HCl, 100 mM
KCl, 0.1% BSA, 0.01% Tween20, pH 7.4) for different time points, expressed in minutes and shown on the top of the figure, at 37◦C. ds dG:dC and
ds rG:dC oligonucleotides were used as negative controls, whereas ds dF:dC oligonucleotide as positive control. S indicates the substrate position, while P
indicates the product position (left). Relative graph illustrating the time-course kinetics activity of the recombinant protein on ds dF:dC and ds rOH:dC
oligonucleotides. Data are expressed as mean ± SD of three independent technical replicas. Standard deviation values were always <10% of the mean of
the experimental points (right). (B) Graph illustrating the time-course kinetics activity of APE1 mutants on ds dF:dC oligonucleotide. Data are expressed
as mean ± SD of three independent technical replicas. Standard deviation values were always <10% of the mean of the experimental points. (C) Graph
illustrating the time-course kinetics activity of APE1 mutants on ds rOH:dC oligonucleotide. Data are expressed as mean ± SD of three independent
technical replicas. Standard deviation values were always <10% of the mean of the experimental points.
Table 1. Kinetic parameters for APE1 endonuclease activity on different substrates
[APE1] (× 10−3 nM) Substrate KM (nM) VMAX (nM/min) kCAT (min−1) kCAT/KM (min.nM)−1
75 ds dF:dC 14.2±6.98 0.95±0.33 12.7±4.39 0.95±0.16
3.125 ds rOH:dC 158±41.79 12.66±3.71 4054±1191.8 26±1.96
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Figure 5. APE1 knock down in human cells impairs the processing of an
rAP site embedded in a duplex DNA substrate. (A) Graph illustrating the
time-course kinetics activity of NCE on ds dF:dC in control and APE1-
knocked down conditions. Data are expressed as mean ± SD of three in-
dependent technical replicas. Standard deviation values were always less
than 10% of the mean of the experimental points. (B) Graph illustrating
the time-course kinetics activity of NCE on ds rOH:dC oligonucleotide in
control and APE1-knocked down conditions. Enzymatic reaction was per-
formed at 37◦C in APE1-buffer with 10 ng of NCE. Data are expressed as
mean ± SD of three independent technical replicas.
nuclear cell extracts in which APE1 was knocked-down
through specific siRNAs (Supplementary Figure S3A), as
explained in Materials and Methods. The endonuclease
activity of APE1-kd (siAPE1) cell extracts, was reduced
on both ds dF:dC (Figure 5A and Supplementary S4D)
and ds rOH:dC (Figure 5B and Supplementary S4D), as
compared to its respective control SCR-treated extracts. As
western blot analysis shows (Supplementary Figure S3A),
the expression of APE1 protein did not exert any effect on
the expression of RNase H2 protein itself, demonstrating
that the observed reduction of the processing activity
of the abasic rNMP-containing substrate, observed with
APE1-kd cell extracts, was likely due to the reduced
expression of the APE1 protein. We further examined
the specificity of the enzymatic activity of APE1 using
the tetrahydrofuran ribonucleotide mimicking an abasic
residue. We tested the activity of the APE1 E96A mutant
to cleave at a ds rF:dC substrate compared to that of
APE1 WT (Figure 6A). As a control, the activity on
the ds dF:dC substrate was also analyzed. As it can be
observed, mutant E96A showed a reduced cleavage on
the ds rF:dC substrate. Indeed, APE1 WT gave a 96% of
cleavage at 5 and 10 nM (lanes 2 and 3), whereas mutant
APE1 E96A had 32% cleavage at 5 nM and 38% at 10 nM
(lanes 5 and 6). Cleavage of ds rF:dC by APE1 WT was
89% at 5 nM and 90% at 10 nM (lanes 8 and 9), and there
was minimal activity for APE1 E96A on the ds rF:dC sub-
strate in the same conditions (lanes 11 and 12). Moreover,
pre-treatment of cell extracts with 0.2 nM of Compound
#3 (i.e. N-(3-(benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7-
tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide)), a specific
APE1 endonuclease inhibitor (53,56), exerted a significant
inhibitory effect upon APE1 enzymatic activity on both
ds dF:dC in DNA and ds rF:dC substrates demonstrating
that the main enzymatic activity of cell extracts was due
to APE1 function (Figure 6, panels B and C).These data
demonstrate that human APE1 is the major enzyme
capable of specifically cleaving at abasic rNMPs in DNA
while being unable to process normal rNMPs, which are
the preferential substrates of RNase H2.
Human RNase H2 does not process an r8oxoG embedded in
a duplex DNA
An abasic site can be generated spontaneously or following
the processing of an oxidized lesion from a specific glyco-
sylase. While known glycosylases (such as OGG1) are re-
sponsible for this activity on 8oxo-dG, no enzyme is known
to be able to process the oxidized rG substrate. We then fo-
cused our attention on r8oxoG removal. The r8oxoG con-
taining oligonucleotide was in-house synthesized and, as
observed from MALDI-MS analysis and HPLC purifica-
tion (Supplementary Figure S5, panels A and B), the un-
desirable presence of secondary products of the chemical
synthesis of this substrate can be excluded. First of all, we
investigated whether human RNase H2 was able to recog-
nize and cleave at r8oxoG site using an oligonucleotide con-
taining this type of lesion called ds r8oxoG:dC (Figure 7A,
see also Supplementary Table S1, Supplementary Figure
S1). In these experiments, we always compared the specific
enzymatic activity of RNase H2 with that exerted on the
canonical ds rG:dC substrate, as positive control, and using
the ds d8oxoG:dC oligonucleotide as negative control. As
Figure 7B shows, while the ds rG:dC oligonucleotide was
efficiently processed by RNase H2, the same activity was
not observed for ds r8oxoG:dC. As expected, the d8oxoG-
containing oligonucleotide was not cleaved by RNase H2.
These data confirm that RNase H2 was not able to pro-
cessmodified rNMPs embedded inDNA. Similarly, we con-
firmed these data using RNase H2-kd nuclear extracts from
HeLa cells. As expected, control nuclear extracts (Scramble)
displayed a time-dependent endoribonuclease activity on
ds rG:dC, whereas the down regulation of RNase H2 pro-
tein expression (siRNase H2) was associated with a marked
reduction of the endoribonuclease activity on the same sub-
strate (Figure 7C). On the contrary, once we tested the abil-
ity of the nuclear extracts on ds r8oxoG:dColigonucleotide,
we found only a weak endoribonuclease activity on it (see
the band indicated by an asterisk), which was not affected
by RNase H2 silencing (Figure 7C). These data support the
conclusion that the r8oxoG site in DNA is not recognized
by human RNase H2.
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Figure 6. Recombinant human APE1 efficiently processes a tetrahydrofuran ribonucleotide mimicking an abasic residue site (rF) embedded in a duplex
DNA substrate. (A) Cleavage result of 10 nM of 32P double-stranded oligonucleotides ds dF:dC or ds rF:dC substrates with different concentrations of
APE1 WT protein (lanes 1–3 and 7–9) and mutant APE1 E96A protein (lanes 4–6 and 10–12) at 37◦C for 1 h in APE1-reaction 1× buffer containing 50
mMTris–HCl pH 7.5, 50 mMKCl, 10 mMMgCl2, 0.001 mg/mLBSA and 0.05% Triton X-100. First lane on the left, M is a ssDNA ladder (barely visible)
and the black arrows on the left show specific band sizes. Both oligonucleotides were incubated with 0 nM (lanes 1,4,7,10), 5 nM (lanes 2,5,8,11) or 10 nM
(lanes 3,6,9,12) of APE1 WT protein (lanes 1–3 and 7–9) or mutant E96A protein (lanes 4–6 and 10–12), respectively. The percentages of cleavage of each
reaction are displayed below the image as enzymatic activity (%). (B) Cleavage result of 10 nM ds dF:dC or ds rF:dC radioactive substrates using 12.5 ng
of whole HeLa cell extracts untreated (lanes 1, 3) and treated (lanes 2, 4) with 0.20 nM of Compound #3, a specific APE1-endonuclease inhibitor, at 37◦C
for 10 min. The black arrows on the left of the gel image indicate the size of uncut and cut substrates following denaturation. The cleavage percentage of
this experiment is displayed below the image as enzymatic activity (%). (C) Histograms showing data from four independent experimental replicas shown
in panel (B) with ranges as bars. P values of <0.05 are marked by asterisk. WCE, whole cell extracts.
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Figure 7. Human RNase H2 is not able to process an r8oxoG site embedded in a duplex DNA substrate. (A) Scheme of ds DNA 25-mer substrates (single
strand (ss) oligonucleotide annealed to ss dC containing- or ss dA containing-complementary oligonucleotide) containing a d8oxoG, r8oxoG and dF site
in the 13th position. The ‘IRD700’ and ‘IRD800’ in green indicates IRDye 800 phosphoramidite and IRDye700 phosphoramidite dye tagged at the 5′
end. (B) Representative denaturing polyacrylamide gel of oligonucleotides (25 nM) incision by human recombinant RNase H2 (5 fmol). Reaction was
performed in RNase H2-buffer (20 mM Tris–HCl, 25 mMKCl, 0.1% BSA, 0.01% Tween20, 4 mMMgCl2, pH 7.4) at 37◦C. ds rG:dC and ds d8oxoG:dC
oligonucleotides were used as positive and negative controls, respectively. Time points are shown on the top of the figure. S indicates the substrate position,
while P indicates the product position. (C) Representative denaturing polyacrylamide gel of oligonucleotides (0.25 !M) incision by nuclear HeLa cell
extracts (NCE). In order to discriminate the activity of RNase H2, 500 ng of NCE in which RNase H2 expression was previously knocked down through
specific siRNA (indicated as siRNase H2) were tested in comparison to control cells (Scramble) at different time points (minutes), shown on top of the
figure. The endoribonuclease activity detected for r8oxoG oligonucleotide was indicated with an asterisk on the right side of each panel. S indicates the
substrate position while P indicates the product position.
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OGG1 has neither lyase nor glycosylase activities on oxidized
rG substrate
We then tested whether enzymes of the BER pathway
may be involved in processing the r8oxoG substrate. To
this purpose, we used recombinant purified human OGG1
and APE1 proteins (Supplementary Figure S4A and S5C).
OGG1 protein belongs to the bi-functional glycosylases
family having both lyase and glycosylase activities on ox-
idized dG (57). We examined the processing activity of
OGG1 on r8oxoG substrate in comparison to the d8oxoG-
containing oligonucleotide, as a positive control. First, we
tested the ability of OGG1 to recognize an r8oxoG site
through electrophoretic mobility shift assay (EMSA). As
shown in Figure 8A, increasing amount of recombinant
OGG1 formed a stable retarded complex with the r8oxoG
oligonucleotide in a dose-dependent manner. As confirmed
in the data shown in Supplementary Figure S5E, OGG1
binding was specific for the modified r8oxoG- containing
oligonucleotide (lanes 2 and 3). Indeed, the same retarded
band was observed when the recombinant OGG1 was in-
cubated with the positive control ds d8oxoG:dC (lanes 11
and 12) but not with the negative controls: ds rG:dC (lanes
5 and 6) and ds dG:dC (lanes 8 and 9).
Furthermore, we tested the lyase activity ofOGG1on dif-
ferent substrates. Figure 8B shows that when we incubated
increasing amounts of recombinant protein for 30 min at
37◦C with different substrates, OGG1 was able to process
only the canonical substrate ds d8oxoG:dC in a dose re-
sponse manner (Supplementary Figure S5D), whereas no
lyase activity was apparent for any of the other substrates
used, including the ds r8oxoG:dC and the ds r8oxoG:dA.
Since OGG1 is the major glycosylase enzyme in the
BER pathway, coordinating with the downstream endonu-
clease APE1, which is able to recognize and process the
abasic site generated by the glycosylase activity of OGG1
(28,58,59), we measured its glycosylase activity on the same
substrates using recombinant purified APE1 (Figure 8C).
In this case, we co-incubated a fixed amount of recombi-
nant OGG1 with increasing amounts of APE1 for 30 min.
While OGG1 displayed a robust glycosylase activity on the
canonical ds d8oxoG:dC substrate, particularly in the pres-
ence of the APE1 protein, we detected only a weak activity
on ds r8oxoG:dC oligonucleotide (indicated by a single as-
terisk) (Figure 8D).Moreover, the presence of an additional
highermobility band, increasing as a function ofAPE1 con-
centration (indicated with a double asterisk) was observed
only in the case of the ds r8oxoG:dC substrate.We conclude
that OGG1 has neither lyase nor glycosylase activity on the
r8oxoG substrate, and that APE1 can weakly process this
substrate alone. AboutAPE1 activity, a detailed description
is explained in the next paragraph.
APE1 has a weak endo-/exo-nuclease activities on the
r8oxoG-containing substrate depending on Mg2+ concentra-
tion and on the presence of its N-terminal domain
Based on the above presented data, we then checked
whetherAPE1 ‘per se’ had any endoribonuclease activity on
ds r8oxoG:dC substrate (Figures 9 and 10). Compared to
the ds dF:dC substrate, APE1 displayed a modest, though
significant, processing activity on both ds r8oxoG:dC and
ds r8oxoG:dA oligonucleotides, while no activity was ob-
served in the case of the dG- and the d8oxoG-containing
substrates (Figure 9, panels A and B), as expected. As ob-
served above, the appearance of an additional faster migrat-
ing cleavage product (indicated by a double asterisk corre-
sponding to a 11-nt product in Figure 8D) was visible in
the case of the ds r8oxoG:dC substrate, which might be
associated with a recently identified 3′-exonuclease activ-
ity by the protein (42). We checked the occurrence of the
cleavage at the expected ribonucleotide sites, by oligonu-
cleotide sequences of increasing length, ranging from 10
to 16 nucleotides, as molecular markers (Supplementary
Figure S6A) and through alkaline hydrolysis experiments
(Supplementary Figure S6B). As it is visible (Supplemen-
tary Figure S6A), cleavage products of the ds r8oxoG:dC
oligonucleotide were of the expected size and comprised be-
tween 11- and 12-nucleotides and are thus compatible with
endonucleolytic cleavage occurring only at the 5′ side of
the lesion (fragment 12-nt long) and with a 3′-exonuclease
activity giving rise to the fragment of 11-nt long. In or-
der to exclude that the observed cleavage product was
due to the processing of a residual non-annealed oligonu-
cleotide possibly present after the annealing reaction, we in-
cubated APE1 protein with single stranded oligonucleotide
(ss r8oxoG) and compared the cleavage product with the
annealed oligonucleotide (ds r8oxoG:dC). Comparing the
result with both ss dF and ds dF:dC oligonucleotides, a
product was detectable only using the double stranded
oligonucleotides as substrates. No bands were observed us-
ing the ss r8oxoG oligonucleotide (Supplementary Figure
S6C) demonstrating the requirement for secondary struc-
tured oligonucleotide sequences for efficient enzymatic ac-
tivities by APE1. In contrast, using the oligonucleotide con-
taining the mismatched ds r8oxoG:dA, most of the frag-
ments produced after incision by the AP endonucleolytic
activity (indicated with a single asterisk) were not further
degraded by the exonucleolytic activity (Figure 9A). There-
fore, these data demonstrate that the APE1 enzymatic activ-
ity on the r8oxoG substrate requires a dsDNAmolecule and
exonuclease activity is dependent on the paired nucleotide,
possibly as a consequence of a different stereochemical ge-
ometry between the 8oxoG:A and the 8oxoG:C.
It has been previously demonstrated that the exonucle-
ase activity of APE1 strictly depends on salt concentra-
tions (60). We therefore tested whether the 3′-exonuclease
activity observed on the ds r8oxodG:dC shared some com-
mon features (in terms of dependence on the ionic strength
conditions) with the 3′-exonuclease activity on mispaired
DNA, as previously described (60). Firstly, we determined
the optimalMgCl2 (Figure 10A) andKCl (Figure 10B) con-
centrations required for the 3′-exonuclease activity. Indeed,
the 3′-exonuclease activity was present up to a concentra-
tion of 2 mM MgCl2. An inhibitory effect was apparent at
MgCl2 concentrations above 4 mM. At the same time, the
3′-exonuclease activity was poorly affected at KCl concen-
tration equal to 100mM.These results are in line with previ-
ous data on 3′-mispairedDNA (60) and suggest that the ob-
served 3′-exonuclease activity strongly depends on the elec-
trostatic interaction of APE1 with the substrate during the
cleavage reaction and with the role of Mg2+ ions.
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Figure 8. Human OGG1 has neither lyase nor glycosylase activities on r8oxoG-containing oligonucleotide. (A) Representative native EMSA polyacry-
lamide gel of OGG1 binding on ds r8oxoG:dC oligonucleotide (25 nM) is shown. The ‘Bound’ arrow indicates the retarded complex between OGG1 and
the probe whereas the ‘Free’ arrow the unbound substrate. Amounts of OGG1 protein, expressed in pico moles, are shown on the top of the figure. Reac-
tions were performed as explained in ‘Materials andMethods’ section. (B) Representative denaturing polyacrylamide gel of lyase activity of human OGG1
on different duplex DNA oligonucleotides (25 nM). Doses of OGG1 protein expressed in femto moles are shown on the top of the figure. Reactions were
performed in OGG1-buffer (20 mM Tris–HCl, 100 mM KCl, 0.1% BSA, 0.01% Tween20, pH 7.4) at 37◦C for 30 min. S indicates the substrate position,
while P indicates the product position. (C) Representative denaturing polyacrylamide gel of incision by different doses of APE1 co-incubated with a fixed
amount of OGG1 (3.125 nM) on different duplex DNA oligonucleotides (25 nM) in order to investigate glycosylase activity of OGG1. Different doses of
APE1 protein, expressed in femtomoles, are shown on top of the figure. Reactions were performed in a buffer containing 20 mM Tris–HCl, 100 mMKCl,
0.1% BSA, 0.01% Tween20, pH 7.4 at 37◦C for 30 min. S indicates the substrate position while P indicates the product position. Moreover, at the right of
the panel, a longer product of about 12 nucleotides is indicated by an asterisk whereas a smaller one of 11 nucleotides is indicated by a double asterisk.
(D) Histograms represent the dose response of OGG1 glycosylase activity on ds d8oxoG:dC and paired and mismatched ds r8oxoG oligonucleotides.
ds d8oxoG oligonucleotide was used as a positive control whereas ds dG:dC and ds rG:dC oligonucleotides were used as negative controls. The activity is
reported as percentage of substrate converted to product. Data are expressed as mean ± SD of three independent technical replicas.
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Figure 9. Human APE1 shows a weak endo- and a 3′-exonuclease activities on r8oxoG substrate. (A) Representative denaturing polyacrylamide gel of
APE1 incision on different duplex DNA oligonucleotides (25 nM), in which ds dF:dC oligonucleotide was used as a positive control, whereas ds dG:dC
and ds rG:dC oligonucleotides were used as negative controls. The doses of APE1 protein used, expressed in femtomoles, are shown on the top of the figure.
On the right side, a schematic representation of the cleavage products, showing the position of the ribonucleotide (red box with R) embedded in the DNA
oligonucleotide and theAPE1 cleavage on it, producing a longer product of about 12 nucleotides (*) and a smaller one of 11 nucleotides (**). Reactions were
performed in APE1-buffer containing 20 mM Tris–HCl, 100 mM KCl, 0.1% BSA, 0.01% Tween20, pH 7.4 for 30 min at 37◦C. S indicates the substrate
position while P indicates the product position. (B) Relative graph indicates a dose–response APE1 activity on paired and mismatched ds r8oxoG:dC
oligonucleotide in comparison to ds dF:dC positive control. Data are expressed as mean ± SD of three independent technical replicas.
After choosing the optimal salts conditions, in which
both endo- and exo- activities of APE1 (100 mMKCl and 1
mMMgCl2) are present, we then evaluated whether the en-
zymatic activity of APE1 on ds r8oxoG:dC was dependent
on the same catalytic site responsible for the endonuclease
activity observed on abasic dsDNA and abasic rNMP. To
this aim, the enzymatic activity of the E96A mutant was
compared to that of the WT protein (Supplementary Fig-
ure S6D). These data demonstrate that the APE1 E96A
mutant has a reduced endoribonuclease activity showing
no 3′-exonuclease activity over the ds r8oxoG:dC substrate.
Due to the effect of salt concentration on this latter ac-
tivity, we also tested the enzymatic activity of the APE1
N!33 deletion mutant (Supplementary Figure S6D). In-
terestingly, while this protein retained the endoribonuclease
activity of the WT protein, its 3′-exonuclease activity was
abolished. Moreover, treatment with APE1 inhibitor Com-
pound #3 confirmed that the catalytic site responsible for
the endonuclease activity is also responsible for the endori-
bonuclease activity over the r8oxoG substrate (Supplemen-
tary Figure S6E). These results show that APE1 has a weak,
though significant, endoribonuclease activity on r8oxoG
substrates with an additional specific 3′-exonuclease activ-
ity dependent on: (i) the kind of pair: i.e. ds r8oxoG:dC or
ds r8oxoG:dA; (ii) salt concentrations (i.e. Mg2+); (iii) the
presence of the 33 N-terminal domain.
Overall, our data demonstrate that BER enzymes but not
RER are involved in the processing of non-canonical rN-
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Figure 10. Human APE1 activities on r8oxoG substrate depend on mono- and di-valent cations. (A) Representative denaturing polyacrylamide gel of
APE1 (5 nM) incision on ds r8oxoG:dC oligonucleotide under different MgCl2 concentrations that is expressed in mM (top) performing a reaction long
30 minutes in APE1 buffer. S indicates the substrate position while P indicates the product position. Moreover, at the right of the panel, a longer product
of about 12 nucleotides is indicated by an asterisk whereas a smaller one of 11 nucleotides is indicated by a double asterisk Also shown on the right is a
schematic representation of the cleavage products, showing the position of the ribonucleotide (red box with R) embedded in the DNA oligonucleotide and
the APE1 cleavage on it, producing a longer product of about 12 nucleotides (*) and a smaller one of 11 nucleotides (**). Relative graph shows the ratio
between two products obtained as a function ofMgCl2 concentration (bottom). (B) Representative denaturing polyacrylamide gel of APE1 (5 nM) incision
on ds r8oxoG:dC oligonucleotide under different KCl concentrations in combination with two different MgCl2 concentrations, 1 mM and 10 mM (top)
performing a reaction long 30 min in a buffer containing 20 mM Tris–HCl, 0.1% BSA, 0.01% Tween20, pH 7.4. S indicates the substrate position, while P
indicates the product position. Moreover, at the right of the panel, a longer product of about 12 nucleotides is indicated by an asterisk whereas a smaller
one of 11 nucleotides is indicated by a double asterisk. Relative graph shows product levels in association with different salts concentrations (bottom).
MPs, such as abasic or oxidized, incorporated in DNA. Be-
cause the repair pathway catalyzed byAPE1 toward the oxi-
dized rG is fundamentally different from that of BER, since
no bases are excised, we can conclude that the observed ef-
fect could be ascribed to an alternative damage-specific en-
donuclease initiated repair pathway, previously referred to
as either alternative excision repair (AER) or nucleotide in-
cision repair (NIR) (reviewed in (61,62)).
APE1 and RNase H2 do not biochemically and functionally
interact in human cells
To support the functional independence between BER and
RER, we tested whether APE1 and RNase H2 proteins
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functionally interact.We tested whether this hypothesis was
confirmed in HeLa cells transfected with siRNAs specific
for APE1 and RNase H2 mRNAs to knock down the cor-
responding endogenous proteins. Whole cell extracts were
prepared as explained in Materials and Methods section,
and western blotting analysis was used to check the effec-
tive protein down regulation (Supplementary Figure S7A).
Then, we checked the ability of APE1 and RNase H2 from
cell extracts to recognize the ds r8oxoG:dC substrate. We
performed EMSA with cell extracts from control (Scram-
ble) and APE1-kd (siAPE1) or RNase H2-kd (siRNase H2)
cells. As demonstrated in Supplementary Figure S7B, incu-
bation of cell extract from control cells displayed a retarded
band containing APE1-complex, as also demonstrated by
supershift EMSA experiments with anti-APE1 specific an-
tibody (Supplementary Figure S7, panels C and D). The in-
tensity of the retarded complex was decreased upon APE1-
kd (siAPE1) (Supplementary Figure S7B, lane 4) and upon
the double APE1/RNase H2-kd (siAPE1 + siRNase H2)
(lane 6) but not upon RNase H2 silencing alone (siRNase
H2) (lane 5), confirming that APE1 is involved in a protein
complex able to recognize r8oxoG damage in which RNase
H2 is not present.
DISCUSSION
Increased body of evidence supports the notion that incor-
poration of rNMPs in DNA is a frequent phenomenon,
having profound detrimental effects on genome stability of
both prokaryotes and eukaryotes (1,2,63,64). In humans, as
well as in yeast and bacteria including Archaea, the main
processing pathway responsible for repairing of these le-
sions is the RER pathway, which involves the RNase H2
enzyme (65,66). RNase H2 importance in higher organisms
is testified by its essentiality for embryonic development in
mouse (67). Moreover, RNase H2 mutations in humans are
causally linked to the onset of AGS, a rare autoimmune
inflammatory disease (68,69). It can be hypothesized that
among the many millions rNMPs that are introduced in the
mammalian genome per cell cycle (3), not only canonical
rNMPs are incorporated but also damaged rNMPs (such
as abasic and oxidized). Indeed, like deoxyribonucleotides,
rNMPs are also susceptible to oxidative insults (5,70), and
a significant generation of abasic sites formation has been
demonstrated upon RNA oxidation and alkylation (71).
While the role of RNase H2-initiated RER mechanism of
DNA repair in recognizing and cleaving rNMPs embedded
in DNA is well established (3,15), nothing is known regard-
ing the DNA repair pathways involved in the removal of
damaged rNMPs.
BER is the main mechanism coping with the repair of
non-distorting single-base lesions, such as abasic sites and
oxidized bases (27). Interestingly, emerging literature, in-
cluding ours, pointed to a new function of BER in RNA
quality control surveillance and RNA-decay with the func-
tions of SMUG1, PARP1 and APE1 in RNA processing
(38,72). At present, however, there is no evidence that BER
may cope with the removal of rNMPs fromDNA. Identify-
ing whether BER may target unmodified and/or modified
rNMPs in DNA is important to better understanding the
mechanism of genotoxicity of oxidative stress and the im-
pact of BER defects in human disease, cancer mechanisms,
and for the development of new anticancer strategies.
In this work, we demonstrate that an rAP site embedded
in DNA is targeted by APE1 of BER rather than RER in
eukaryotic systems (Figure 11A). We have found that eu-
karyotic RNase H2 enzymes from yeast, mouse and hu-
man, and from human cell extracts are unable to process
rAP sites in DNA, whereas recombinant human APE1 is
able to efficiently cleave this type of damage (Figures 2 and
3). APE1 processes the rAP site as efficiently as the canoni-
cal deoxy-abasic site as measured by kinetic data (Table 1).
Data using catalytic inactive APE1 mutants (E96A) clearly
demonstrate that the endonuclease active site of APE1 is
required to perform the endoribonuclease activity on a ri-
bose abasic site in dsDNA. Differently, the cleavage activity
of the 33N-terminal truncated mutant, which does not im-
pact the catalytic function of the enzyme but is involved in
the release of the product upon cleavage (48), is compara-
ble to that of wild-type APE1. This last result demonstrates
that the unstructured N-domain is dispensable for the enzy-
matic reaction on the abasic ribonucleotide site. Moreover,
using HeLa nuclear cell extracts that were siRNA-depleted
of APE1 or RNAse H2 proteins, we showed that the pro-
cessing activity of the rAP site in DNA depends only on
the presence of APE1 and not on RNase H2. These results
highlight a new role of APE1 in repairing rAP sites embed-
ded in DNA, demonstrating that the catalytic site of APE1
and the mechanism of product release is similar to that of
the canonical deoxy-substrate.
rAP sites embedded in DNA may be generated by spon-
taneous hydrolysis or by the action of an unknown glyco-
sylase on oxidized rNMPs, such as r8oxoG. Furthermore,
a potentially significant, yet poorly characterized, source of
rNMPs incorporated inDNA is the oxidative stress. rNMPs
were shown to form during oxidative DNA damage both in
vitro and in vivo (5). Therefore, it is also possible that abasic
and oxidized DNA is converted into RNA. It was estimated
that spontaneous depurination occurs 1,000 times slower in
RNA than DNA (73). For example the rate of depurina-
tion in DNA under physiological conditions is estimated to
be 1 out of 100 000 purines every cell cycle. This rate gives
10 000 abasic sites per day in human cells (74). Considering
the remarkable abundance of rNMPs in DNA, which could
be as many as 600 000 rNMPs in budding yeast genomic
DNA, and therefore a factor of 250 higher in mammalian
genomic DNA (150 000 000) (3), i.e. >300 millions in the
human diploid DNA per cell cycle, it is not unrealistic to
anticipate that cells may contain a non-negligible number
of rAP sites inDNA, or oxidized rNMPs. Interestingly, aba-
sic RNA results significantly more stable than abasic DNA,
suggesting that specific enzymatic mechanisms should exist
in vivo to cope with this harmful lesion (75). In addition,
in conditions of oxidative DNA damage, such as in can-
cer cells, the likelihood of such base modifications can in-
crease. Moreover, recent studies already suggested that r8-
oxoGTP is formed in vivo under oxidative stress conditions
and may be incorporated during replication into DNA by
S. pombe,M. smegmatis and human (34–36). Moreover, the
introduction of r8oxoG inDNA can be catalyzed by human
DNA Pol! (36). However, the level and function of Pol!
in cells are highly regulated by complex signaling mecha-
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Figure 11. Model for repair of oxidized rNMPs and rAP sites embedded in DNA by APE1. (A) 8oxo-ribonucleotides could be generated in the cellular
nucleotide pool or even when they are already incorporated in DNA as a result of an oxidation of the sugar (1) and/or the base (2). After the evidence
that human RNase H2 is not able to process an oxidized rNMP embedded in DNA, we found that APE1 shows a weak but significant activity on it (3).
Similarly, RNase H2 does not process an rAP embedded in DNA, which could be generated spontaneously or by the r8oxoG processing, and again APE1
possesses a strong activity on this type of damage (4). Because APE1 activity on 8oxo-ribonucleotides in DNA is low, we hypothesize that other proteins
(some glycosylases?) may participate in their repair. (B) Structural models with the active site of RNase H2 andAPE1 with an rNMP or an rAP.T. maritima
(left) and human APE1 (right) is in a complex with DNA having a single rNMP or single abasic residue, respectively. DNA is indicated in blue, while the
single rNMP and the abasic residues are shown in red as sticks. The arrows points towards ribose or G base or abasic sites in the panels. Proteins are shown
in green except for three of the several regions on APE1 that engulf the abasic sugar which are in magenta. PDB for RNase H2 is 303-F; for APE1 as
1DEW (92).
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nism and interactome networks (76). Therefore, the proba-
bility of r8oxoG incorporation into genomic DNA by Pol!
is still a question under debate, which needs further exper-
imental proof. Spontaneous formation of rAP sites being
a rare event, it is a key question to find activities produc-
ing rAPs following processing of oxidized rNMPs in DNA.
In addition, a possible RER and BER involvement in re-
moval of r8oxoG from DNA has been proposed in other
reports (36,77). Work in our laboratory is ongoing along
these lines to address these fundamental issues. Considering
these observations, we focused our attention on which BER
protein, if any, may be involved in recognition and cleav-
age of oxidized rNMPs (r8oxoG) embedded in DNA. First,
we tested the RNase H2 activity on r8oxoG substrate (Fig-
ure 7). Similarly to results with the abasic rNMP in DNA
our data clearly demonstrate that RER is not involved in
processing of oxidized rNMPs embedded in DNA. Based
on these findings, we explored a potential role of the BER
pathway. First, we showed that the human OGG1, the main
glycosylase enzyme able to recognize and repair oxidized
dG through its lyase and glycosylase activities, has neither
a lyase nor a glycosylase activity on an oxidized rG site em-
bedded in a DNA substrate, despite its ability to efficiently
bind the oxidized substrate (Figure 8), in agreement with
recent findings (77). Interestingly, we discovered that APE1
has a weak endoribonuclease activity on r8oxoG site em-
bedded in a DNA substrate, and shows a 3′-exonuclease
activity (Figures 9 and 10), similarly to the 3′-exonuclease
activity on DNA demonstrated previously (52,54). In line
with previous results, the 3′-exonuclease activity of APE1 is
strictly dependent on Mg2+ concentration and on the pres-
ence of the first 33 aminoacids. The importance of the N-
terminal domain is to be attributed to different reasons: (i)
it bears the majority of the positive charges of APE1; (ii)
is the target of the main post-translational modifications
of the protein (i.e. acetylation, ubiquitination, proteolysis);
(iii) is involved in modulating the interaction with different
protein partners and finally (iv) may modulate the catalytic
rate, probably acting on the koff of the catalytic reaction due
to increased speed of product release (37,48,78). These un-
expected results, which suggest that APE1 3′-exonuclease
activity strongly depends on the electrostatic interaction of
APE1, involving its unstructured N-terminal domain, with
the substrate (52), may be explained on the basis of the
previously characterized ability of APE1 to process some
particular structured RNA species in a specific manner
(37).The activity of APE1 on r8oxoG embedded in DNA
does not hide the possibility that a similar activity could be
exerted on RNA molecules too. This finding could repre-
sent the first demonstration of an enzyme able to recognize
and process oxidized RNA (78). To date, RNA oxidation
has been shown to exert detrimental physiological effects
and to be a common feature in different human pathologies
ranging from ageing to neurodegenerative and cancer dis-
eases (79). For instance, oxidized RNA (80) or RNA con-
taining abasic sites (75) show inhibitory effects on reverse
transcriptase activity, whereas oxidized mRNA (81,82) or
mRNA with abasic sites (83) exhibit compromised transla-
tion activity as well as translation fidelity (84). The weak
endo- and 3′-exonuclease activities on r8oxoG- contain-
ing substrate and their dependence onMg2+-concentrations
and on the presence of the first N-terminal domain
residues of APE1 are fully in agreement with the pre-
viously described nucleotide incision repair (NIR) func-
tion by APE1 on several oxidized substrates, such as: 5,6-
dihydro-2′-deoxyuridine, 5,6-dihydrothymidine, 5-hydroxy-
2’-deoxyuridine, 5-hydroxycytosine (43–45). Notably, the
limited activity obtained in the experimental conditions
we used (also after changing the pH conditions, data not
shown) are in agreement with previous reports on the NIR
function by APE1 on some particular substrates such as
the "dG:dG and the 5OH-dC:dG (44). In addition, the bio-
chemical characterization throughMALDI-MS andHPLC
analyses we performed (Supplementary Figure S5 panels A
and B) may be suggestive for the existence of an equilib-
rium between different conformational species of r8oxoG
dsDNA, excluding any possible bias due to contaminant
present in the oligonucleotide used for the assays. There-
fore, these findings underscore the importance of identify-
ing the enzyme(s) responsible for the recognition and effi-
cient processing of the r8oxoG substrate, in order to further
extend our studies and our understanding of this hot scien-
tific topic.
We observed that OGG1 is unable to process the r8oxoG
substrate, while being perfectly able to specifically bind it,
similar to what recently published by Sassa et al. (77). At
present, it is possible to speculate that though the base-
flipping occurs, the enzymes is unable to hydrolyze the N-
glycosidic bond and has no lyase activity maybe as a conse-
quence of the steric hindrance with the 2′OH of the ribose
which renders the C1′ unavailable for the nucleophilic at-
tack by the catalytic site. Differently from our results, Sassa
et al. found no enzymatic activity by APE1. This discrep-
ancy with our results may be due to the different experi-
mental conditions for the enzymatic assays, i.e. higherMg2+
concentrations and the use of a small amount of EDTA,
both aspects already demonstrated to strongly affect the
APE1 enzymatic activity on the r8oxoG substrate. A com-
parative experiment we performed (Supplementary Figure
S8) was indeed supportive of this hypothesis, reinforcing the
importance of the experimental conditions when studying
the non-canonical functions of APE1 protein. Interestingly,
Sassa et al. showed that the commercially available prokary-
otic RNase HII preserves the ability to remove an oxidized
rNMP in aDNAduplex. Contrary to these results, our find-
ings show that eukaryotic RNase H2 is completely inactive
on a substrate containing an oxidized rNMP. These data
suggest that the ability to process r8oxoG in DNA has been
lost during evolution and deserves further studies.
To explain why APE1 recognized the abasic rNMP in
DNAandRNaseH2 did not, we compared themodel struc-
tures of DNA with an rNMP or an rAP site in the RNase
H2 and APE1 active site, respectively (Figure 11B). RNase
H2 recognizes the RNA-DNA junction with the substrate
participating in catalysis. Prior to incision by RNase H2,
the rNMP base is hydrogen bonded to the complementary
DNA strand base (85). If the rNMP is abasic, there is no hy-
drogen bonding to stabilize the complex required for RNase
H2. Rather, an orphan base on the complementary DNA
strand is present. We hypothesized that the lack of the hy-
drogen bonding between the abasic rNMP and the opposite
deoxyribonucleotide interferes with the capacity of RNase
18 Nucleic Acids Research, 2017
H2 to recognize an abasic rNMPand cleave it. Thus, the role
of recognizing and cleaving abasic rNMPs is not specific of
RNase H2. Differently from RNase H2, APE1 specifically
recognizes and cleaves an abasic distortion in DNA, and
basically engulfs the sugar-phosphate further distorting the
DNA (86), as seen in Figure 11B. Here, we predicted that
the ribose extra OH would have only minor influence on
the structure. Therefore, this could explain why the abasic
rNMP, like an abasic deoxyribonucleotide in DNA, was ef-
ficiently cleaved by APE1.
Experiments are underway in order to address if other
glycosylasesmay process oxidized rNMPs in order to gener-
ate rAP sites, which are then efficiently processed by APE1.
We previously demonstrated that APE1-defective cells have
increased oxidized rRNA content upon oxidative stress
(37). This result has now a molecular explanation in the
observed endoribonuclease activity of APE1 over r8oxoG
containing oligonucleotides and will deserve further atten-
tion in our future studies. Regarding the formation of aba-
sic ribonucleotides in DNA, this is still a matter of debate.
The existence of specific N-ribohydrolases, including the
toxin ricin, has been already documented (87) to be able to
generate abasic rNMPs in RNA molecules, besides sponta-
neous generation (71). A role for the YB-1 protein in rec-
ognizing oxidized ribonucleotides sites in RNA has also
been hypothesized (88), but no specific enzymatic mecha-
nisms able to remove the oxidized base has been described,
yet. The accumulation of the r8oxoG substrates, which oc-
curs on RNA upon silencing of APE1 expression, may thus
be explained under the assumption that enzymatic removal
of oxidized rNMPs may represent the limiting step in the
process. Besides its direct activity on r8oxoG, APE1 could
be stimulated by a glycosylase activity allowing a faster
turnover as demonstrated for DNA substrates (89). Work
is in progress along these lines to better inspect this mecha-
nism and the putative glycosylase enzymes involved. More-
over, since APE1 is overexpressed in different types of can-
cer, such as ovarian, gastro-esophageal, pancreatico-biliary,
lung and breast cancers (90,91), it would be interesting to
determine whether any correlation exists between its expres-
sion level and presence of modified rNMPs in cancers.
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A B S T R A C T
The Base Excision Repair (BER) pathway, initially studied as a mere DNA repair pathway, has been later found to
be implicated in the expression of cancer related genes in human. For several years, this intricate involvement in
apparently different processes represented a mystery, which we now are starting to unveil.
The BER handles simple alkylation and oxidative lesions arising from both endogenous and exogenous
sources, including cancer therapy agents. Surprisingly, BER pathway involvement in transcriptional regulation,
immunoglobulin variability and switch recombination, RNA metabolism and nucleolar function is astonishingly
consolidating. An emerging evidence in tumor biology is that RNA processing pathways participate in DNA
Damage Response (DDR) and that defects in these regulatory connections are associated with genomic instability
of cancers. In fact, many BER proteins are associated with those involved in RNA metabolism, ncRNA processing
and transcriptional regulation, including within the nucleolus, proving a substantial role of the interactome
network in determining their non-canonical functions in tumor cells. Maybe these new insights of BER enzymes,
along with their emerging function in RNA-decay, may explain BER essential role in tumor development and
chemoresistance and may explain the long-time mystery. Here, we would like to summarize different roles of
BER pathway in human cells. First, we will give a short description of the classical BER pathway, which has been
covered in detail in recent reviews. We will then outline potential new roles of BER in gene expression and RNA
metabolism. Although recent works have provided tremendous amount of data in this field, there are still lot of
open questions.
1. Relevance of the canonical BER pathway and open questions
The BER pathway (Fig. 1) is an essential DNA repair system in
higher eukaryotes and gene deletions of the core BER factors (apurinic/
apyrimidinic endonuclease 1 – APE1, DNA polymerase β− Polβ, X-ray
repair cross-complementing 1 – XRCC1, DNA ligase I − LigI and DNA
ligase III− LigIII) results in embryonic or early post-natal lethality [1].
The pathway is comprised of five major steps, in which enzymatic and
non-enzymatic components cooperate to carry out a highly integrated
set of reactions: i) recognition and excision of the damaged base; ii)
incision of the resulting AP site to generate a nick on the DNA back-
bone; iii) processing of the nick ends; iv) filling of the nucleotide gap;
and v) sealing of the nick (Fig. 2).
Different specific DNA glycosylases scan the DNA substrate, re-
cognize, through a flipping out mechanism, and excise the damaged
base in a lesion-specific manner. Two kinds of DNA glycosylases are
known: mono- or bi-functional, depending on their mechanism of ac-
tion. While monofunctional DNA glycosylases (e.g. the uracil-DNA
glycosylase − UNG) simply cleave the C1′-N-glycosidic bond, gen-
erating an AP-site, bifunctional enzymes also possess an associated β-
lyase activity (e.g. the 8-oxoguanine DNA glycosylase − OGG1) de-
puted to cleave the DNA backbone leaving a 3′-α,β-unsaturated alde-
hyde blocking group. An additional family of DNA glycosylases, re-
presented by the human NEIL1 and NEIL2 enzymes, is also able to
operate a β,δ-elimination reaction, leaving a 3′-phosphate nick [2].
Higher eukaryotes are provided with a vast array of DNA glycosylases
with a significant redundancy in their damage selectivity for this
reason, single knockout of several DNA glycosylases is not lethal per se,
although an accumulation of unrepaired DNA lesions occurs [3].
The glycosylase-catalyzed reaction generally produces an AP-site,
which is immediately processed by APE1 in metazoans. APE1 cleaves at
the 5′ termini of the abasic site, generating a nick on the DNA backbone
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and producing a 3′-OH and a 5′-dRP (deoxyribonucleotide-phosphate)
termini. Usually, APE1-incision activity is sufficient to generate the
DNA ends required for the completion of the DNA repair process. Once
further oxidation of the DNA termini or base-excision operated by bi-
functional glycosylases occurs, other end-processing enzymes may be
involved, such as tyrosyl-DNA phosphodiesterase 1 (TDP1), aprataxin
(APTX) or polynucleotide kinase 3′-phosphatase (PNKP). The dRP-lyase
activity of Polβ, along with APE1 3′-phosphodiesterase activity, con-
tributes to the “end-cleaning” process, ultimately generating a single-
nucleotide gap that can be efficiently filled in and re-ligated [4].
BER is then completed via a “short-patch” (SP) or a “long-patch”
(LP) pathways, depending on the 5′-moiety generated. In the SP-BER,
Polβ is engaged to replace the missing nucleotide, and then is followed
by the XRCC1-LigIII complex, which is responsible for the ligation of
the nick [5]. In the presence of a 5′-moiety refractory to the Polβ lyase
activity, low ligation efficiency, or during the S-phase of the cell cycle
(i.e. when replication-associated proteins are more abundant), BER can
be completed through the LP-BER which involves a strand displace-
ment-dependent gap filling process [1]. Replicating polymerases, such
as DNA polymerase δ and ε, act in concert with the sliding clamp PCNA
(proliferating cell nuclear antigen) in the LP-BER, generating a stretch
of 2–12 nucleotides, which is removed by the flap endonuclease 1
(FEN1). Finally, intervention of the PCNA-associated DNA Ligase I seals
the nick [6].
Notably, BER protein components are involved in at least two sub-
pathways, namely Single Strand Break Repair (SSBR) and Nucleotide
Incision Repair (NIR) [7]. SSBs are generated by different sources in-
cluding reactive oxygen species (ROS), radiomimetic drugs, ionizing
radiation, topoisomerase-mediated DNA cleavage or they are un-
avoidable intermediates generated during BER processing. The SSBR
pathway initiates through recruitment of the poly(ADP-ribose) poly-
merase PARP1, which recognizes exposed SSBs and modulates the re-
pair process through enzymatic ADP-ribosylation of protein substrates.
Tight connection between BER and SSBR has been highlighted by the
observation that many BER proteins (e.g. XRCC1, Polβ) interact with
PARP1 [6] and by the fact that PARP1 has been shown to orchestrate
the BER processing of uracil and AP-sites [8]. Interestingly, it has been
recently demonstrated that APE1 has glycosylase-independent NIR ac-
tivity on particular modified bases, see below. Although very intri-
guing, the physiological impact of the NIR pathway is still under in-
vestigation, as within the intracellular milieu the presence of specific
DNA glycosylases would likely dampen the efficiency of the NIR process
on DNA.
Overall, BER is currently regarded as a dynamic intertwining of
different enzymes and auxiliary proteins that operate in a highly co-
ordinated manner to allow temporal and spatial modulation. The re-
levance of this coordination is remarked by several observations, which
still deserve further studies:
• imbalanced expression of BER components has been linked to
genomic instability. In particular, overexpression of core elements of
the pathway is a hallmark of cancer progression and resistance to
therapy. Increased expression of a single BER factor may result in
competition or in excessive enzymatic activity, which is not com-
pensated by equimolar amounts of other BER proteins. This has been
formally demonstrated, in the case of APE1 [9–11] and Polβ [12].
• abortive intermediates of the pathway are intrinsically cytotoxic
since unprotected intermediates (e.g. SSBs) are much more toxic
than the initial damaged base [13]. Therefore, the fine-tuning and
coordination of the pathway is possibly the result of an evolutionary
tradeoff between the rapid repair of mutagenic lesions and the po-
tentially hazardous intermediates that such repair may generate.
In order to explain mechanisms evolved to optimize the repair ef-
ficiency of the BER pathway, several models have been proposed in-
cluding those of the ‘passing the baton’ and the ‘BERosome’ [7,8,14].
Despite the apparent divergence amongst models that have been put
forward to explain the complexity of BER, each of them probably de-
scribes different aspects of a unique and highly dynamic integrated
process. However, it is clear how it is modulated through a complex
network of more or less stable DNA-mediated or protein-protein inter-
actions, among BER enzymes and non-enzymatic scaffold proteins (e.g.
XRCC1, PCNA) and PTMs (Post-translational modifications). Phos-
phorylation, acetylation, methylation, SUMOylation, as well as ubi-
quitination of almost every BER component have been suggested to
play a role in the modulation of the pathway [7].
An emerging concept in this field is the role of some non-canonical
regulatory proteins as BER modulators. Several proteins, apparently
unrelated to the pathway, have recently been discovered as novel un-
expected coordinators of BER [15]. p53, for instance, has been im-
plicated in the modulation of both APE1 and Polβ [6], whereas our
laboratory discovered nucleophosmin (NPM1) as a modulator of the
APE1 enzymatic activity [16]. Additional regulation of the BER
pathway is also achieved through evolutionarily acquired disordered
extensions of some BER components [17,18]. These accessory proteins
were proposed to be important for stabilizing large complexes, “re-
pairsome”, by providing extended interaction surface area [19].
An interesting link between DNA damage sensing and modulation of
BER protein amount has been recently demonstrated. Indeed, BER
proteins amount, which is generally abundant with a relatively long
half-life, is constantly oscillating in response to the DNA damage load at
the steady-state level. This equilibrium is strictly controlled by the
ubiquitin-proteasome system [4]. It is possible that the high level of
them (such as APE1 and Polβ) observed in several tumors is the result of
perturbations of this equilibrium. Understanding these aspects will shed
light on the role of BER proteins in cancer development.
2. NIR activity of APE1 on non-canonical substrates
In the last decade, Nucleotide Incision Repair (NIR) pathway has
been described as a new function of APE1 which works as back up of
BER pathway ensuring a correct removal of damaged bases as a result of
oxidative stress [20–25]. NIR activity by APE1 consists of an incision at
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Fig. 1. BER exerts different functions in human cells.
Schematic representation of different biological functions of Base Excision Repair (BER)
pathway in human cells including DNA repair player of alkylated and oxidative DNA
lesions; regulator of expression of genes involved in response to genotoxicants; regulator
in RNA metabolism, control of nucleolar function and regulation of immunoglobulin Class
Switching together with AID.
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the 5′ next to a oxidatively damaged base in a DNA glycosylase–inde-
pendent manner, providing a proper 3′-OH group for further processing
[20]. After the removal of the dangling damaged nucleotide by a flap
endonuclease [26,27], DNA backbone can be efficiently repaired by a
DNA polymerase. In this way, the NIR action avoids the generation of
potentially toxic AP-intermediates [28]. Several uncanonical substrates
are processed by APE1 through NIR activity, including 5,6-dihydro-2′-
deoxyuridine (DHU) [20,28], 5,6-dihydrothymidine (DHT) [20,28], 5-
hydroxy-2′-deoxyuridine (5OHU) [20,28], 5-hydroxy-2′-deoxycitidine
(5OHC) alpha-2′-deoxynucleosides (αdA, αdT and αdC) [20,28–31],
the majority of which are generated under ionizing radiation (IR) and
exposure to certain drugs. This non-canonical activity of APE1 could
explain how, on the contrary to what is observed in APE1 deficient cells
[32–34], the lack of DNA glycosylases does not sensitize cells or mice to
oxidative agents and IR [35–37]. Although NIR pathway plays an im-
portant role as a back-up of BER, experimental working conditions,
such as salts and pH conditions, seem to affect the NIR function of
APE1. The optimal conditions for NIR activity are very similar to those
required for the 3′–>5′ exonuclease activity by APE1, characterized by
a pH around 6.4–6.8, and a KCl concentration of 50 mM [20]. More-
over, NIR is more active to 100-fold lower MgCl2 concentration com-
pared to that of the canonical AP-endonuclease activity [20]. Interest-
ingly, the N-terminal domain of APE1 deputed to modulate protein-
protein interaction and indispensable to redox activity but not AP-
endonuclease activity [38], is contrarily essential for the NIR activity;
indeed the lack of the first 33 N-terminal aminoacids of the protein
produces a 20-fold-decrease of APE1 NIR activity [20]. Moreover, Ti-
mofeyeva et al. demonstrated that Lysine in position 98 contributes
significantly in the 5′-phospodiester bond hydrolysis of DNA substrate,
but not in the dissociation of the enzyme-product complex [21]. In-
terestingly, the substitution of this amino acid influences the APE1 NIR
activity more than BER, demonstrating that the APE1 active site in-
volved in NIR and BER pathways is the same, but different conforma-
tional requirements are responsible for APE1 NIR or BER activities [21].
3. Unusual involvement of BER enzymes in the regulation of gene
expression
Generation of single base modifications is not only a harmful DNA
modification caused by genotoxic agents but it may have important
regulatory functions also at the basis of epigenetic mechanisms. For
instance, 5-methylcytosine and Uracil, which are enzymatically gener-
ated during epigenetic regulation of gene expression and in antibody
diversification processes, respectively, are the most well-known ex-
amples of this phenomenon. Very recently, a number of studies pointed
to 8-oxoG (8-oxo-7,8-dihydroguanine) modification as a new epigenetic
mark with a relevant role in the control of gene expression [39]. Gen-
eration of 8-oxoG on different promoters regulates the activity of
Fig. 2. Schematic representation of consecutive BER
steps during the repair of different DNA lesions.
BER is endowed to repair different lesions including
modified dNMPs (blue star) and modified rNMPs
(red star). Different types of mono- and bi- functional
glycosylases exist in order to recognize damaged
dNMPs, such as oxidized dNMPs, uracil, etc., and
generate deoxy-abasic sites, which are subsequently
processed by APE1. At the same way, an oxidized
rNMPs, embedded in DNA, could be recognized by
specific glycosylases such as YB-1 and NEIL1, and be
converted in ribo-abasic sites, efficiently processed
by APE1. For both types of damages, APE1 possesses
a NIR activity in which APE1 cleaves directly the
lesion bypassing the glycosylases action. BER
pathway is finally terminated by different specific
enzymes depending on whether the Short Patch or
Long Patch pathways.
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several transcription factors (e.g. Hif1α, STAT1, NF-κB and MYC) in
conjunction with OGG1 protein and, in turn, regulates the expression of
important genes involved in cancer development, such as VEGF [40],
SIRT-1 [41] and inflammatory genes such as TNF-α and CXCL2 [42].
Interestingly, this last role of OGG1 on inflammatory genes may explain
the reduced inflammatory response in Ogg1−/− mice [43].
Canonical epigenetic mechanisms seem to crosstalk with new DNA
damage epigenetic marks. In fact, it has been recently shown that de-
methylation of histone H3 at Lys9 by LSD1 de-methylase, through
generation of H2O2, promotes oxidation of estrogen-receptor responsive
promoters in breast cancer cell lines with a consequent OGG1-depen-
dent promoter activation [44]. In a similar way, also Myc-induced,
retinoic acid-induced and androgen receptor-induced transcription has
been proved [45–47] demonstrating that the transcriptional function of
OGG1 is a much more general non canonical function than previously
thought. OGG1, in complex with 8-oxoG free base, has been recently
suggested to play a role in signal transduction as a new Guanine Ex-
change Factor (GEF) for Ras, Rac and Rho GTPases [48–50]. These
findings open new completely unpredicted perspectives for this unusual
DNA-repair enzyme in controlling gene expression.
Another well-known enzyme of the BER pathway having important
function in transcriptional regulations is APE1 [11,51]. APE1 plays a
role in the regulation of expression of human genes during oxidative
stress conditions and it is important for cancer biology, through in-
direct- and direct-mechanisms [52]. Thus, besides providing a crucial
role in the genome stability maintenance, APE1 acts also as a master
regulator of cellular response to genotoxic damage via indirect me-
chanisms. Indeed, by regulating the expression of several tumor related
genes, through the stimulation of DNA binding activity of transcription
factors such as NF-ĸB, Egr-1, Hif-1α, Nrf1, APE1 can influence the onset
of inflammatory and metastatic progression [11]. Through the redox-
mediated activation of NF-ĸB and Hif1α, for example, APE1 indirectly
drives IL-8 and VEGF expression, respectively, thus acting as a key
regulator of inflammatory and tumor-associated neo-angiogenesis pro-
cesses. Moreover, APE1 has been implicated in chemoresistance, con-
sidering its ability to stimulate the expression of the multi-drug re-
sistance gene MDR1 through the interaction with Y-box-binding protein
1 (YB-1) [53], and its regulatory abilities on the PTEN tumor suppressor
[54,55]. We recently characterized a direct role of APE1 in the tran-
scription of SIRT1 gene through the binding of nCaRE-sequences pre-
sent on its promoter, demonstrating that BER-mediated DNA repair
promotes the initiation of transcription of SIRT1 gene upon oxidative
DNA damage [41]. A recently published paper gave a definitive prove
to our previous findings and suggested a novel role of APE1 in epige-
netic regulation, through modulating in a redox-mediated manner the
DNMT1 expression and causing consequent suppression of Oct4 and
Nanog expression through specific promoter methylation [56]. The
epigenetic role of 8-oxoG modification was further supported by a re-
cent publication showing a regulatory function of BER enzymes on
specific gene expression by controlling the topological superstructure of
G-quadruplex containing promoters, such as those of VEGF and NTHL1
genes [57], as also discussed in another article of this issue by A.
Fleming and C. Burrows. All these studies highlight a new unsuspected
function of oxidative DNA lesions as novel epigenetic mechanisms of
gene regulation through the action of BER enzymes.
Moreover, despite the previous consistent research into APE1
Fig. 3. APE1 protein interactors are highly inter-
connected.
The top four functional annotation clusters of APE1
interactors identified by DAVID enrichment analysis
based on gene ontology terms of biological processes.
Protein interactors that are found in more than one
cluster are colored accordingly.
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molecular mechanisms in DNA damage repair, only recently it has been
hypothesized that this protein may play an unsuspected though im-
portant function in RNA metabolism impacting on the post-transcrip-
tional control of gene expression [17,58,59].
Overall, these pioneering studies hold the promise to change the
focus of scientific research from investigating the canonical roles of BER
enzymes in DNA repair to the study of their function in gene regulation
highlighting the BER peculiarity for eukaryotic cells. Overall, these
studies will contribute to open the DNA repair world to RNA universe.
4. BER enzymes and RNA metabolism: unexpected findings from
interactomics studies
Emerging evidences have pointed out that DNA damage repair and
RNA metabolism are more closely related than previously thought. In
addition, ncRNAs and miRNAs act at multiple levels of DNA damage
response regulation and have been proposed as novel anticancer ther-
apeutic targets [59]. DNA repair enzymes, in particular a large cohort
of BER proteins, have been implicated in RNA metabolism and in
transcriptional regulation of genes suggesting that DNA damage repair
and RNA pathways are tightly inter-regulated [59].
A number of recent interactomic studies significantly contributed to
open new scenarios for the comprehension of non-canonical functions
of BER proteins, including understanding their unusual distribution in
the nucleolar compartment [17,60,61] (Antoniali et al., submitted). The
APE1-interactome network, characterized in part in our laboratory and
in different literature works, actually comprises more than 100 different
protein species whose functions are related to four biological pathways
intimately interconnected: DNA repair, Excision Repair, RNA proces-
sing and Transcriptional Regulation (Fig. 3).
Actually, the major focus is on APE1, SMUG1 and PARP1, as pro-
totypical examples [17,59,62–64]. In this review, in particular, we
highlight current knowledge of APE1 in controlling RNA metabolism.
Interested readers are referred to the aforementioned references for
further details about SMUG1 and PARP1.
5. BER enzymes and miRNA regulation: a new paradigm in gene
expression?
We recently found that many ncRNAs, few miRNAs and some
functional RNAs are directly bound by APE1 in cancer cells (Antoniali
et al., submitted). Furthermore, preliminary analysis from our labora-
tory indicated a potential role of APE1 in miRNA biology through an
effect on the Microprocessor complex. These observations prompt a
new model that links DNA damage responses and the modulation of
target genes, and highlight how APE1 may regulate gene expression
through its direct binding and/or processing of specific RNA. Therefore,
studying APE1 new function in miRNAs processing may represent a
novel field of investigation in cancer biology, which may be linked to its
role during cancer progression.
MicroRNAs (miRNAs) are small non-coding RNA that function as a
guide in RNA silencing of most protein-coding transcripts thereby being
critical regulators of nearly all physiological and pathological pro-
cesses. As a consequence, a delicate temporal/spatial balance between
miRNAs and their targets is central to achieve the appropriate biolo-
gical outcome and, it is not surprising, that any deregulations of miRNA
biogenesis and expression have been linked to a broad spectra of pa-
thological features of human diseases including cancer [65]. Under-
standing whether APE1 regulation of target genes of genotoxic re-
sponse, could be mediated through miRNA processing will definitively
increase our knowledge regarding its role in tumor progression and
chemoresistance.
An increasing number of evidences indicate that miRNA post-tran-
scriptional maturation, rather than transcription, is often perturbed in
cancer. The accumulation of miRNAs precursor forms and the corre-
sponding depletion of mature forms have been evidenced in human
cancers compared to normal tissue [66], strongly indicating that the
impairment of key steps in miRNA biogenesis could be the underlying
cause. RNA binding proteins (RBPs) are crucial components in the de-
termination of miRNA function and stability, as they control different
steps of miRNA biogenesis, localization, degradation and activity.
Mechanisms regulating mammalian miRNA biogenesis are quite
complex and comprise a series of biochemical steps converting a pri-
mary miRNA transcript (pri-miRNA) into a biologically active mature
form [65,67]. The canonical miRNA biogenesis pathway is character-
ized by two subsequent ribonuclease reaction steps. First, in the nu-
cleus, where the transcription by RNA polymerase II takes place, pri-
miRNAs are recognized and cropped into hairpin-structure precursors
(pre-miRNAs) by the Microprocessor complex minimally composed by
the nuclear RNase III Drosha and the RNA binding protein DGCR8
(DiGeorge critical region 8)[68]. Subsequently, pre-miRNAs are ac-
tively exported by Exoportin-5 in the presence of its Ran-GTP co-factor
into the cytoplasm [69] where a second-round ribonuclease reaction
mediated by another RNase III enzyme, Dicer, generates a mature
∼22nt duplex miRNA [70]. Only one strand of this miRNA duplex is
loaded onto the RNA-induced silencing complex (RISC) whereas the
other is usually degraded. Mature miRNAs function as guides by base
pairing the RISC complex to its target mRNAs, whereas the Argonaute
(Ago) family proteins serve as effectors by recruiting factors that induce
translational repression, mRNA deadenylation and mRNA decay [71].
In the last decade, as scientists began to characterize a larger frac-
tion of miRNA genes, it appeared that the complexity and pleotropic
nature of miRNAs have been underestimated [72]. The multiple steps of
miRNA maturation could potentially provide a variety of molecular
options revealing a complex dynamic in miRNA processing. Recent
studies have pointed out alternative pathways for maturation of certain
miRNAs that deviate from the canonical miRNA biogenesis pathway
bypassing one of the RNase III cleavage steps [72–74]. This is the case
of the mirtrons, pre-miRNA hairpins generated by splicing and deb-
ranching of short hairpin introns, and other small nucleolar RNAs
(snoRNAs), transfer RNAs (tRNAs), tailed endogenous shRNA, long
hairpin RNAs (hp-RNAs) derived from short interspersed nuclear ele-
ments (SINEs) that bypass the cleavage step of Drosha [75–77]. To date,
miR-451, an erythropoietic miRNA conserved in vertebrates, is instead
the only Dicer-independent miRNA identified [78].
Furthermore, there is still a great uncertainty regarding the exact
composition of the miRNA-processing complex. Although the core
components, Drosha and DGCR8 are required for the biogenesis of al-
most all miRNAs, the Drosha complex contains numerous auxiliary
factors including the DEAD-box RNA helicase p68 (DDX5) and p72/p82
(DDX17) which selectively promote the activity of Drosha processing
over certain pri-miRNAs. Dicer is instead associated with TAR RNA-
binding protein (TRBP) and the kinase R-activating protein (PACT)
[67]. Several studies have further revealed a number of further RNA
binding proteins that are required for miRNA biogenesis. These mod-
ulators have been shown to positively or negatively regulate miRNA
biosynthesis by directly binding miRNA terminal loop region, thus af-
fecting Drosha and/or Dicer interaction with pri-miRNA or pre-miRNA.
More importantly, deregulation of RBPs expression and activity has
been linked to several malignancies. Among the panel of factors iden-
tified for example: DDX1, BRCA, ARS2, DR5, ADAR1, hRNP A1, KSRP,
Lin 28, SMADs, YAP, ERα, ERβ, wtp53 and mutant p53 [79,80]. Of
note, included in this list of RBPs, there are few DNA damage response
(DDR) proteins [81].
Remarkably, several groups pointed to a specific miRNA-RBP in-
terplay in response to external stimuli including DNA damage. Different
enzymes involved in DDR have been shown to participate in miRNA
processing and maturation (Fig. 4). Up-regulation of specific miRNAs
such as miR-16-1, miR-143, miR-206 and miR-145 has been shown to
be induced in a p53-dependent manner after DNA damage. p53 is able
to interact with the Drosha complex through p68 increasing pri-miRNA
biogenesis. Interestingly, transcriptionally inactive p53 mutants disrupt
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Drosha and p68 complex suppressing miRNA processing activity of
Drosha by sequestering p68 cofactor [79,82].
Additionally, BRCA1, a key player in DSBs (Double Strand Breaks)
response, has been recently shown to increase the expression of let-7a-
1, miR-16-1, miR-145, and miR-34a through a direct binding of p68
RNA helicase in Drosha complex [83].
ATM, a crucial kinase in DDR, regulates miRNA expression in re-
sponse to DNA damage through the phosphorylation of different targets
including, KSPR [84], p53 [84,85], ΔNp63α [86] and BRCA1 by in-
directly promoting the processing of a subset of pri-miRNAs [83].
MMR pathway can also mediate miRNA processing. The hetero-
dimer MLH1-PMS2 (MutLα) has been shown to positively regulate the
processing of miR-422a and other miRNAs by specifically stimulating
the Drosha/DGCR8-catalyzed processing of pri-miRNAs to pre-miRNAs
[87].
Different studies have also suggested a possible involvement of BER
proteins in miRNA processing, particularly those proteins found to be
multifunctional enzyme with unique features such as: YB-1, Poly(ADP-
ribose) polymerases (PARPs) and APE1.
YB-1 is a multifunctional protein participating in a variety of DNA/
RNA-dependent events such as DNA replication and RNA-processing
events including mRNA transcription, splicing, translation and stability.
Interestingly, in light of its interaction with different DNA repair en-
zymes, it is considered as a non-canonical BER protein [88]. In addition,
genome-wide analysis of YB-1-RNA interaction in glioblastoma cell line
unraveled a novel role of YB-1 in the regulation of miRNA biogenesis
during tumorigenesis. Wu et al., recently demonstrated that YB-1 in-
teraction with the loop region of pre- and pri-miR-29b-2 interferes with
Drosha and Dicer cleavage step. Interestingly, down-regulation of miR-
29b-2 expression as a consequence of this missed recruitment of Drosha
and Dicer to miR-29b-2 precursor due to YB-1 blockage, has crucial
implication in glioblastoma proliferation [89].
Recent data suggest that miRNA biogenesis can be also modulated
by post-translational modifications of each member of the Argonaute
family by PARPs [90,91]. Indeed, poly(ADP-ribose) modification of key
RNA regulatory proteins has been documented for every step of RNA
metabolism including miRNA biogenesis. There are five specific PARPs
that can be considered RBPs because of the presence of RNA binding
domain in their sequence (i.e. CCCH zing finger and RRMs, RNA re-
cognition motif): PARP7, PARP12, PARP13, PARP10 and PARP14. In
particular, it has been observed that, upon stress condition, an in-
creased PARP13 activity near the Argonaute/miRNA complex might
result in the disruption of the electrostatic interaction between miRNA
and its mRNA target with a consequent mRNA cleavage relief [91].
APE1 possible involvement in miRNA biogenesis was previously
only speculative based on different findings. It has been demonstrated
that APE1 can directly bind, in vitro, structured RNA molecules through
its 33 amino acids N-terminal domain [92] and, more interestingly, that
APE1 is endowed with RNA-processing activity over single-stranded
RNA, regulating for example c-Myc mRNA level and half-life in tumor
cells [93] and, of note, it can cleave pre-miR10b and pre-miR-21 in-
terfering with Dicer processing in vitro [94]. In addition, to further
support APE1 involvement in RNA processing it has been also demon-
strated its 3′-RNA phosphatase and 3′-exoribonuclease activities [95].
As a supplementary indirect observation, it has been recently found
that APE1 down-regulation is associated with alteration in miRNAs
expression, which are involved in pathways relating to developmental
and regulation of cellular processes, cell signaling and cancer [96].
Very recently, in order to improve our knowledge on APE1 possible
involvement in miRNA maturation, by using a combination of different
unbiased high-throughput approaches at the transcriptomic and pro-
teomic levels, we demonstrated that APE1 is involved in miRNome
regulation by acting on early phases of miRNAs processing (Antoniali
et al., submitted). We found more than 1000 APE1-bound RNA among
which many ncRNAs and notably pri-miRNAs that are directly bound
by APE1 in cancer cells. In particular, we showed that APE1 en-
donuclease activity over pri-miR-221/222 mediates the regulation of
the tumor suppressor PTEN, a known target of these miRNAs [97].
Moreover, we evidenced, for the first time, that APE1 associates with
the Drosha microprocessor complex during oxidative stress suggesting a
possible contribution of APE1 in RNA-decay pathways controlling
miRNAs precursors stability in the genotoxic cell response. Therefore,
since APE1 is an interacting partner of Drosha and of p53 [98] and
hRNPA1 (Antoniali et al., submitted), both proteins described as
modulator of Drosha-mediated cleavage, we may speculate that APE1
endoribonuclease activity is part of inducible mechanisms regulating
Fig. 4. Is BER involved in miRNA processing?
Regulation of miRNA biogenesis pathway by DNA damage response (DDR) proteins. Several DNA repair enzymes influence the processing of a subset of miRNA by recognizing specific
miRNA features or by associating with key components of the miRNA maturation pathway. Red boxes indicate DDR proteins involved in miRNA biogenesis.
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the processing of miRNA biogenesis in the nucleus especially during
oxidative stress or genotoxic damage. This is further support by the
observation that oxidative stress promotes APE1/Drosha interaction
and that APE1-kd is associated to increase oxidation levels of precursors
miRNAs. These findings, together with previous data that APE1 silen-
cing is associated with increased RNA oxidation [99], would support a
major role of APE1 in the RNA-decay mechanisms of precursors pri-
miRNAs.
Of note, not only RNA-binding factors can influence miRNA pro-
cessing, but also post-transcriptional modification such as RNA-editing
may change both maturation and expression of miRNAs. Adenosine to
inosine (A-to-I) RNA-editing within the hairpin region of miRNA pre-
cursors is among the major effective mechanism described to alter the
primary sequence of RNA. A-to-I miRNA editing is mediated by ade-
nosine deaminases acting on RNA (ADAR) protein, ADAR1 and ADAR2,
having consequences in miRNA biogenesis both at the level of Drosha
and Dicer [100]. Recently, Wang et al. demonstrated that also oxidation
represents another miRNA post-transcriptional modification with re-
markably pathological outcomes. They proposed a new model in which
ROS may modulate cellular events by oxidatively modifying miRNAs, as
in the case of miR-184, which after oxidation changed its binding
proprieties from native targets to new ones [101].
In light of our previous data, demonstrating that APE1 has en-
doribonuclease activity over abasic RNA [99], we should therefore re-
interpret the roles of APE1 in modulating cellular responses to geno-
toxic stresses and in the pathogenesis of human diseases, taking into
account the new role of this multifunctional protein in RNA biology.
Our data demonstrate that APE1 is involved in specific miRNA pro-
cessing and highlight a new mechanism of miRNA regulation with
profound relevance in tumor biology.
In conclusion, recent advances in miRNA maturation pathways have
demonstrated that the multiple stages of miRNA biogenesis could serve
a multitude of regulatory options in control of miRNA-dependent gene
regulation. These findings have changed the conventional concept of
miRNA processing and have shown an additional level of complexity in
the miRNA network. miRNAs are often deregulated in human pathol-
ogies including cancer; frequently this change is a consequence of im-
paired transcription rate and/or miRNA processing. RBPs and their
interacting modulators mostly account for these observed changes in
miRNAs processing and activity.
Further investigations on the additional mechanisms that control
the processing of miRNAs under various cellular conditions and the role
of DNA repair proteins will extend our knowledge on miRNA function
in both physiological and pathological processes. These findings will
also offer a molecular basis for diagnostic and therapeutic strategies
based on miRNA biology.
6. New insights about BER involvement into removal of modified
ribonucleotides embedded in DNA
A “new type of damage”, abundantly explored in the very last years,
is the presence of ribonucleotides monophosphate (rNMPs) within
genomic DNA. It has been studied how the additional presence of a
reactive 2′-hydroxyl group on the sugar ring may: i) alter the DNA
physical properties, reducing its elasticity [102,103] and structure in a
sequence dependent manner [104–108]; ii) induce DNA replication or
transcription arrest making the DNA backbone prone to hydrolysis
triggering a persistent genomic instability [103,108,109]. This in-
corporation occurs quite frequently into the cell [110,111], potentially
during every DNA replication reaction [110]. It has been estimated that
a few thousands of rNMPs are embedded in budding yeast genome
[110] and over a million in mouse genome [112]. The higher amount of
the cellular pool of ribonucleotides (rNTPs), compared to their corre-
sponding deoxyribonucleotides (dNTPs) [110] counterparts, combined
to an incomplete elimination of RNA primers used in the generation of
Okazaki fragments [113] and an imprecise 3′-exonucleolytic
proofreading activity of replicative DNA polymerases [113–117] are
some of the major causes of the rNMPs incorporation into genomic
DNA. Moreover, another potential significant, yet poorly characterized,
source of rNMPs incorporated in DNA is oxidative stress. Specifically,
ROS, among which the hydroxyl radical ‘OH is the most reactive, can
attack all components of DNA, including the deoxyribose giving rise to
ribose [118], both in vitro and in vivo. Moreover, oxidation can occur
not only in DNA but also in the nucleotides pool and then rNMP may be
incorporated into neo-replicated DNA. During last years, several ap-
proaches have been developed [119], including Ribose-seq, in order to
map rNMPs sites into genomic DNA [111]. By using these methods, it
has been discovered that the incorporation of rNMPs has a widespread
but not random distribution in chromosomal DNA of budding and fis-
sion yeast [111] and their number, per nuclear chromosome, seems to
be proportional to the chromosome size [111].
It is imperative that mis-incorporated rNMPs should be efficiently
and rapidly repaired by the cell, otherwise the effect on genome sta-
bility and cell survival can be disastrous. Processing of single rNMPs
embedded in DNA is guided by the Ribonucleotide Excision Repair
(RER) pathway in which the leading initiating enzyme is RNase H2
[120] deputed to incise the phosphodiester linkage at 5′ end of rNMPs
[121]. Conditions in which human RNASEH2 is mutated, are associated
with a neurological auto-inflammatory childhood disorder named Ai-
cardi-Goutières Syndrome (AGS), characterized by an over production
of IFNγ [122–124]. It has been demonstrated that AGS patients, having
altered RNase H2 activity, may accumulate rNMPs in DNA, which could
induce a chronic, low-level DNA damage response signaling that sti-
mulates innate immune pathways [125]. Moreover, RNase H2-null
murine embryonic fibroblasts (MEFs) accumulate over 1 million rNMPs
in their genomic DNA, activating a p53-dependent damage response,
whereas null-RNase H2 are embryonic lethal [121]. While, under
normal physiologic conditions, the involvement of functional RER
pathway in repairing the rNMPs incorporated in DNA is known
[112,120] information is scanty about possible back-up mechanisms,
provided by other DNA-repair pathways, when RER is functionally
impaired. In the absence of RNase H2, Topoisomerase I cleavage [126]
followed by nick processing by Srs2–Exo1 can remove some rNMPs
[127,128]. Paired and mispaired rNMPs in DNA can also be targeted by
the nucleotide excision repair (NER) in bacteria [129] but likely not in
mammalian cells [130], and by the mismatch repair (MMR) systems
[131,132]. About this last pathway, it was hypothesized the in-
corporation of ribonucleotides into mismatching damaged DNA could
be interpreted as a putative “benefic” role, verifiable in a signal for the
activation of MMR pathway [133].
However, nothing is currently known about the mechanisms, if any,
responsible for repairing modified rNMPs embedded in DNA such as
abasic or oxidized rNMPs. Future studies are required to address this
issue.
7. Open questions and future perspectives
Based on the observations described so far, many open questions
remain to be addressed:
• Considering that many BER enzymes are catalytically active in many
different RNA substrates, are their main functions linked to RNA-
decay processes or in the editing processes?
• May the role of BER enzymes, both mRNA and ncRNA, affect the
protein translational machinery thus contributing to gene expres-
sion regulation through post-transcriptional mechanisms?
• It is unknown whether abasic RNA may derive from enzymatic
processing of modified (i.e. oxidized, alkylated) RNA. Are there
specific BER glycosylases responsible for recognition and processing
of these substrates?
• Is the BER involved in processing modified ribonucleotides em-
bedded in human genome, which are not repaired through canonical
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RER?
• Based on the emerging role of 8-oxoG as a new epigenetic mark, do
BER proteins work as novel epigenetic regulators?
• Pondering the many evidences about the relevance of non-canonical
function of BER proteins, should we reinterpret the overall biolo-
gical function of BER and their role in cancer and neurodegenera-
tion?
Answer to these questions may help us to better understand the role
of BER pathway in different pathological processes from neurodegen-
eration to cancer development moving from an old tolemaic and re-
ductive vision, which considers BER only a mere DNA repair pathway,
to a more galileian theory which regards also its essential function in
RNA biology and thus may explain its unpredicted role in gene ex-
pression.
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MOLECULAR CARCINOGENESIS
Inhibitors of the Apurinic/Apyrimidinic Endonuclease 1
(APE1)/Nucleophosmin (NPM1) Interaction That Display
Anti-Tumor Properties
Mattia Poletto,1 Matilde C. Malfatti,1 Dorjbal Dorjsuren,2 Pasqualina L. Scognamiglio,3,4
Daniela Marasco,3 Carlo Vascotto,1 Ajit Jadhav,2 David J. Maloney,2 David M. Wilson III,5
Anton Simeonov,2* and Gianluca Tell1**
1Department of Medical and Biological Sciences, University of Udine, Udine, Italy
2NIH Chemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health,
Bethesda, Maryland
3Department of Pharmacy, CIRPEB (Centro Interuniversitario di Ricerca sui Peptidi Bioattivi), University of Naples ‘Federico II’,
Naples, Italy
4Center for Advanced Biomaterials for Healthcare@CRIB, Istituto Italiano di Tecnologia (IIT), Naples, Italy
5Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, Maryland
The apurinic/apyrimidinic endonuclease 1 (APE1) is a protein central to the base excision DNA repair pathway and
operates in the modulation of gene expression through redox-dependent and independent mechanisms. Aberrant
expression and localization of APE1 in tumors are recurrent hallmarks of aggressiveness and resistance to therapy. We
identified and characterized the molecular association between APE1 and nucleophosmin (NPM1), a multifunctional
protein involved in the preservation of genome stability and rRNAmaturation. This protein–protein interaction modulates
subcellular localization and endonuclease activity of APE1.Moreover, we reported a correlation between APE1 and NPM1
expression levels in ovarian cancer, with NPM1 overexpression being a marker of poor prognosis. These observations
suggest that tumors that display an augmented APE1/NPM1 association may exhibit increased aggressiveness and
resistance. Therefore, targeting the APE1/NPM1 interaction might represent an innovative strategy for the development
of anticancer drugs, as tumor cells relying on higher levels of APE1 and NPM1 for proliferation and survival may be more
sensitive than untransformed cells. We set up a chemiluminescence-based high-throughput screening assay in order to
find small molecules able to interfere with the APE1/NPM1 interaction. This screening led to the identification of a set of
bioactive compounds that impair the APE1/NPM1 association in living cells. Interestingly, some of these molecules display
anti-proliferative activity and sensitize cells to therapeutically relevant genotoxins. Given the prognostic significance of
APE1 and NPM1, these compounds might prove effective in the treatment of tumors that show abundant levels of both
proteins, such as ovarian or hepatic carcinomas. © 2015 Wiley Periodicals, Inc.
Key words: APE1; NPM1; protein/protein interaction; small molecule; combination therapy
INTRODUCTION
Targeting DNA repair pathways to improve tumor
therapy is currently one of the most active topics in
cancer research.Many compounds targeting different
DNA repair components are currently undergoing
clinical and pre-clinical investigation as promising
molecules that display either a selective cancer killing
action or, more often, that improve sensitivity to
traditional therapy [1–3].
The human apurinic/apyrimidinic endonuclease 1
(APE1) is a pivotal DNA repair protein, being a central
enzyme to the base excision repair (BER) pathway. As
Abbreviations: APE1, apurinic apyrimidinic endonuclease 1; BER, base excision repair; E3330, (2E)-3-[5-(2,3-dimethoxy-6-methyl 1,4-
benzoquinoyl)]-2-nonyl-2-propenoic acid; HTS, high-throughput screening NPM1, nucleophosmin; PLA, proximity ligation assay; MMS, methyl-
methanesulphonate; MTS, [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; SPR, surface
plasmon resonance; TNF-a, tumor necrosis factor-a.
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the main abasic endonuclease in mammalian cells,
this protein is essential for embryonic develop-
ment [4,5]. In addition, APE1 acts as a master
regulator of cellular transcription, by modulating in
a redox-dependent and independent fashion theDNA
binding activity of several cancer-related transcrip-
tion factors (including NF-kB, Egr-1, p53, HIF-1a
among others) [6]. Aberrant subcellular localization,
expression levels, and post-translationalmodification
patterns of APE1 have been linked to increased tumor
aggressiveness and decreased differentiation, as well
as to the onset of chemo- and radio-resistance in
different kinds of cancer [7–12]. In light of the
association between APE1 and cancer, several labora-
tories over the last decadehave developed strategies to
target either its endonuclease activity or its redox
function bymeans of smallmolecule inhibitors [3,13–
15]. Since APE1 is a ubiquitous protein [10], it is not
clear whether these approaches could achieve speci-
ficity of action in the contest of a systemic adminis-
tration of the APE1 inhibitor.
We previously reported and characterized themolec-
ular association between APE1 and nucleophosmin
(NPM1) [16–18], a nucleolar phosphoprotein involved
in tumorigenesis, either as a proto-oncogene or as a
tumor suppressor, in a context-dependent man-
ner [19,20]. The interaction with NPM1 modulates
several functions of APE1: it promotes APE1’s accumu-
lation within nucleoli, stimulates its endonuclease
activity, and, likely, regulates its post-translational
modifications and protein interaction network, by
masking the unstructured N-terminal domain of the
protein [8,16,21]. Very recently, we showed that NPM1
is involved in the functional modulation of the BER
pathway in cells through direct interaction with APE1
and stimulation of its AP-endonuclease activity [22].
Accordingly, theoccurrenceof an aberrant cytoplasmic
APE1/NPM1 association, observed in acute myeloid
leukemia (AML) patients bearing a NPM1 mutation
(NPM1cþ) [20,23], leads to an impairment of the BER
pathway and to an increased sensitivity to genotox-
ins [22]. Moreover, the expression of an APE1 mutant
unable to stably interactwithNPM1 is linked toa strong
reduction in the rate of cellular proliferation [21].
Altogether, these observations suggest that a functional
APE1/NPM1 interaction plays a pivotal role in tumor
cell proliferation and cell response to genotoxins.
NPM1 overexpression is considered a prognostic
marker of recurrence and progression in solid tu-
mors [19,24,25]. Furthermore, altered expression of
APE1 has been linked to progression of hepatocellular
and ovarian carcinomas [7,9]. Interestingly, in
ovarian cancer specimens [25], as well as in hepatic
carcinoma cell lines (unpublished data), we detected a
positive correlation between NPM1 and APE1 expres-
sion levels and the aggressiveness of the malignant
phenotype, pointing to these proteins as negative
prognostic markers in these pathologies. Such observa-
tions suggest that ovarian and hepatic tumors express-
ing higher amounts of APE1 and NPM1 might display
an increased APE1/NPM1 interaction, which may
positively impact on tumor cell proliferation and
anticancer agent resistance. Interfering with the
APE1/NPM1 association, therefore, might prove effec-
tive in directly targeting tumor cell proliferation rate
and/or in sensitizing them toDNAdamaging agents. In
addition, this approach might prove more specific and
efficient toward cancer cells over-expressing both APE1
and NPM1, overcoming potential systemic toxicity
problems.
Here, we describe the discovery, through high-
throughput screening (HTS), of small molecules able
to interfere with the APE1/NPM1 association. We
made use of the AlphaScreen
1
technology to screen
several commercially available smallmolecule libraries
in order to identify, for the first time, a set ofmolecules
that target the APE1/NPM1 interaction. Among the
positivehits,wedetectedknownbioactive compounds
with novel interesting anti-tumor properties, such as
genotoxin-sensitizing and anti-proliferative activities.
This study opens new perspectives to target cancer cell
proliferation and therapy resistance, while also pro-
viding new tools to investigate thoroughly the
biological relevance of the APE1/NPM1 association
in experimental models and during tumorigenesis.
MATERIALS AND METHODS
Pilot Libraries of Bioactive Compounds
The screening collection included the following
libraries with number of compounds in parentheses:
FDAPharmaceutical Collections (2,816),MicroSource
Spectrum collection (1,408), Tocris/TimTec (1,395),
and bioactive compounds from Sigma–Aldrich LO-
PAC1280 (1,280), FDA-Tocris-KU-DP (1,376), Pre-
stwick (1,120), BU-GP-BioMol (1,302), Kinacore
(2,037), and NCGC chemistry analogues.
AlphaScreen
1
-Based High-Throughput Screening Assay
Assay buffer consisted of 20mM potassium
phosphate pH 7.0, 50mM NaCL, 5mM MgCL2,
0.01% Tween-20, and 2mM DTT. Microplates used
were 384- or 1,536-well white solid-bottom type from
Greiner Bio-One (Monroe, NC). Glutathione S-trans-
ferase-APE1 fusion protein (GST-APE1) and hexahis-
tidine-labeled NPM1 (His(6)-NPM1) proteins were
expressed and purified to homogeneity as described
previously [16]. AlphaScreen
1
detection was per-
formed with PerkinElmer Glutathione S-Transferase
(GST) and Histidine (Nickel Chelate) Detection Kits
(Waltham, MA).
Protein–protein interaction assessment for GST-
APE1 and His(6)Tag-NPM1 was initially conducted in
384-well plates. The optimized assay was further
miniaturized in 1,536-well plates where, briefly, 3mL
of GST-APE1 (125nM final) was dispensed by
BioRAPTR (Beckman Coulter, Fullerton, CA) flying
reagent dispenser, followed by addition of 23nl of
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DMSO solution of compound library members (final
DMSO concentration was 0.7% [v/v]) achieved by a
Kalypsys pintool [26]; after compound addition, 1mL
of His(6)Tag-NPM1 (200 nM final) was dispensed and
the assay plates were incubated for 20minutes at room
temperature. For detection, 1mL of 20mg/mL Gluta-
thione donor/Ni2þ chelate acceptor AlphaScreen
1
bead mix was added. Plates were briefly centrifuged
and incubated for 20min at room temperature. The
AlphaScreen
1
chemiluminescence signal was mea-
sured with an EnVision multilabel plate reader
(PerkinElmer) equipped with a 1,536 Plate HTS
AlphaScreen
1
aperture (80ms excitation time,
240ms measurement time). The signal was compared
with that of DMSO-containing control samples;
importantly, DMSO had a negligible effect on the
assay signal.
Cell Culture, Chemicals and Viability Assays
HeLa, Huh7, and MCF7 cells from ATCC (Manassas,
VA) were grown in DMEM (Invitrogen, Milan, Italy).
TOV-112D, HCC70 andOvcar5 cells (fromATCC) were
cultured in RPMI 1640 (EuroClone, Milan, Italy),
respectively. JHH6 cells (from Health Science Research
Resources Bank) [27] were cultured in William’s Medi-
um (Sigma, Milan, Italy). OCI/AML cells were obtained
and cultured as previously described [22]. Media were
supplemented with 10% (v/v) fetal bovine serum (FBS)
(EuroClone), 100U/mL penicillin, and 100mg/mL
streptomycin sulphate. Screening compounds were
dissolved in DMSO as 10mM stocks. MMS was from
Sigma–Aldrich and bleomycin sulphate was from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA).
For viability measurements 4-12"103 cells were
seeded in 96-well plates; 24h later cells were treated
with the indicated compound and cell viability was
assessed at the indicated time points through theMTS
assay (CellTiter 96
1
AQueous One Solution Cell
Proliferation Assay – Promega, Milan, Italy) as per
manufacturer’s instructions. For MMS-combined
treatments cells were pre-treated with the selected
protein–protein interaction inhibitor as indicated,
incubation was then carried out for further 8h with
increasing amount ofMMS, in presence of unchanged
inhibitor concentration. For combined treatments
with bleomycin 3.0"104 cells were seeded into 12-
well plates; 24h later cells were pre-treated for 8h
with the APE1/NPM1 inhibitors at the indicated
concentration and then incubation was carried out
for 1h in presence of bleomycin and unchanged
compound concentration. Medium was replaced and
viability measured 48h later by Trypan Blue exclu-
sion. All viability assays were performed in triplicate
or quadruplicate and reproduced at least twice in
independent experimental sessions.
Immuno-Fluorescence and Proximity Ligation Assay (PLA)
Immuno-fluorescence procedures were carried out
as described earlier [21]. To monitor the interaction
between APE1 and NPM1 in living cells, we used the
in situ Proximity Ligation Assay kit (Olink Biosci-
ence, Uppsala, Sweden). This assay detects stable, as
well as transient interactions by means of a pair of
antibodies against the target proteins; short oligo-
nucleotides linked to the antibodies allow a rolling
cycle amplification-based detection of the protein–
protein interaction. The signal is visualized though
hybridization of fluorescent probes to the amplified
oligonucleotides and appears as bright spots
that are readily detected through confocal micros-
copy [28,29]. HeLa cells stably expressing a FLAG-
tagged form of APE1 [21] were seeded on glass slides,
treated with the selected compounds, fixed with 4%
(w/v) paraformaldehyde immediately after the treat-
ment and incubated with a FITC-conjugated mouse
anti-FLAG antibody (1:200– Sigma) for 3h at 378C.
Cells were then incubated with a rabbit anti-NPM1
(1:200–Abcam, Cambridge, UK) overnight at 4 8C.
PLA was performed following manufacturer’s in-
structions. Technical controls, represented by the
omission of either the anti-NPM1 or the anti-FLAG
primary antibodies, resulted in the complete loss of
PLA signal. Determination and scoring of PLA
signals was performed using a Leica TCS SP laser-
scanning confocal microscope (Leica Microsystems,
Wetzlar, Germany) equipped with a 488-nm argon
laser, a 543-nm HeNe laser, and a 63X oil objective
(HCX PL APO 63X Leica). At least 35 randomly
selected cells per condition were analyzed by
sectioning the whole cell height into six focal stacks,
which were averaged and combined into a single
image. This procedure allowed us to detect the PLA
signals present throughout the cell, regardless of
their subcellular localization. PLA-spots present in
each single cell were then scored using the Blob-
Finder software (Center for Image Analysis, Uppsala
University, Uppsala, Sweden); anti-FLAG staining
for APE1 was used to identify cell nuclei, allowing us
to distinguish between nuclear and cytoplasmic
interaction signals.
Surface Plasmon Resonance (SPR) Experiments
Real time binding assays were performed on a
Biacore T-100 Surface Plasmon Resonance (SPR)
instrument (GE Healthcare, Milan, Italy). Recombi-
nant APE1, APE1 ND33, APE1 KA and NPM1 were
immobilized at similar immobilization levels (#2600,
2400, 2400, and 2800 RU, respectively) on a CM5
Biacore sensor chip in 10mM sodium acetate, pH 5.5,
by using the EDC/NHS chemistry, with a flow rate of
5ml/min and an injection time of 7min, as previously
described [16]. Binding assays were carried out by
injecting 100ml of analyte, at 60ml/min, with HBS
(10mM Hepes, 150mM NaCL, 3mM EDTA, pH 7.4),
0.1mM TCEP, 10% (v/v) DMSO as running-buffer.
The BIAevaluation analysis package (version 4.1, GE
Healthcare), was used to subtract the signal of the
reference channel.
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In Vivo Assessment of the APE1 Redox Activity
The APE1 redox function was assessed as described
in Ref. [27]. Briefly, 1.1!104 JHH6 hepatocarcinoma
cells were seeded in 96-well plates, 24h later cells were
co-transfected with 78.4ng of pIL-8 (interleukin 8
promoter-driven firefly luciferase reporter), 1.6ng of
pRL-CMV (Renilla reporter, as a reference for transfec-
tion efficiency), and 120ng of pUC9 carrier plasmid,
using the Lipofectamine
1
2000 Reagent (Invitrogen)
as per manufacturer’s instructions. One day after
transfection cells were pre-treated with the selected
APE1/NPM1 inhibitor (10mM for 5h), or with (2E)-3-
[5-(2,3-dimethoxy-6-methyl 1,4-benzoquinoyl)]-2-
nonyl-2-propenoic acid (E3330, Sigma) as positive
control (100mM for 4h) in serum-free medium and
subsequently challenged with 2000U/ml TNF-a
(PeproTech Inc., Rocky Hill, NJ) for further 3h. The
activity of luciferases was eventually measured using
the Dual-Glo
1
Luciferase Assay System (Promega)
using a ModulusTM II Microplate Multimode Reader
(Turner Biosystems Inc. Sunnyvale, CA).
Colony Formation Assays and Assessment of the Cellular
Growth Rate
For colony formation assays 2!102 HeLa cells were
plated onto 6-well plates; 24h later cells were exposed
to the selected compound(s) and cells were allowed to
grow until formation of visible colonies (9–11days)
and stained as described earlier [17]. To test the effect
of chronic exposure to the APE1/NPM1 inhibitors,
medium with the indicated amount of fresh com-
pound was replaced every three days. In the experi-
ments combining bleomycin and the APE1/NPM1
inhibitors, the indicated amount of bleomycin was
mixed with 10mM inhibitor and treatment was
carried out for 1h, medium was replaced and cells
were allowed to form colonies in fresh medium.
For cellular growth ratemeasurements, 2!104 cells
were seeded in 24-well plates, treated 24h later and
counted at the indicated time points using a coulter
counter (Beckman Coulter).
DNA Damage Accumulation Measurements
Genomic DNA was isolated from 1!106 HeLa cells
by using the Get pureDNA Kit (Dojindo, Rockville,
MD) and AP-sites content was measured by using the
DNA Damage Quantification Kit (Dojindo) as per
manufacturer’s indications. Briefly, 1mg of genomic
DNA was labeled with a biotinylated aldehyde
reactive robe (ARP) for 1h at 378C, and ARP-DNA
was purified following the manufacturer’s instruc-
tions. The amount of labeled ARP–DNA was then
quantified through a colorimetric reaction and
eventually measured using a calibration curve pro-
vided with the kit.
Alkali comet assay was carried out essentially as
described in ref. [30]. Briefly, HeLa cells were exposed
to the indicated concentrations of the APE1/NPM1
inhibitors for 16h and washed twice with ice-cold
PBS. Approximately 3!103 cells were embedded on
slides in 0.5% (w/v) low melting point agarose
(Cambrex Corporate, East Rutherford, NJ) in PBS.
The slides were placed in cold lysis solution (2.5M
NaCL, 100mM EDTA, and 10mM Tris pH 10.0,
1% (v/v) Triton X-100) for 1h at 48C, and washed in
cold 0.4M Tris (pH 7.4). Next, the slides were
incubated in alkali solution (300mM NaOH, 1mM
EDTA, final pH 13.0) for 30min at 48C and then
electrophoresed horizontally for 30min at 25V,
350mA at 48C. Slides were briefly neutralized with
0.4M Tris (pH 7.4), stained with ethidium bromide
(2mg/ml) and viewed on a Zeiss Axiovert 200M
fluorescent microscope (Zeiss, Thornwood, NY). The
analysis of the comet tail was carried out using the
Comet Assay IV software (Perceptive Instruments,
Suffolk, UK) to determine the Olive tail moment. At
least 100 cells per experimental condition were
scored.
rRNA Maturation Kinetics
rRNA processing was monitored as described in
ref. [31] with minor modifications. In brief, 5!105
HeLa cells were treated with the indicated inhibitors.
For metabolic labeling cells were trypsinized and
immediately phosphate-depleted under rocking at
378C for 1h in presence of unchanged drug concen-
trations, by incubation in phosphate-free DMEM
supplemented with 10% (v/v) dialyzed FBS (Invitro-
gen). Medium was then replaced with phosphate-free
DMEM supplemented with 10% (v/v) dialyzed FBS
containing 15mCi/ml [32P]orthophosphate (Perkin
Elmer, Milan, Italy) and cells were labeled for 1h.
Medium was again replaced with normal DMEM
supplemented with 10% (v/v) FBS in presence of
unchanged drug concentrations and total RNA was
isolated after 2h using the Trizol
1
Reagent (Invitro-
gen). RNA was separated on an agarose-formaldehyde
gel loading the same amount of radioactivity per lane.
Gels were vacuum-dried and subjected to
autoradiography.
AP-Site Incision Assays
APE1 endonuclease activity was monitored using
purified recombinant APE1. Enzymatic reactionswere
carried out in a final volume of 10ml using 2.3 fmol of
protein in a buffer containing 50mM HEPES pH 7.5,
50mM KCl, 10mM MgCL2, BSA 1mg/ml and 1mM
DTT; samples were pre-incubated for 15min at 378C
with 230pmol of the selected inhibitors. Reactions
were started by adding 100nM of double stranded
abasic DNA substrate (obtained by annealing a
DY-782-labeled oligonucleotide 50-CTTGGAACTG-
GATGTCGGCACFAGCGGATACAGGAGCA-30 (Dyo-
mics), where F indicates a tetrahydrofuran residue,
with the complementary sequence 50-TGCTCCTGTA-
TCCGCTGTGCCGACATCCAGTTCCAAG-30) and in-
cubated at 378C for the indicated time points.
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Reactions were halted by addition of formamide
buffer (96% formamide, 10mM EDTA and gel
Loading Buffer 6! (Fermentas)), separated onto a
20% (w/v) denaturing polyacrylamide gel and ana-
lyzed on anOdysseyCLx scanner (Li-Cor Biosciences).
The percentage of substrate converted to product was
determined using the ImageStudio software (Li-Cor
Biosciences).
Statistical Analyses
Statistical analyses were performed by using the
Student’s t test. P<0.05 was considered as statistically
significant.
RESULTS
An AlphaScreen
1
- Based High-Throughput Screening
Assay for the Identification of Low Molecular Weight
APE1/NPM1 Interaction Disruptors
Screening for low molecular weight compounds
that target a protein–protein interaction interface is a
challenging task. In order to find molecules able to
impair the APE1/NPM1 association, we exploited the
AlphaScreen
1
technology using recombinant purified
full length GST-tagged APE1 and His(6)-tagged NPM1.
The AlphaScreen
1
assay relies on a proximity-based
reporting system used to measure the binding
between two cognate partners. Laser excitation at
680nmof a colloidal-size donor bead releases a flowof
singlet oxygen (Figure 1A). Acceptor beads in close
proximity (<200nm) utilize this singlet oxygen to
generate a chemiluminescence signal emitting in the
520–620nm range. Here, we have configured an
AlphaScreen
1
assay by using glutathione-coated
donor beads and Ni2þ chelate-coated acceptor beads
to measure binding of GST-APE1 to His(6)-NPM1. To
search for compounds with the ability to disrupt the
APE1/NPM1 interaction, we screened a pilot set of
libraries composed of 12700 small molecules at a
seven-concentration dilution series (3.7 nM–57mM).
An excellent Z’ score (>0.65) was maintained
throughout the screen (Figure 1B). Compounds that
Figure 1. Development of an HTS assay to individuate APE1/NPM1
interaction inhibitors. (A) Schematic representation of the HTS assay
principle. The interaction between full length GST-APE1 and His(6)-
NPM1 is monitored in solution upon excitation at 680nm. The
glutathione-coated donor beads release singlet oxygen, which excites
only proximal (#200 nm) Ni2þ-chelating acceptor beads. The presence
of APE1/NPM1 interaction is revealed by luminescence emission at
520–620 nm. (B) Graphic summary reporting the Z' screening score; a
stable value above 0.65 was maintained throughout the screening. (C)
Representative curves observed from eight screening hits selected
during downstream analyses. The graph reports the concentration-
dependent loss of APE1/NPM1 interaction signal for the indicated
compounds, relative to the vehicle-treated samples. Structures and
additional data associated with the best characterized hits are
presented in Figure 5.
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showed inhibitory activity in the primary screen
were rescreened for confirmation. To eliminate false
positives, we used a counterscreen assay to measure
the binding AlphaScreen
1
beads to a GST-His(6)
conjugate, which served as a recognition moiety for
both donor and acceptor beads outside the context of
the APE1/NPM1 interaction. With this approach, we
confirmed 58 compounds as true hits (chosen based
on availability, Supplementary Table 1), which were
used in further downstream analyses. Representative
dose-response curves for a subset of positive com-
pounds are reported in Figure 1C.
Secondary Validation Assays for the Selection of
Molecules Able to Impair the APE1/NPM1 Interaction in
Living Cells
The positive hits from the primary screening
analyses were subjected to a panel of orthogonal
cell-based secondary validation assays in order to
focus on those molecules able to impair the APE1/
NPM1 association in living cells. HeLa cells are a well-
characterized cell model that has been widely used by
our and other laboratories to study APE1 biology [32–
35] and to screen for APE1 inhibitors [36,37]. Thus, we
used them as a general model to probe the activity of
the putative APE1/NPM1 inhibitors. All 58 of the
initial positive compounds was preliminarily tested
over a wide range of doses (0.1–100mM) and time
points (4–24h) assessing cell viability through the
MTS assay. These initial experiments allowed us to
estimate the range of solubility in the cell medium
(evaluating particle deposition through a phase
contrast microscope) and the cytotoxicity for each
compound (not shown).
As the interaction with NPM1 is known to
modulate the subcellular localization of APE1
[21,22], we used an immuno-fluorescence-based
approach to detect any change in subcellular
distribution of APE1 upon treatment with the
molecules. Timing and dosage of the treatments
were selected on the basis of the individual toxicity
and solubility of every compound. In order to reduce
the likelihood of confounding effects, for each of the
58 putative inhibitors, we tested at least two
conditions (time and/or dosage) at which cell
viability was affected by less than 50%. Treatment
with the molecules affected the APE1 subcellular
localization in different ways (Supplementary Ta-
ble 1): a number of compounds (e.g., SB 206553,
spiclomazine, etc.) increased the cytoplasmic locali-
zation of APE1, while others (e.g., ZM 241385,
troglitazone, fiduxosin) led to a reduction of the
APE1 nucleolar accumulation (Figure 2A).
Only compounds affecting APE1 staining (17 out
of 58—Supplementary Table 1) were further
screened through a proximity ligation assay
(PLA) [22,28,29], which was designed to measure
the extent of the residual APE1/NPM1 association
upon cell treatment. As the AlphaScreen
1
was
carried out using a recombinant GST-tagged form
of APE1, we sought to exclude any possible artifact
arising from the presence of the N-terminal tag by
exploiting a HeLa cell line stably expressing a C-
terminally FLAG-tagged version of APE1 [21]. The
presence of the tag, in this case, was necessary to
improve the quality of the PLA signal, and was
already shown not to affect the interaction with
NPM1 [22]. PLA was carried out by fixing cells
immediately after treatment with the putative
inhibitors and revealing the molecular association
between APE1 and NPM1 with an anti-FLAG/anti-
NPM1 pair of antibodies (Figure 2B). Quantification
of the PLA signal allowed us to determine whether a
particular compound was able to decrease the
extent of the APE1/NPM1 interaction below that
of vehicle-treated cells. This approach allowed us to
narrow the number of putative inhibitors to eight
molecules effectively able to interfere with the
APE1/NPM1 interaction in cells (Figure 2C—top
panel). As anticipated by the immuno-fluorescence
preliminary screening, some of the compounds that
caused relocalization of APE1 (e.g., fiduxosin,
spiclomazine) led to an accumulation of the
interaction signal from the nucleoplasm to the
cytoplasm (Figure 2C—bottom panel). Treatment
with other compounds, while leading to APE1
relocalization to the cytoplasm, did not produce
any increase in the APE1/NPM1 interaction in this
cellular compartment (e.g., SB 206553). In summa-
ry, our approach, exploiting a panel of secondary
cell-based screens, allowed us to validate a set of
eight low molecular weight compounds (i.e.,
FSCPX, troglitazone, SB 206553, ZM 241385, rote-
none, spiclomazine, fiduxosin, and myoseverin B)
able to effectively displace the APE1/NPM1 interac-
tion upon cell treatment. Rotenone, a respiratory
chain poison and myoseverin B, known to bind
microtubules [38], were excluded from additional
analyses, because of their previously noted off-
target effects.
To better characterize the six remaining hits, we
analyzed their ability to interfere with the APE1
redox function. We exploited the JHH6 hepatocar-
cinoma cell line, which has already been shown to
activate NF-kB in an APE1-mediated and redox-
dependent manner after a challenge with TNF-
a [27]. JHH6 cells were transfected with a reporter
plasmid bearing an interleukin 8 (IL-8) promoter
with NF-kB consensus sequences, and treated with
the APE1/NPM1 inhibitors prior to TNF-a addition
(Figure 3A). Most of the tested molecules had no or
little effect on the basal IL-8 promoter transcription;
the effect of the APE1/NPM1 inhibitors on the
redox-dependent promoter activation ranged from
strong (e.g., troglitazone), mild (e.g., spiclomazine)
to null (e.g., SB 206553). As expected [27], cell
pre-treatment with the APE1 redox inhibitor E3330,
strongly impaired the TNF-a-induced NF-kB
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activation. Notably, the APE1/NPM1 inhibitor tro-
glitazone had an effect similar to E3330, even at a
tenfold lower concentration.
Selected Compounds Sensitize Tumor Cells to Genotoxins
and Display Anti-Proliferative Activity as Single Agent
Wenext focusedon the anti-tumorproperties of the
six selected APE1/NPM1 inhibitors. We investigated
their ability to sensitize HeLa cells to different
genotoxins. Cell viability was measured through the
MTS assay upon pre-treatment with the inhibitors,
followed by challenge with methyl-methanesulpho-
nate (MMS), which induces DNA alkylation that is
repaired by the BER pathway [39]. Pre-treatment of
cells with SB 206553 or spiclomazine resulted in a
synergistic cytotoxicity when combined with MMS
(Figures 3B and 5). Likewise, through both cell
counting and colony formation experiments, a
sensitization effect was observed when combining
fiduxosin, spiclomazine, or SB 206553 with the
radiomimetic drug bleomycin, which is known to
induce DNA strand breaks, along with a subset of
oxidative DNA lesions that are repaired with the
intervention of APE1 [40] (Figures 3C, D and 5).
Neither FSCPX nor ZM 241386 had a statistically
significant effect on cell viability in combinationwith
any genotoxic drug (not shown), and were therefore
excluded from further characterization.
In addition to the enhancement of the cytotoxic
effect of therapeutically relevant DNA damaging
drugs, a desirable feature for an adjuvant to conven-
tional anti-tumor therapy is an anti-proliferative
Figure 2. Secondary orthogonal assays to validate the hits from the
primary screening. (A) Representative immuno-fluorescence analysis
on HeLa cells treated with positive hits from the primary screening. The
subcellular localization of APE1 was assessed through immuno-
staining with an anti-APE1 antibody (red). Note the absence of
nucleolar accumulation of APE1 upon stimulation with ZM 241385.
Q LUT (quantitative color look-up table) rendering highlights the
increased cytoplasmic localization after SB 206553 treatment. (B) PLA-
based secondary validation of the APE1/NPM1 inhibitors. Representa-
tive PLA experiment performed onfixedHeLa cells upon treatmentwith
fiduxosin (10mM, 16h) or troglitazone (10mM, 8 h). APE1 expression is
detected by using an anti-FLAG antibody (green), while PLA signal is
visible as red dots. Control reaction is carried out without the anti-
NPM1 antibody and shows no or little PLA signal. (C) The extent of
APE1/NPM1 association upon treatment with a subset of inhibitors was
measured through PLA, and the effect of the inhibitors on such
interaction is reported as a boxplot graph (top panel). The average
number of interaction spots scored in vehicle-treated cells was used as
reference and arbitrarily set to 1; the relative extent of APE1/NPM1
association upon inhibition of the interaction was calculated by scoring
the average of PLA signals in the inhibitor-treated cells. Cell challenge
with the indicated molecules determines a statistically significant
reduction in the extent of cellular APE1/NPM1 interaction. Boxplot
representation reporting the median cytoplasm-to-nucleus ratios of
the amount of PLA interaction spots scored in HeLa cells upon
treatment with the indicated APE1/NPM1 inhibitors (bottom panel).
Black bars in the graphs report the median for each distribution. A red
line indicates the median of the vehicle-treated cells, for easier
identification of differences. The amount and the localization of the
APE1/NPM1 interaction signals were assessed as described in
“Materials and Methods.” N! 35, *P< 0.05, **P< 0.01,
***P< 0.001, NS: not statistically significant.
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activity. We tested whether the three inhibitors that
promoted sensitization toMMSor bleomycin had any
effect on cellular proliferation as a single agent.
Remarkably, treatment of HeLa cells with either
fiduxosin or spiclomazine, but not with SB 206553,
resulted in a dose-dependent reduction of the cellular
growth rate. This effect was visible at sub-lethal
dosage (5–20mM), both upon acute (24–72h) or
chronic (10 days) treatment (Figures 4A, B and 5).
Characterization of the Molecular Target of the Top Hit
Compounds
In order to understand whether the molecular
target of the inhibitors is APE1 or NPM1, we analyzed
their binding properties using surface plasmon reso-
nance (SPR). Despite the absence of any synergistic
effect in combination with genotoxins (not shown),
troglitazone was also characterized in these assays,
given its powerful inhibitory effect on the APE1 redox
activity (Figure 3A). SPR experiments showed that the
four most promising small molecules preferentially
bind immobilized recombinant APE1, rather than
NPM1 (Figure 6A). Note that fiduxosin and spiclo-
mazine could not be used at higher concentration due
to their limited solubility in aqueous buffer. We then
compared the binding affinity of SB 206553 and
troglitazone tomutant forms of APE1. The interaction
with both small molecules was severely impaired by
the loss of the APE1 unstructured N-terminal exten-
sion, which is responsible for the interaction with
NPM1 [21] (Figure 6B, compare APE1 WT and
the APE1 ND33 truncation mutant). Comparison
of the APE1 WT and the APE1 KA form, which
preserves theN-terminal extension but loses its ability
to interact with NPM1 [21], revealed no difference in
the binding capacity of the inhibitors (Figure 6B).
Figure 3. Inhibition of the APE1/NPM1 interaction has differential
impact on the APE1 redox activity and sensitizes HeLa cells to genotoxic
treatment. (A) The APE1/NPM1 inhibitors differently affect the redox
function of APE1. JHH6 cells were transfected with a luciferase
reporter bearing the IL-8 promoter with NF-kB consensus sequen-
ces [27] and then pre-treated with the indicated APE1/NPM1
inhibitors. After 5 h cells were challenged with TNF-a and luciferase
activity was measured to assess the APE1-mediated NF-kB activation.
While the inhibitors activity onAPE1 basal redox activitywas negligible,
they showed differential inhibitory capacity over TNF-a-mediated NF-
kB activation. Results reported are the mean! SD of at least three
independent experiments, *P< 0.05, **P< 0.01. E3330 was used as
positive control for inhibition of APE1. (B) SB 206553 and spiclomazine
sensitize HeLa cells toMMS. HeLa cells were pre-treatedwith 10mMSB
206553 or spiclomazine for 8 h and then co-treated for further 8 hwith
unchanged inhibitor concentration andMMS. The effect of SB 206553
and spiclomazine as single agent was, respectively, 1.08! 0.08% and
0.99! 0.04% relative to the vehicle. (C) Bleomycin cytotoxicity is
increased in presence of either SB 206553 or fiduxosin. HeLa cells were
co-incubated with increasing amounts of bleomycin in presence of
10mM of the indicated APE1/NPM1 inhibitor for 1 h. Cell viability was
monitored 48 h later through cell counting. The effect of SB 206553
and fiduxosin as single agent was, respectively, 1.22! 0.02% and
0.86! 0.06% relative to the vehicle. (D) Combination with spicloma-
zine increases the potency of bleomycin. HeLa cells were co-incubated
with increasing amounts of bleomycin in presence of 10mM
spiclomazine for 1 h. Cell viability was monitored through colony
formation assays, showing synergic behavior of bleomycin and
spiclomazine. The cell killing effect of spiclomazine as single agent
was 0.90! 0.08% relative to the vehicle. Data reported are the
mean! SD of at least three independent experiments, *P< 0.05,
**P< 0.01.
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Figure 4. Fiduxosin and spiclomazine, but not SB 206553, impair cell growth as single agents. (A) HeLa cells were grown in presence of the
indicated APE1/NPM1 inhibitor (10 or 20mM) and cell proliferationwas assessed after 24, 48 and 72h through cell counting. Acute treatmentwith
fiduxosin or spiclomazine, but not with SB 206553, affects the cellular proliferation rate in a dose-dependent fashion. (B) HeLa cells were
chronically stimulated with increasing amounts of the indicated inhibitor during colonies growth. The percentage of surviving colonies relative to
vehicle-treated cells is reported. Inhibition of the APE1/NPM1 interaction using fiduxosin or spiclomazine, but not SB 206553, results in a dose-
dependent impairment of colony formation capacity. Data reported are the mean! SD of at least three independent experiments, *P< 0.05.
Figure 5. Sensitizing and anti-proliferative capacity of the APE1/NPM1 inhibitors. The figure schematically
summarizes the properties for each top-hit inhibitor. For every compound analyzed the “þ” symbol indicates the
presence of sensitization in combination with the indicated genotoxin. “þþ” and “þ” indicate the strength of the
phenotype on the APE1 redox and AP-endonuclease functions, as strong or mild, respectively. The anti-proliferative
activity of each molecule as single-agent is also reported, along with the chemical structure and the commercial
name of the compound. NA: not available, “#”: no effect.
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Taken together, these data suggest that APE1, rather
than NPM1, is the preferred binding partner for some
of the molecules active in this assay.
The above observations were further corroborated
by in vitro assays assessing the endonuclease activity
of APE1. These experiments showed that the inhib-
itors, at least slightly, inhibited the catalytic incision
activity of purified recombinant APE1, with some
molecules (i.e., spiclomazine and fiduxosin) having
an effect comparable to that of the known APE1
inhibitor compound #3 [37] (Figure 6C and Supple-
mentary Fig. S1).
The APE1/NPM1 Inhibitors Do Not Impair Ribosome
Biogenesis and Only Fiduxosin Leads to Accumulation of
AP-Sites
It is conceivable that the effects of the APE1/NPM1
inhibitors are mediated by the downregulation of one
or both proteins. Notably, none of the threemolecules
effective in the combination studies (i.e., fiduxosin,
spiclomazine, and SB 206553) led to a significant
reduction of either APE1 or NPM1 protein amounts
(Figure 7). Thus, neither the observed APE1/NPM1
interaction impairment,nor themeasuredeffectoncell
Figure 6. The APE1/NPM1 inhibitors show preferential binding to
APE1. (A) Histogram representation of the SPR analysis on the small
molecules–protein interaction studies. The graph reports the RUmax for
each binding experiment using the indicated concentration of analyte
on immobilized recombinant APE1 or NPM1; Note the lower response
for NPM1. E3330 was used as positive control for interaction with
APE1. (B) The indicated recombinant APE1 forms were compared for
the interaction with SB 206553 or troglitazone The histogram reports
the RUmax for each binding experiment using the indicated
concentration of analyte; signal was normalized to the molecular
weight of each small molecule. (C) The APE1/NPM1 inhibitors
negatively impact on the AP-site incision activity of APE1. APE1
endonuclease activity was measured in vitro as indicated in the
“Materials andMethods” section in presence of 100-foldmolar excess
of the indicated molecules. APE1 activity is reported as percentage of
substrate converted to product as a function of time. The APE1
inhibitor compound #3 [37] was used as positive control; the APE1 AP-
site incision profile in presence of this inhibitor is highlighted in red.
Data are expressed as mean! SD of three technical replicates from
two independent assays.
Figure 7. Inhibition of the APE1/NPM1 interaction does not affect
the expression levels of APE1 or NPM1.RepresentativeWestern blotting
showing the APE1 and NPM1 expression levels in HeLa whole cell
extracts. After treatment with the indicated inhibitors (10mM for 16 h)
no significant variation of the protein expression pattern is observed.
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growthorsensitivity toDNAdamage, canbeascribed to
variations in the expression levels of these proteins.
Focusing on fiduxosin or spiclomazine, immuno-
fluorescence analyses revealed that NPM1 maintains
its nucleolar residence over a 72h treatment with
either compound (Figure 8A). Over the same time
course, APE1 did not change its nucleolar localization
when cells were treated with spiclomazine. On the
other hand, in cells treated with fiduxosin, APE1 was
depleted from nucleoli during the first 48h
(Figure 8B), as already observed during the im-
muno-fluorescence based secondary screening (Sup-
plementary Table 1). These observations suggest that
the cytostatic effect of these two APE1/NPM1 inhib-
itors is not driven by the disruption of nucleolar
integrity, as NPM1 localization was unaffected [31].
Fiduxosin, in this case, represented a notable excep-
tion, showing intact nucleoli, but relocalization of
APE1. In accordance with the absence of nucleolar
disruption, the ribosome processing kinetics in HeLa
cells treated with either fiduxosin or spiclomazine did
not show any obvious alteration (Figure 9A), indicat-
ing that other mechanisms might account for the
impairment in cell proliferation.
To gain further insight into the mechanism of
action of the selected APE1/NPM1 inhibitors we
assessed any inhibitor-dependent accumulation of
DNA damage through measurement of AP-sites and
the use of the alkaline comet assay. Our data indicate
that treatment of HeLa cells with fiduxosin induced a
small, albeit significant, increase in the genomic AP-
site content (Figure 9B); spiclomazine or SB 206553,
conversely, didnot induce anymajor accumulationof
DNA damage (Figure 9B and C).
Figure 8. NPM1 localization is not affected by prolonged treatment with fiduxosin or spiclomazine; whereas APE1 nucleolar accumulation is
affected by fiduxosin only. (A) Representative immuno-fluorescence analysis on HeLa cells treatedwith either fiduxosin or spiclomazine (20mM for
the indicated time points). NPM1 staining (red) shows the constant nucleolar accumulation of the protein throughout the treatment. Merged
panels show the superimposition of NPM1 and TO-PRO-3 staining (blue). (B) Representative micrographs showing a typical immuno-fluorescence
analysis on HeLa cells treated with either fiduxosin or spiclomazine (20mM for the indicated time points). APE1 staining (green) shows a decreased
nucleolar accumulation of the protein in presence of fiduxosin, but not upon treatment with spiclomazine. Merged panels show the
superimposition of APE1 and TO-PRO-3 staining (blue).
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The Cytotoxic Effect of the APE1/NPM1 Is Common to
Different Tumor Cell Lines
In order to extend our findings to other cell lines,
we estimated the IC50 of fiduxosin, spiclomazine and
SB 206553 on a panel of tumor cell lines representing
different cancer histotypes, such as hepatic (Huh7,
JHH6), breast (HCC70, MCF7), glial (SF767), and
ovarian (Ovcar5, TOV-112D). As shown in Table 1 and
in Figure 10, the IC50 of the APE1/NPM1 inhibitors
was similar among the samples, with few cell line-
specific exceptions. Notably, HeLa cells were quite
resistant to the cytotoxicity induced by the
APE1/NPM1 inhibitors, having very high IC50 values.
Sensitization assays were also carried out on TOV-
112D. Here, the sensitization effect of fiduxosin and
spiclomazine was reproduced in the TOV-112D
Figure 9. Inhibition of the APE1/NPM1 interaction does not affect rRNA processing or DNA integrity. (A) rRNA maturation kinetics were
monitored in HeLa cells as described in “Materials and Methods” after treatment with either spiclomazine or fiduxosin (20mM) for the indicated
time. The proteasome inhibitor MG132 (50mM, 2 h) was used as positive control [31]. Cell treatment under these experimental conditions does
not lead to any obvious rRNA processing impairment. V: vehicle. (B) Genomic AP-site content quantification on HeLa cells upon treatment with the
APE1/NPM1 inhibitors does not reveal any major damage accumulation. HeLa cells were treated with fiduxosin or spiclomazine (10mM, 48h), SB
206553 (20mM, 16h), orMMS (250mM, 16h) as positive control. AP-sites amount was calculated as described in “Materials andMethods.”Data
are expressed asmean! SD of three replicatemeasurements, *P< 0.01. (C) Comet assay performed on HeLa cells shows the lack of accumulation
of alkali-sensitive sites on genomic DNA after treatment with the APE1/NPM1 inhibitors (16 h). HeLa cells were exposed to fiduxosin, spiclomazine
(30mM), SB 206553 (100mM), or H2O2 (200mM, 10min) as positive control, and tail momentwasmeasured as described. The boxplot reports the
median tail moment in at least 100 cells per condition. ** P< 0.001.
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ovarian cancer cell line with bleomycin (Figure 11A),
but not with MMS. In addition, viability assays
comparing the AML cell lines OCI/AML-2 (expressing
wild-type NPM1) and OCI/AML-3(expressing the
NPM1c mutant and having an impaired APE1/
NPM1 interaction [22]), showed a sensitizing effect
for the SB 206553-bleomycin combination only in the
cell line expressing wild-type NPM1 (Figure 11B).
Altogether, these data suggest that the cytotoxic
and the sensitizing effects of spiclomazine, SB 206553
and fiduxosin are not restricted to HeLa cells.
Moreover, these data further suggest that a functional
APE1/NPM1 interaction is likely needed for the SB
206553 sensitization effect to occur in AML cell lines.
DISCUSSION
The study presented herein represents the first
attempt to target the APE1 protein in tumor cells
through the disruption of its interactome. Exploiting
Table 1. IC50 Estimates for Spiclomazine, Fiduxosin and SB 206553 on Different Tumor Cell Lines
Compound HeLa Huh7 HCC70 JHH6 SF767 MCF7 Ovcar5 TOV-112D
Fiduxosin NA 39.8 43.5* 31.3 43.3* NA 52.7* 45.6*
Spiclomazine NA 38.0 46.3* 48.8* NA NA NA 40.2
SB 206553 109.4* NA 56.0 84.2 55.8 77.5 NA NA
The indicated cell lineswere exposed to theAPE1/NPM1 inhibitors for 48h and cell viabilitywas assessedusing theMTS assay.
IC50 values are expressed in mM and were calculated using the GraphPad Prism v6.0 software. Starred values (
*) are slightly
above the experimental curve and were therefore extrapolated using the same software. “NA” indicates an IC50 far above the
tested range.
Figure 10. IC50 estimates for spiclomazine, fiduxosin, and SB 206553 on different tumor cell lines.
Representative cytotoxicity curves used for the calculation of the IC50 of selected APE1/NPM1 inhibitors. The
indicated cell lines were grown in presence of increasing concentrations of spiclomazine (A), fiduxosin (B) or SB
206553 (C) for 48 h; cell viability was measured through the MTS assay. Maximum dosage was limited by the poor
solubility of fiduxosin and spiclomazine in aqueous medium. Values plotted are the average! SD of five
experimental replicates. 50% survival is highlighted by a red line.
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the AlphaScreen
1
technology using full length re-
combinant proteins, we were able to screen a set of
commercially available small molecule libraries for
putative inhibitors of the APE1/NPM1 interaction.
Although our data do not allow us to exclude the
possibility of in vivo off target effects of the top-hits,
using our proof of concept approach, we have
successfully demonstrated that structurally unrelated
bioactive molecules are able to impair the
APE1/NPM1 interaction in living cells. Moreover,
the inhibition of this interaction leads to interesting
drug potentiation and growth impairment pheno-
types in tumor cell lines.
Targeting protein–protein interactions with small
molecules is a challenging task. The issue is often
complicated by the presence of large surface areas
involved in the protein–protein binding, and by the
lack of obvious binding pockets for the small
molecules at many interaction interfaces [41,42].
Since the APE1/NPM1 protein–protein interaction is
known to involve the N-terminal region of both
proteins [16,17], we speculate that the compounds
identified herein are targeting either the NPM1
oligomerization domain, or the APE1 unstructured
extension [18], or even the APE1/NPM1 interface. The
propensity of many positive hits to induce relocaliza-
tion of APE1 implies that this class of inhibitors has
greater affinity for the N-terminal region of the
endonuclease, which is responsible for its nuclear
localization [43] and interaction with NPM1 and
rRNA [16–18]. The negative effects measured on APE1
redox function and on the endonuclease activity of
the enzyme, together with the SPR data, strongly
support preferential binding to APE1. In this study we
did not carry out structural analyses to pinpoint the
precise binding site of the hit compounds on APE1.
Figure 11. Spiclomazine and fiduxosin sensitize TOV-112D cells to bleomycin, while SB 206553 shows differential sensitization to bleomycin in
AML cell lines. (A) TOV-112D ovarian cancer cells were incubated with 20mM of either fiduxosin or spiclomazine for 7 h and subsequently
challenged with increasing amounts of bleomycin for 1 h in presence of unchanged inhibitor concentration. Cell viability wasmonitored 48 h later
through cell counting. The cell killing effect of fiduxosin and spiclomazine as single agent was, respectively, 0.98! 0.07% and 0.91! 0.10%
relative to the vehicle. Data reported are the mean! SD of at least three independent experiments, *P< 0.05, **P< 0.01. (B) OCI/AML-2 or OCI/
AML-3 cells were incubated for 24 h with 20mMSB 206553, challengedwith bleomycin (1 h, 100mg/ml), washed and incubated with unchanged
SB 206553 concentration for further 24 h. Cell viability was assessed through cell counting. Data reported are the mean! SD of at least four
experimental replicates, **P< 0.01. The effect of SB 206553 relative to the vehicle as single agent was 1.40! 0.06% for OCI/AML-2 and
1.27! 0.09% for OCI/AML-3 cells.
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Therefore, we cannot exclude that the small mole-
culesmay interact with different sites and/or affinities
at the interaction interface. A preliminary observa-
tion of the molecular structure of the top hit
compounds (Figure 5) suggests, for instance, that
different chemical features of the molecules may
affect their activity towards APE1. The experiment
described in Figure 6C shows that both spiclomazine
and fiduxosin inhibit APE1 with potency comparable
to that of compound #3 [37]. Structure-activity
relationship (SAR) studies have also shown that
thiazolinic and thienopyridinic groups within com-
pound #3 are associated with increased inhibitory
activity of the molecule [37]. Interestingly, both
fiduxosin and spiclomazine contain a thienopyrimi-
dinic and thiazin moieties, presumably involved in
the APE1 inhibitionmechanism. The lower inhibitory
effect of troglitazone and SB 206553 might be
explained by (1) the presence of a less efficient
thiazolinic moiety and (2) the absence of any sulfur-
containing group. These features could explain the
different behavior shown by molecules selected to
target the same protein–protein interaction. Howev-
er, these speculations need to be further addressed by
targeted SAR investigations.
The impairment of the APE1 redox function might
be, per se, an appealing feature for anti-cancer
treatment, as already suggested [15], and a subset of
the APE1/NPM1 inhibitors counteract the TNF-a-
induced NF-kB activation in hepatocarcinoma cells.
Among the positive hits in this study we found
troglitazone, a well-known anti-diabetic PPARg
agonist that has been withdrawn from the market
for its hepatotoxicity [44]. Notably, troglitazone has
been proposed to exert anti-inflammatory action
through the NF-kB pathway [45], and various reports
have described interesting anti-tumor properties of
this compound in different cell models [46,47].
These findings might be explained by our observa-
tion that the compound is a very potent APE1 redox
inhibitor.
Polischouk and colleagues previously reported an
interesting enhancing effect of the antipsychotic
trifluoperazine (TFP) on bleomycin-mediated cyto-
toxicity [48]. One of the present APE1/NPM1 inhib-
itors, namely spiclomazine, is a member of the same
class of drugs (i.e., phenothiazines), and we consis-
tently observe here a synergic effect of bleomycin and
spiclomazine. Although TFP has been suggested to
impair the non-homologous end joining process [48],
an involvement of either APE1 [40] or NPM1 [19] in
the elimination of bleomycin-induced DNA damage
should not be excluded. Interestingly, spiclomazine
has recently been proposed as a selective molecule for
targeting pancreatic carcinoma, being able to reduce
proliferation of cancer cell lines, withminor effects on
non-transformed cell models. In the same study,
spiclomazine was proposed to regulate the expression
levels of apoptotic proteins, reducing the mitochon-
drial membrane potential, elevating reactive oxygen
species levels and suppressing the metastatic poten-
tial of pancreatic carcinoma cell lines [49]. The redox
activity of APE1, moreover, has been shown to be an
ideal key target in pancreatic cancer [15]. In light of
our findings, we speculate that the dual effect of
spiclomazine on both the APE1 endonuclease and its
redox activity might be linked to the effects observed
on pancreatic tumor cell lines.
In this study, we show that molecules already
known for different biological activities display
previously uncharacterized anti-tumor properties.
The sensitization effects observed when disrupting
the APE1/NPM1 interaction, in combination with
MMS or bleomycin, appear to be only partially related
to a direct impact of the compounds on the BER
capacity. In fact, while the inhibitory effect displayed
by some molecules toward the APE1 endonuclease
and redox activities is correlated with a negative
impact on cellular proliferation (compare for instance
fiduxosin and spiclomazine with SB206553), our data
did not record any significant DNA damage accumu-
lation under the experimental conditions tested (with
fiduxosin being a clear exception). This apparent
contradiction could reflect the low sensitivity of the
assays used, since the negative effect on the APE1
endonuclease activity is fairly limited in terms of
magnitude, at least at the concentrations tested in
vitro. On the other hand, it is conceivable that non-
canonical APE1 activities, distinct from its DNA
repair-related function (e.g., RNA binding/cleavage,
exonuclease, or RNase [6]), are involved in the
response to the DNA damaging agents used in our
experiments. Notably, genotoxins tested within this
study are likely to induce the accumulation of RNA
damage, along with DNA damage [50–52]. These
considerations reflect the possible relevance of the
APE1/NPM1 interaction in pathways different from
DNA repair. Accordingly, the observed anti-prolifer-
ative effect of some of the inhibitors (i.e., spicloma-
zine and fiduxosin) may reflect a potential role of the
APE1/NPM1 association in tumor cell proliferation,
but not specifically in DNA repair, as previously
suggested [21]. The impairment of any potential RNA
cleansing function of the APE1/NPM1 complex [17]
without obvious accumulation of DNAdamagemight
explain why these inhibitors are cytostatic and
cytotoxic. In addition, it is worth highlighting that
the APE1/NPM1 inhibitors were identified for their
ability to induce relocalization of APE1; therefore, it is
possible that some of the effects observed (including
the reduction in redox activity of APE1) are provoked
by a relocalization of APE1 itself.
A limitation of this study is represented by the fact
that our data cannot completely rule out that the
effect of the smallmolecules ismediated in part by the
disruption of the interaction between APE1 and other
protein partners. It is clear, fromour SPR data, that the
N-terminal extension of APE1 is required for the
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interaction with two of the inhibitors. However,
further interaction experiments exploiting the APE1
ND33 and the APE1 KA mutants to address the
specificity of the inhibitors are not feasible. The
results of the experiments, in fact, would be biased in
that both the mutant proteins display increased AP-
endonuclease activity, impaired RNA binding and
reduced binding activity toward known APE1
binding partners, as already reported [16,17,21]. To
the best of our knowledge, however, our study
represents the first example of the selection of low
molecular weight protein–protein inhibitors target-
ing the flexible N-terminal region of APE1. It is worth
underlining that the compounds identified in this
study were screened using commercially available
small molecule libraries, in the absence of any
structure-based design. Further SAR studies will
have to be carried out in order to improve the
selectivity and specificity of the mechanism of action
of these molecules.
In conclusion, these results show that bioactive
molecules selected for their ability to impair the
APE1/NPM1 association within cells are able to
synergize with therapeutically relevant DNA damag-
ing agents, increasing their cytotoxicity. Moreover,
some of the molecules show interesting anti-prolifer-
ative activity as single agents. The anti-cancer
properties of these molecules and their mechanism
of action deserve further characterization; additional
studies aimed at the improvement of the APE1/NPM1
inhibitors as novel therapeutic compounds are
warranted. Design of more potent inhibitors might
be useful for a thorough characterization of the
relevance of this protein–protein interaction in
vivo, as well as to improve existing therapeutic
approaches in combination therapy.
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